BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Dasari A, Shen C, Halperin D, Zhao B, Zhou S, Xu Y, Shih T, Yao JC. Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States. JAMA Oncol 2017;3:1335-42. [PMID: 28448665 DOI: 10.1001/jamaoncol.2017.0589] [Cited by in Crossref: 967] [Cited by in F6Publishing: 894] [Article Influence: 241.8] [Reference Citation Analysis]
Number Citing Articles
1 Zhang X, Lu L, Shang Y, Liu P, Wei Y, Ma L, Gong P. The number of positive lymph node is a better predictor of survival than the lymph node metastasis status for pancreatic neuroendocrine neoplasms: A retrospective cohort study. Int J Surg 2017;48:142-8. [PMID: 29107188 DOI: 10.1016/j.ijsu.2017.10.064] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
2 Del Olmo-García MI, Muros MA, López-de-la-Torre M, Agudelo M, Bello P, Soriano JM, Merino-Torres JF. Prevention and Management of Hormonal Crisis during Theragnosis with LU-DOTA-TATE in Neuroendocrine Tumors. A Systematic Review and Approach Proposal. J Clin Med 2020;9:E2203. [PMID: 32664679 DOI: 10.3390/jcm9072203] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
3 Kunz PL. Angiogenesis inhibitors in neuroendocrine tumours: finally coming of age. Lancet Oncol 2020;21:1395-7. [PMID: 33152282 DOI: 10.1016/S1470-2045(20)30560-X] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
4 He CB, Zhang Y, Cai ZY, Lin XJ. The impact of surgery in metastatic pancreatic neuroendocrine tumors: a competing risk analysis. Endocr Connect 2019;8:239-51. [PMID: 30726772 DOI: 10.1530/EC-18-0485] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
5 Hou J, Long T, He Z, Zhou M, Yang N, Chen D, Zeng S, Hu S. Evaluation of 18F-AlF-NOTA-octreotide for imaging neuroendocrine neoplasms: comparison with 68Ga-DOTATATE PET/CT. EJNMMI Res 2021;11:55. [PMID: 34106351 DOI: 10.1186/s13550-021-00797-4] [Reference Citation Analysis]
6 von Arx C, Rea G, Napolitano M, Ottaiano A, Tatangelo F, Izzo F, Petrillo A, Clemente O, Di Sarno A, Botti G, Scala S, Tafuto S. Effect of Octreotide Long-Acting Release on Tregs and MDSC Cells in Neuroendocrine Tumour Patients: A Pivotal Prospective Study. Cancers (Basel) 2020;12:E2422. [PMID: 32859050 DOI: 10.3390/cancers12092422] [Reference Citation Analysis]
7 Young K, Starling N, Sadanandam A. The molecular biology of pancreatic neuroendocrine neoplasms: Challenges and translational opportunities. Semin Cancer Biol. 2020;61:132-138. [PMID: 31577961 DOI: 10.1016/j.semcancer.2019.09.024] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
8 Hong X, Qiao S, Li F, Wang W, Jiang R, Wu H, Chen H, Liu L, Peng J, Wang J, Jia C, Liang X, Dai H, Jiang J, Zhang T, Liao Q, Dai M, Cong L, Han X, Guo D, Liang Z, Li D, Zheng Z, Ye C, Li S, Zhao Y, Wu K, Wu W. Whole-genome sequencing reveals distinct genetic bases for insulinomas and non-functional pancreatic neuroendocrine tumours: leading to a new classification system. Gut 2020;69:877-87. [PMID: 31462556 DOI: 10.1136/gutjnl-2018-317233] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 11.0] [Reference Citation Analysis]
9 Thiis-Evensen E, Poole AC, Nguyen HT, Sponheim J. Achieving objective response in treatment of non-resectable neuroendocrine tumors does not predict longer time to progression compared to achieving stable disease. BMC Cancer 2020;20:466. [PMID: 32448245 DOI: 10.1186/s12885-020-06963-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Ma ZY, Gong YF, Zhuang HK, Zhou ZX, Huang SZ, Zou YP, Huang BW, Sun ZH, Zhang CZ, Tang YQ, Hou BH. Pancreatic neuroendocrine tumors: A review of serum biomarkers, staging, and management. World J Gastroenterol 2020; 26(19): 2305-2322 [PMID: 32476795 DOI: 10.3748/wjg.v26.i19.2305] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 4] [Article Influence: 8.0] [Reference Citation Analysis]
11 Toriihara A, Baratto L, Nobashi T, Park S, Hatami N, Davidzon G, Kunz PL, Iagaru A. Prognostic value of somatostatin receptor expressing tumor volume calculated from 68Ga-DOTATATE PET/CT in patients with well-differentiated neuroendocrine tumors. Eur J Nucl Med Mol Imaging 2019;46:2244-51. [PMID: 31350603 DOI: 10.1007/s00259-019-04455-9] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 7.0] [Reference Citation Analysis]
12 Zhuge X, Wang Y, Chen X, Guo C. Diabetes in Patients With Pancreatic Neuroendocrine Neoplasms. Front Endocrinol (Lausanne) 2020;11:615082. [PMID: 33424776 DOI: 10.3389/fendo.2020.615082] [Reference Citation Analysis]
13 Eusebi LH, Thorburn D, Toumpanakis C, Frazzoni L, Johnson G, Vessal S, Luong TV, Caplin M, Pereira SP. Endoscopic ultrasound-guided fine-needle aspiration vs fine-needle biopsy for the diagnosis of pancreatic neuroendocrine tumors. Endosc Int Open 2019;7:E1393-9. [PMID: 31673610 DOI: 10.1055/a-0967-4684] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
14 Sharma R, Lythgoe MP, Slaich B, Patel N. Exploring the Epigenome in Gastroenteropancreatic Neuroendocrine Neoplasias. Cancers (Basel) 2021;13:4181. [PMID: 34439335 DOI: 10.3390/cancers13164181] [Reference Citation Analysis]
15 Mei W, Ding Y, Wang S, Jia Y, Cao F, Li F. Head and body/tail pancreatic neuroendocrine tumors have different biological characteristics and clinical outcomes. J Cancer Res Clin Oncol 2020;146:3049-61. [PMID: 32601815 DOI: 10.1007/s00432-020-03303-w] [Reference Citation Analysis]
16 Cloyd JM, Poultsides GA. The Landmark Series: Pancreatic Neuroendocrine Tumors. Ann Surg Oncol 2021;28:1039-49. [PMID: 32948965 DOI: 10.1245/s10434-020-09133-x] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
17 Shaheen S, Moradi F, Gamino G, Kunz PL. Patient Selection and Toxicities of PRRT for Metastatic Neuroendocrine Tumors and Research Opportunities. Curr Treat Options Oncol 2020;21:25. [PMID: 32172368 DOI: 10.1007/s11864-020-0711-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
18 Frilling A, Clift AK. Combining radiolabelled therapies for neuroendocrine neoplasms. Nat Rev Endocrinol 2020;16:347-8. [DOI: 10.1038/s41574-020-0367-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Chauhan A, Yu Q, Ray N, Farooqui Z, Huang B, Durbin EB, Tucker T, Evers M, Arnold S, Anthony LB. Global burden of neuroendocrine tumors and changing incidence in Kentucky. Oncotarget 2018;9:19245-54. [PMID: 29721198 DOI: 10.18632/oncotarget.24983] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
20 Kochar T, Dhingra P, Shah H. When Adenocarcinoma Went Hand in Hand with Neuroendocrine Tumor: A Rare Case of Adenocarcinoma Synchronous with Neuroendocrine Tumor in Ampulla of Vater. Cureus 2019;11:e5168. [PMID: 31528518 DOI: 10.7759/cureus.5168] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
21 Trillo Aliaga P, Spada F, Peveri G, Bagnardi V, Fumagalli C, Laffi A, Rubino M, Gervaso L, Guerini Rocco E, Pisa E, Curigliano G, Fazio N. Should temozolomide be used on the basis of O6-methylguanine DNA methyltransferase status in patients with advanced neuroendocrine tumors? A systematic review and meta-analysis. Cancer Treat Rev 2021;99:102261. [PMID: 34332293 DOI: 10.1016/j.ctrv.2021.102261] [Reference Citation Analysis]
22 Yang W, Pham D, Vierra AT, Azam S, Gui D, Yoon JC. Pulmonary embolism as the presenting symptom and a confounder in ACTH-secreting bronchial carcinoid. Endocrinol Diabetes Metab Case Rep 2019;2019. [PMID: 31352698 DOI: 10.1530/EDM-19-0033] [Reference Citation Analysis]
23 Luo G, Fan Z, Gong Y, Jin K, Yang C, Cheng H, Huang D, Ni Q, Liu C, Yu X. Characteristics and Outcomes of Pancreatic Cancer by Histological Subtypes. Pancreas. 2019;48:817-822. [PMID: 31210663 DOI: 10.1097/mpa.0000000000001338] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 13.0] [Reference Citation Analysis]
24 Cella D, Beaumont JL, Hudgens S, Marteau F, Feuilly M, Houchard A, Lapuerta P, Ramage J, Pavel M, Hörsch D, Kulke MH. Relationship Between Symptoms and Health-related Quality-of-life Benefits in Patients With Carcinoid Syndrome: Post Hoc Analyses From TELESTAR. Clin Ther 2018;40:2006-2020.e2. [PMID: 30477789 DOI: 10.1016/j.clinthera.2018.10.008] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 5.3] [Reference Citation Analysis]
25 Sadowski SM, Christ E, Bédat B, Kollár A, Karenovics W, Perren A, Triponez F; SwissNET registry. Nationwide multicenter study on the management of pulmonary neuroendocrine (carcinoid) tumors. Endocr Connect 2018;7:8-15. [PMID: 29229628 DOI: 10.1530/EC-17-0271] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
26 Ahmed M. Gastrointestinal neuroendocrine tumors in 2020. World J Gastrointest Oncol 2020; 12(8): 791-807 [PMID: 32879660 DOI: 10.4251/wjgo.v12.i8.791] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 14] [Article Influence: 18.0] [Reference Citation Analysis]
27 Zhang Y, Shang L, Zhang PP, Chen LH, Wang W, Fang C, Qiu M, Feng XY, Zhou L, Zhang M, Tan HY, Qiu XD, Wang H, Lin R, Zhang Q, Zeng YJ, Jin KZ, Yu XJ, Shen L, Chen MH, Li J, Li LP, Chen J. Clinicopathological features and prognostic validity of the European Neuroendocrine Tumor Society (ENETS) and American Joint Committee on Cancer (AJCC) 8th staging systems in colonic neuroendocrine neoplasms. Cancer Med 2019;8:5000-11. [PMID: 31293053 DOI: 10.1002/cam4.2370] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
28 Carvão J, Dinis-Ribeiro M, Pimentel-Nunes P, Libânio D. Neuroendocrine Tumors of the Gastrointestinal Tract: A Focused Review and Practical Approach for Gastroenterologists. GE Port J Gastroenterol 2021;28:336-48. [PMID: 34604465 DOI: 10.1159/000512089] [Reference Citation Analysis]
29 Vesterinen T, Säilä J, Blom S, Pennanen M, Leijon H, Arola J. Automated assessment of Ki-67 proliferation index in neuroendocrine tumors by deep learning. APMIS 2021. [PMID: 34741788 DOI: 10.1111/apm.13190] [Reference Citation Analysis]
30 Mahdi M, Ozer M, Tahseen M. A Challenging Case of Carcinoid Crisis in a Patient With Neuroendocrine Tumor. Cureus 2021;13:e15626. [PMID: 34277243 DOI: 10.7759/cureus.15626] [Reference Citation Analysis]
31 Zhang J, Peng CS, Tian YH. Primary site surgery for elderly patients with distant metastatic pancreatic neuroendocrine tumor: to do or not to do? Clin Interv Aging 2019;14:1419-32. [PMID: 31496669 DOI: 10.2147/CIA.S209428] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
32 Horton TM, Sundaram V, Lee CH, Hornbacker K, Van Vleck A, Benjamin KN, Zemek A, Longacre TA, Kunz PL, Annes JP. PAM staining intensity of primary neuroendocrine neoplasms is a potential prognostic biomarker. Sci Rep 2020;10:10943. [PMID: 32616904 DOI: 10.1038/s41598-020-68071-6] [Reference Citation Analysis]
33 Wong JJM, Ginter PS, Tyryshkin K, Yang X, Nanayakkara J, Zhou Z, Tuschl T, Chen YT, Renwick N. Classifying Lung Neuroendocrine Neoplasms through MicroRNA Sequence Data Mining. Cancers (Basel) 2020;12:E2653. [PMID: 32957587 DOI: 10.3390/cancers12092653] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
34 Lin JX, Weng XF, Xie XS, Lian NZ, Qiu SL, Wang JB, Lu J, Chen QY, Cao LL, Lin M, Tu RH, Yang YH, Liu SJ, Hu M, Lin YK, Huang CM, Zheng CH, Li P, Xie JW. CDK5RAP3 inhibits angiogenesis in gastric neuroendocrine carcinoma by modulating AKT/HIF-1α/VEGFA signaling. Cancer Cell Int 2019;19:282. [PMID: 31728130 DOI: 10.1186/s12935-019-0997-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
35 Bongiovanni A, Maiorano BA, Azzali I, Liverani C, Bocchini M, Fausti V, Di Menna G, Grassi I, Sansovini M, Riva N, Ibrahim T. Activity and Safety of Immune Checkpoint Inhibitors in Neuroendocrine Neoplasms: A Systematic Review and Meta-Analysis. Pharmaceuticals (Basel) 2021;14:476. [PMID: 34067837 DOI: 10.3390/ph14050476] [Reference Citation Analysis]
36 Lahner H, Mathew A, Klocker AL, Unger N, Theysohn J, Rekowski J, Jöckel KH, Theurer S, Schmid KW, Herrmann K, Führer D. Streptozocin/5-fluorouracil chemotherapy of pancreatic neuroendocrine tumours in the era of targeted therapy. Endocrine 2021. [PMID: 34480724 DOI: 10.1007/s12020-021-02859-y] [Reference Citation Analysis]
37 Williamson LM, Steel M, Grewal JK, Thibodeau ML, Zhao EY, Loree JM, Yang KC, Gorski SM, Mungall AJ, Mungall KL, Moore RA, Marra MA, Laskin J, Renouf DJ, Schaeffer DF, Jones SJM. Genomic characterization of a well-differentiated grade 3 pancreatic neuroendocrine tumor. Cold Spring Harb Mol Case Stud 2019;5:a003814. [PMID: 31160355 DOI: 10.1101/mcs.a003814] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
38 VanDerslice J, Taddie MC, Curtin K, Miller C, Yu Z, Hemmert R, Cannon-Albright LA, Neklason DW. Early life exposures associated with risk of small intestinal neuroendocrine tumors. PLoS One 2020;15:e0231991. [PMID: 32324813 DOI: 10.1371/journal.pone.0231991] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
39 Shinji S, Sasaki N, Yamada T, Koizumi M, Ohta R, Matsuda A, Yokoyama Y, Takahashi G, Hotta M, Hara K, Takeda K, Ueda K, Kuriyama S, Ishiwata T, Ueda Y, Murakami T, Kanazawa Y, Yoshida H. Establishment and characterization of a novel neuroendocrine carcinoma cell line derived from a human ascending colon tumor. Cancer Sci 2019;110:3708-17. [PMID: 31648389 DOI: 10.1111/cas.14221] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
40 Fazio N, Spada F, Bertani E. Looking for the right TNM staging system for pancreatic neuroendocrine tumors. Hepatobiliary Surg Nutr 2021;10:382-4. [PMID: 34159169 DOI: 10.21037/hbsn-2021-1] [Reference Citation Analysis]
41 Zhai H, Li D, Feng Q, Qian X, Li L, Yao J. Pancreatic neuroendocrine tumours: Grade is superior to T, N, or M status in predicting outcome and selecting patients for chemotherapy:A retrospective cohort study in the SEER database. Int J Surg 2019;66:103-9. [PMID: 30872175 DOI: 10.1016/j.ijsu.2019.03.006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
42 Jiménez B, Abellona U MR, Drymousis P, Kyriakides M, Clift AK, Liu DSK, Rees E, Holmes E, Nicholson JK, Kinross JM, Frilling A. Neuroendocrine Neoplasms: Identification of Novel Metabolic Circuits of Potential Diagnostic Utility. Cancers (Basel) 2021;13:374. [PMID: 33498434 DOI: 10.3390/cancers13030374] [Reference Citation Analysis]
43 Chang TM, Chu PY, Hung WC, Shan YS, Lin HY, Huang KW, Chang JS, Chen LT, Tsai HJ. c-Myc promotes lymphatic metastasis of pancreatic neuroendocrine tumor through VEGFC upregulation. Cancer Sci 2021;112:243-53. [PMID: 33128283 DOI: 10.1111/cas.14717] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
44 Mazziotti G, Mosca A, Frara S, Vitale G, Giustina A. Somatostatin analogs in the treatment of neuroendocrine tumors: current and emerging aspects. Expert Opin Pharmacother. 2017;18:1679-1689. [PMID: 29067877 DOI: 10.1080/14656566.2017.1391217] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 3.5] [Reference Citation Analysis]
45 Jepsen DNM, Fiehn AK, Garbyal RS, Engel U, Holm J, Federspiel B. Immunohistochemical Staining With Neuroendocrine Markers is Essential in the Diagnosis of Neuroendocrine Neoplasms of the Esophagogastric Junction. Appl Immunohistochem Mol Morphol 2021;29:454-61. [PMID: 33480601 DOI: 10.1097/PAI.0000000000000906] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
46 Punekar SR, Kaakour D, Masri-Lavine L, Hajdu C, Newman E, Becker DJ. Characterization of a Novel Entity of G3 (High-grade Well-differentiated) Colorectal Neuroendocrine Tumors (NET) in the SEER Database. Am J Clin Oncol 2020;43:846-9. [PMID: 32910023 DOI: 10.1097/COC.0000000000000761] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
47 Pellat A, Cottereau AS, Terris B, Coriat R. Neuroendocrine Carcinomas of the Digestive Tract: What Is New? Cancers (Basel) 2021;13:3766. [PMID: 34359666 DOI: 10.3390/cancers13153766] [Reference Citation Analysis]
48 Grande E, Díaz Á, López C, Munarriz J, Reina JJ, Vera R, Bernárdez B, Aller J, Capdevila J, Garcia-Carbonero R, Jimenez Fonseca P, Trapero-Bertran M. Economics of gastroenteropancreatic neuroendocrine tumors: a systematic review. Ther Adv Endocrinol Metab 2019;10:2042018819828217. [PMID: 30815246 DOI: 10.1177/2042018819828217] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
49 Liu Y, Chen W, Cui W, Liu H, Zhou X, Chen L, Li J, Chen M, Chen J, Wang Y. Quantitative Pretreatment CT Parameters as Predictors of Tumor Response of Neuroendocrine Tumor Liver Metastasis to Transcatheter Arterial Bland Embolization. Neuroendocrinology 2020;110:697-704. [PMID: 31639795 DOI: 10.1159/000504257] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
50 Mehta R, Lam-Chung CE, Hinojosa-Amaya JM, Roldán-Sarmiento P, Guillen-Placencia MF, Villanueva-Rodriguez G, Juarez-Leon OA, Leon-Domínguez J, Grajales-Gómez M, Ventura-Gallegos JL, León-Suárez A, Gómez-Pérez FJ, Cuevas-Ramos D. High Molecular Weight ACTH-Precursor Presence in a Metastatic Pancreatic Neuroendocrine Tumor Causing Severe Ectopic Cushing's Syndrome: A Case Report. Front Endocrinol (Lausanne) 2020;11:557. [PMID: 32903471 DOI: 10.3389/fendo.2020.00557] [Reference Citation Analysis]
51 Broder MS, Cai B, Chang E, Yan T, Benson AB. First-line systemic treatment adherence, healthcare resource utilization, and costs in patients with gastrointestinal neuroendocrine tumors (GI NETs) in the USA. Journal of Medical Economics 2018;21:821-6. [DOI: 10.1080/13696998.2018.1474748] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
52 Kinslow CJ, May MS, Saqi A, Shu CA, Chaudhary KR, Wang TJC, Cheng SK. Large-Cell Neuroendocrine Carcinoma of the Lung: A Population-Based Study. Clin Lung Cancer 2020;21:e99-e113. [PMID: 31601526 DOI: 10.1016/j.cllc.2019.07.011] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 3.5] [Reference Citation Analysis]
53 Kim S, Marcus R, Wells ML, Sheedy SP, Hansel SL, Bruining DH, Barlow JM, Carter RE, Lee YS, Johnson MP, Fidler JL, Goenka AH, McCollough CH, Fletcher JG. The evolving role of imaging for small bowel neuroendocrine neoplasms: estimated impact of imaging and disease-free survival in a retrospective observational study. Abdom Radiol (NY) 2020;45:623-31. [PMID: 31980866 DOI: 10.1007/s00261-020-02410-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
54 Song YL, Xu J, Zhao DC, Zhang TP, Jin KZ, Zhu LM, Yu S, Chen YJ. Mutation and Expression of Gene YY1 in Pancreatic Neuroendocrine Tumors and Its Clinical Significance. Endocr Pract 2021;27:874-80. [PMID: 33705973 DOI: 10.1016/j.eprac.2021.02.016] [Reference Citation Analysis]
55 Cai W, Tan Y, Ge W, Ding K, Hu H. Pattern and risk factors for distant metastases in gastrointestinal neuroendocrine neoplasms: a population-based study. Cancer Med 2018;7:2699-709. [PMID: 29733523 DOI: 10.1002/cam4.1507] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
56 Raiker R, Chauhan A, Hasanein H, Burkeen G, Horn M, Veedu J, Vela C, Arnold S, Kolesar J, Anthony L, Evers BM, Cavnar M. Biliary tract large cell neuroendocrine carcinoma: current evidence. Orphanet J Rare Dis 2019;14:266. [PMID: 31752927 DOI: 10.1186/s13023-019-1230-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
57 Bocchini M, Nicolini F, Severi S, Bongiovanni A, Ibrahim T, Simonetti G, Grassi I, Mazza M. Biomarkers for Pancreatic Neuroendocrine Neoplasms (PanNENs) Management-An Updated Review. Front Oncol 2020;10:831. [PMID: 32537434 DOI: 10.3389/fonc.2020.00831] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
58 Wang JB, Xue Z, Lu J, He QL, Zheng ZF, Xu BB, Xie JW, Li P, Xu Y, Lin JX, Chen QY, Cao LL, Lin M, Tu RH, Huang ZN, Lin JL, Huang CM, Zheng CH. Effect of sarcopenia on short- and long-term outcomes in patients with gastric neuroendocrine neoplasms after radical gastrectomy: results from a large, two-institution series. BMC Cancer 2020;20:1002. [PMID: 33059606 DOI: 10.1186/s12885-020-07506-9] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
59 Rodriguez-Freixinos V, Thawer A, Capdevila J, Ferone D, Singh S. Advanced Pancreatic Neuroendocrine Neoplasms: Which Systemic Treatment Should I Start With? Curr Oncol Rep 2021;23:80. [PMID: 33937962 DOI: 10.1007/s11912-021-01071-5] [Reference Citation Analysis]
60 Partelli S, Mazza M, Andreasi V, Muffatti F, Crippa S, Tamburrino D, Falconi M. Management of small asymptomatic nonfunctioning pancreatic neuroendocrine tumors: Limitations to apply guidelines into real life. Surgery 2019;166:157-63. [DOI: 10.1016/j.surg.2019.04.003] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 8.5] [Reference Citation Analysis]
61 Wang R, Zheng-Pywell R, Chen HA, Bibb JA, Chen H, Rose JB. Management of Gastrointestinal Neuroendocrine Tumors. Clin Med Insights Endocrinol Diabetes. 2019;12:1179551419884058. [PMID: 31695546 DOI: 10.1177/1179551419884058] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 8.0] [Reference Citation Analysis]
62 Nikeghbalian S, Eshraghian A, Kazemi K, Shamsaeefar A, Hosseinzadeh M, Geramizadeh B, Malek-Hosseini SA. Liver Transplantation for High-Grade Primary Hepatic Neuroendocrine Tumor with Diffuse Liver Metastasis. J Gastrointest Cancer 2020;51:304-6. [PMID: 31028538 DOI: 10.1007/s12029-019-00244-7] [Reference Citation Analysis]
63 Gao X, Wang X. Performance of deep learning for differentiating pancreatic diseases on contrast-enhanced magnetic resonance imaging: A preliminary study. Diagn Interv Imaging. 2020;101:91-100. [PMID: 31375430 DOI: 10.1016/j.diii.2019.07.002] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
64 Mcelroy KM, Binkovitz LA, Trout AT, Czachowski MR, Seghers VJ, Lteif AN, States LJ. Pediatric applications of Dotatate: early diagnostic and therapeutic experience. Pediatr Radiol 2020;50:882-97. [DOI: 10.1007/s00247-020-04688-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
65 Tsuchikawa T, Tanaka K, Nakanishi Y, Asano T, Noji T, Nakamura T, Okamura K, Shichinohe T, Hirano S. Clinical Impact of Organ-Preserving Surgery for Pancreatic Neuroendocrine Neoplasms: A Single-Center Experience. Pancreas 2021;50:196-200. [PMID: 33565795 DOI: 10.1097/MPA.0000000000001739] [Reference Citation Analysis]
66 Tran CG, Sherman SK, Howe JR. The Landmark Series: Management of Small Bowel Neuroendocrine Tumors. Ann Surg Oncol 2021;28:2741-51. [PMID: 33452604 DOI: 10.1245/s10434-020-09566-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
67 Anthony LB, O'Dorisio TM. Opportunities to Improve Symptom Control with Somatostatin Congeners in GEP-NETs: A Review of Key Issues. Oncologist 2021;26:e1171-8. [PMID: 34097784 DOI: 10.1002/onco.13847] [Reference Citation Analysis]
68 Artale S, Barzaghi S, Grillo N, Maggi C, Lepori S, Butti C, Bovio A, Barbarini L, Colombo A, Zanlorenzi L, Castiglioni E, Trojani A. Role of Diet in the Management of Carcinoid Syndrome: Clinical Recommendations for Nutrition in Patients with Neuroendocrine Tumors. Nutr Cancer 2020;:1-10. [PMID: 33148022 DOI: 10.1080/01635581.2020.1838572] [Reference Citation Analysis]
69 Grossi U, Bonis A, Carrington EV, Mazzobel E, Santoro GA, Cattaneo L, Centonze G, Gallo G, Kazemi Nava A, Romano M, Di Tanna GL, Zanus G. Mixed adenoneuroendocrine carcinoma (MANEC) of the lower gastrointestinal tract: A systematic review with Bayesian hierarchical survival analysis. Eur J Surg Oncol 2021:S0748-7983(21)00497-2. [PMID: 34052038 DOI: 10.1016/j.ejso.2021.05.021] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
70 Lee L, Ito T, Jensen RT. Everolimus in the treatment of neuroendocrine tumors: efficacy, side-effects, resistance, and factors affecting its place in the treatment sequence. Expert Opin Pharmacother 2018;19:909-28. [PMID: 29757017 DOI: 10.1080/14656566.2018.1476492] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 7.0] [Reference Citation Analysis]
71 Calanchini M, Tadman M, Krogh J, Fabbri A, Grossman A, Shine B. Measurement of urinary 5-HIAA: correlation between spot versus 24-h urine collection. Endocr Connect 2019;8:1082-8. [PMID: 31265996 DOI: 10.1530/EC-19-0269] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
72 Egger ME, Armstrong E, Martin RC 2nd, Scoggins CR, Philips P, Shah M, Konda B, Dillhoff M, Pawlik TM, Cloyd JM. Transarterial Chemoembolization vs Radioembolization for Neuroendocrine Liver Metastases: A Multi-Institutional Analysis. J Am Coll Surg. 2020;230:363-370. [PMID: 32032719 DOI: 10.1016/j.jamcollsurg.2019.12.026] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 15.0] [Reference Citation Analysis]
73 Fujimori N, Miki M, Lee L, Matsumoto K, Takamatsu Y, Takaoka T, Teramatsu K, Suehiro Y, Murakami M, Igarashi H, Oono T, Ohtsuka T, Nakamura M, Koga Y, Oda Y, Ito T, Ogawa Y. Natural history and clinical outcomes of pancreatic neuroendocrine neoplasms based on the WHO 2017 classification; a single-center experience of 30 years. Pancreatology 2020;20:709-15. [PMID: 32360001 DOI: 10.1016/j.pan.2020.04.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
74 Mohamed A, Strosberg JR. Medical Management of Gastroenteropancreatic Neuroendocrine Tumors: Current Strategies and Future Advances. J Nucl Med 2019;60:721-7. [DOI: 10.2967/jnumed.118.214882] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
75 Giannetta E, Guarnotta V, Rota F, de Cicco F, Grillo F, Colao A, Faggiano A; NIKE. A rare rarity: Neuroendocrine tumor of the esophagus. Crit Rev Oncol Hematol 2019;137:92-107. [PMID: 31014519 DOI: 10.1016/j.critrevonc.2019.02.012] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 7.5] [Reference Citation Analysis]
76 Vega EA, Kutlu OC, Alarcon SV, Salehi O, Kazakova V, Kozyreva O, Chan JA, Conrad C. Clinical Prognosticators of Metastatic Potential in Patients with Small Pancreatic Neuroendocrine Tumors. J Gastrointest Surg 2021. [PMID: 33660111 DOI: 10.1007/s11605-021-04946-x] [Reference Citation Analysis]
77 Lv Y, Pu N, Mao W, Chen W, Wang H, Han X, Ji Y, Zhang L, Jin D, Lou W, Xu X. Development of predictive prognostic nomogram for NECs of rectum on population-based exploration. Endocr Connect 2018:/journals/ec/aop/ec-18-0353. [PMID: 30352397 DOI: 10.1530/EC-18-0353] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
78 Palmieri LJ, Dermine S, Barré A, Dhooge M, Brezault C, Cottereau AS, Coriat R. Medical Treatment of Advanced Pancreatic Neuroendocrine Neoplasms. J Clin Med 2020;9:E1860. [PMID: 32549203 DOI: 10.3390/jcm9061860] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
79 Krug S, Weissbach J, Blank A, Perren A, Haybaeck J, Fendrich V, Rinke A, Gress TM, Rosendahl J, Michl P. CUX1-Transcriptional Master Regulator of Tumor Progression in Pancreatic Neuroendocrine Tumors. Cancers (Basel) 2020;12:E1957. [PMID: 32707646 DOI: 10.3390/cancers12071957] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
80 Holmager P, Willemoe GL, Nielsen K, Grøndahl V, Klose M, Andreassen M, Langer SW, Hansen CP, Kjær A, Federspiel BH, Knigge U. Neuroendocrine neoplasms of the appendix: Characterization of 335 patients referred to the Copenhagen NET Center of Excellence. Eur J Surg Oncol 2021;47:1357-63. [PMID: 33589240 DOI: 10.1016/j.ejso.2021.02.005] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
81 Awe AM, Rendell VR, Lubner MG, Winslow ER. Texture Analysis: An Emerging Clinical Tool for Pancreatic Lesions. Pancreas 2020;49:301-12. [PMID: 32168248 DOI: 10.1097/MPA.0000000000001495] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
82 Minon M, Soriano C, Morland D, Walter T, Lepage C, Tabarin A, Deblock M, Rousset P, Barbe C, Hoeffel C, Cadiot G. Prospective comparison of whole-body MRI with diffusion-weighted and conventional imaging for the follow-up of neuroendocrine tumors. Endocrine 2020;67:243-51. [DOI: 10.1007/s12020-019-02095-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
83 Vitali E, Piccini S, Trivellin G, Smiroldo V, Lavezzi E, Zerbi A, Pepe G, Lania AG. The impact of SST2 trafficking and signaling in the treatment of pancreatic neuroendocrine tumors. Mol Cell Endocrinol 2021;527:111226. [PMID: 33675866 DOI: 10.1016/j.mce.2021.111226] [Reference Citation Analysis]
84 Herrera-Martínez AD, Gahete MD, Sánchez-Sánchez R, Alors-Perez E, Pedraza-Arevalo S, Serrano-Blanch R, Martínez-Fuentes AJ, Gálvez-Moreno MA, Castaño JP, Luque RM. Ghrelin-O-Acyltransferase (GOAT) Enzyme as a Novel Potential Biomarker in Gastroenteropancreatic Neuroendocrine Tumors. Clin Transl Gastroenterol 2018;9:196. [PMID: 30297816 DOI: 10.1038/s41424-018-0058-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
85 Di Domenico A, Wiedmer T, Marinoni I, Perren A. Genetic and epigenetic drivers of neuroendocrine tumours (NET). Endocr Relat Cancer 2017;24:R315-34. [PMID: 28710117 DOI: 10.1530/ERC-17-0012] [Cited by in Crossref: 47] [Cited by in F6Publishing: 28] [Article Influence: 11.8] [Reference Citation Analysis]
86 Refardt J, Hofland J, Wild D, Christ E. New Directions in Imaging Neuroendocrine Neoplasms. Curr Oncol Rep 2021;23:143. [PMID: 34735669 DOI: 10.1007/s11912-021-01139-2] [Reference Citation Analysis]
87 Gangi A, Howe JR. The Landmark Series: Neuroendocrine Tumor Liver Metastases. Ann Surg Oncol 2020;27:3270-80. [PMID: 32632880 DOI: 10.1245/s10434-020-08787-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
88 Cuthbertson DJ, Barriuso J, Lamarca A, Manoharan P, Westwood T, Jaffa M, Fenwick SW, Nuttall C, Lalloo F, Prachalias A, Pizanias M, Wieshmann H, McNamara MG, Hubner R, Srirajaskanthan R, Vivian G, Ramage J, Weickert MO, Pritchard DM, Vinjamuri S, Valle J, Yip VS. The Impact of 68Gallium DOTA PET/CT in Managing Patients With Sporadic and Familial Pancreatic Neuroendocrine Tumours. Front Endocrinol (Lausanne) 2021;12:654975. [PMID: 34163434 DOI: 10.3389/fendo.2021.654975] [Reference Citation Analysis]
89 Sheikhbahaei S, Sadaghiani MS, Rowe SP, Solnes LB. Neuroendocrine Tumor Theranostics: An Update and Emerging Applications in Clinical Practice. AJR Am J Roentgenol 2021;217:495-506. [PMID: 34076455 DOI: 10.2214/AJR.20.23349] [Reference Citation Analysis]
90 Chan H, Zhang L, Choti MA, Kulke M, Yao JC, Nakakura EK, Bloomston M, Benson AB, Shah MH, Strosberg JR, Bergsland EK, Van Loon K. Recurrence Patterns After Surgical Resection of Gastroenteropancreatic Neuroendocrine Tumors: Analysis From the National Comprehensive Cancer Network Oncology Outcomes Database. Pancreas 2021;50:506-12. [PMID: 33939661 DOI: 10.1097/MPA.0000000000001791] [Reference Citation Analysis]
91 Milione M, Fazio N. G3 GEP NENs category: are basic and clinical investigations well integrated? Endocrine 2018;60:28-30. [DOI: 10.1007/s12020-017-1365-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
92 Wen J, Chen J, Chen D, Liu D, Xu X, Huang L, Cao J, Zhang J, Gu Y, Fan M, Chen Y. Evaluation of the prognostic value of surgery and postoperative radiotherapy for patients with thymic neuroendocrine tumors: A propensity-matched study based on the SEER database. Thorac Cancer 2018;9:1603-13. [PMID: 30276969 DOI: 10.1111/1759-7714.12868] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
93 Iwaya H, Fukukura Y, Hashimoto S, Tanoue S, Kawahira M, Hinokuchi M, Fujita T, Komaki Y, Arima S, Sasaki F, Kanmura S, Higashi M, Tamada K, Ido A. Prognostic significance of extracellular volume fraction with equilibrium contrast-enhanced computed tomography for pancreatic neuroendocrine neoplasms. Pancreatology 2021;21:779-86. [PMID: 33714670 DOI: 10.1016/j.pan.2021.02.020] [Reference Citation Analysis]
94 Dermine S, Palmieri LJ, Lavolé J, Barré A, Dohan A, Abou Ali E, Cottereau AS, Gaujoux S, Brezault C, Chaussade S, Coriat R. Non-Pharmacological Therapeutic Options for Liver Metastases in Advanced Neuroendocrine Tumors.J Clin Med. 2019;8. [PMID: 31703375 DOI: 10.3390/jcm8111907] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
95 Wang Z, Cheng S, Zhou F, Han X, Lu X, Sun D, Zhang X. [Systemic Therapy for Low-grade Pulmonary Neuroendocrine Tumor]. Zhongguo Fei Ai Za Zhi 2019;22:34-9. [PMID: 30674391 DOI: 10.3779/j.issn.1009-3419.2019.01.07] [Reference Citation Analysis]
96 Bonet I, Sanchez-Cabús S, González JA, Moral A. Non-functioning neuroendocrine tumor retrograde. Gastroenterol Hepatol 2021;44:495-6. [PMID: 33172695 DOI: 10.1016/j.gastrohep.2020.07.017] [Reference Citation Analysis]
97 Ahmadi Bidakhvidi N, Cuyle PJ, Sagaert X, Ballaux F, Deroose CM. 68Ga-DOTATATE PET/CT Distinguishes Neuroendocrine Tumor Mesenteric Lymph Node Metastasis From an Extensive IgG4-Positive Fibrosis Surrounding It. Clin Nucl Med 2021;46:e510-2. [PMID: 34034320 DOI: 10.1097/RLU.0000000000003722] [Reference Citation Analysis]
98 Pea A, Tanno L, Nykänen T, Prasad P, Tunçer C, Robinson S, Marchegiani G. Comparison of Oncological and Surgical Outcomes Between Formal Pancreatic Resections and Parenchyma-Sparing Resections for Small PanNETs (<2 cm): Pancreas2000 Research and Educational Program (Course 9) Study Protocol. Front Med (Lausanne) 2020;7:559. [PMID: 33015105 DOI: 10.3389/fmed.2020.00559] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
99 Wang XY, Chai NL, Linghu EQ, Li HK, Zhai YQ, Feng XX, Zhang WG, Zou JL, Li LS, Xiang JY. Efficacy and safety of hybrid endoscopic submucosal dissection compared with endoscopic submucosal dissection for rectal neuroendocrine tumors and risk factors associated with incomplete endoscopic resection. Ann Transl Med 2020;8:368. [PMID: 32355812 DOI: 10.21037/atm.2020.02.25] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
100 Kaçmaz E, Chen JW, Tanis PJ, Nieveen van Dijkum EJM, Engelsman AF. Postoperative morbidity and mortality after surgical resection of small bowel neuroendocrine neoplasms: A systematic review and meta-analysis. J Neuroendocrinol 2021;33:e13008. [PMID: 34235792 DOI: 10.1111/jne.13008] [Reference Citation Analysis]
101 Kiritani S, Arita J, Matsumura M, Nishioka Y, Kudo H, Ichida A, Ishizawa T, Akamatsu N, Kaneko J, Hasegawa K. Repeat hepatectomy for patients with recurrent neuroendocrine liver metastasis: Comparison with first hepatectomy. Surgery 2020;167:404-9. [DOI: 10.1016/j.surg.2019.08.020] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
102 Yu S, Hornick JL, Gonzalez RS. An algorithmic approach utilizing CK7, TTF1, beta-catenin, CDX2, and SSTR2A can help differentiate between gastrointestinal and pulmonary neuroendocrine carcinomas. Virchows Arch 2021. [PMID: 33733343 DOI: 10.1007/s00428-021-03085-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
103 Al-Toubah T, Schell MJ, Cives M, Zhou JM, Soares HP, Strosberg JR. A Phase II Study of Ibrutinib in Advanced Neuroendocrine Neoplasms. Neuroendocrinology 2020;110:377-83. [PMID: 31357193 DOI: 10.1159/000502383] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
104 Alnimri F, Ng MW, Modak P. Rectal carcinoid tumour presenting as polyp: a challenge in management in rural settings. ANZ J Surg 2021;91:1318-9. [PMID: 34121291 DOI: 10.1111/ans.16857] [Reference Citation Analysis]
105 Koumarianou A, Kaltsas GA, Chatzellis E, Kyriakopoulos G, Kolomodi D, Alexandraki KI. Immunotherapeutics at the spearhead: current status in targeting neuroendocrine neoplasms. Endocrine 2021;73:232-9. [PMID: 33544352 DOI: 10.1007/s12020-021-02639-8] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
106 Saadeh H, Abdullah N, Erashdi M, Sughayer M, Al-Kadi O. Histopathologist-level quantification of Ki-67 immunoexpression in gastroenteropancreatic neuroendocrine tumors using semiautomated method. J Med Imaging (Bellingham) 2020;7:012704. [PMID: 31824983 DOI: 10.1117/1.JMI.7.1.012704] [Reference Citation Analysis]
107 Vitali E, Boemi I, Piccini S, Tarantola G, Smiroldo V, Lavezzi E, Brambilla T, Zerbi A, Carnaghi C, Mantovani G, Spada A, Lania AG. A novel insight into the anticancer mechanism of metformin in pancreatic neuroendocrine tumor cells. Mol Cell Endocrinol 2020;509:110803. [PMID: 32251713 DOI: 10.1016/j.mce.2020.110803] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
108 Chen KS, Lawhn-Heath C, Behr S, Juarez R, Whitman J, Paciorek A, Nakakura EK, Fidelman N, Feng MU, Bergsland EK, Anwar M. Outcomes after high-dose radiation in the management of neuroendocrine neoplasms. PLoS One 2021;16:e0252574. [PMID: 34077464 DOI: 10.1371/journal.pone.0252574] [Reference Citation Analysis]
109 Galgano SJ, Wei B, Rose JB. PET Imaging of Neuroendocrine Tumors. Radiol Clin North Am 2021;59:789-99. [PMID: 34392919 DOI: 10.1016/j.rcl.2021.05.006] [Reference Citation Analysis]
110 Kessler J, Singh G, Ituarte PHG, Allen R, Chang S, Li D. A Comparison of Liver-Directed Therapy and Systemic Therapy for the Treatment of Liver Metastases in Patients with Gastrointestinal Neuroendocrine Tumors: Analysis of the California Cancer Registry. J Vasc Interv Radiol 2021;32:393-402. [PMID: 33358144 DOI: 10.1016/j.jvir.2020.10.019] [Reference Citation Analysis]
111 Caplin M. The recent European approval of lutetium ( 177 Lu) oxodotreotide increases treatment options for gastroenteropancreatic neuroendocrine tumors. International Journal of Endocrine Oncology 2018;5:IJE09. [DOI: 10.2217/ije-2018-0002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
112 Xia Y, Zhang L, Wu H, Qiao L, Xia L. Primary hepatic neuroendocrine tumor with multiple liver metastases: A case report with literature review. J Int Med Res 2020;48:300060520932114. [PMID: 32589085 DOI: 10.1177/0300060520932114] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
113 Johnston ME 2nd, Carter MM, Wilson GC, Ahmad SA, Patel SH. Surgical management of primary pancreatic neuroendocrine tumors. J Gastrointest Oncol 2020;11:578-89. [PMID: 32655937 DOI: 10.21037/jgo.2019.12.09] [Reference Citation Analysis]
114 Gibbs J, Mei S, Economos K, Lee YC, Kanis MJ. Clinicopathologic features, incidence, and survival trends of gynecologic neuroendocrine tumors: a SEER database analysis. Am J Obstet Gynecol 2019;221:53.e1-6. [PMID: 30849352 DOI: 10.1016/j.ajog.2019.02.052] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
115 Ni K, Yang JY, Baeg K, Leiter AC, Mhango G, Gallagher EJ, Wisnivesky JP, Kim MK. Association between somatostatin analogues and diabetes mellitus in gastroenteropancreatic neuroendocrine tumor patients: A Surveillance, Epidemiology, and End Results-Medicare analysis of 5235 patients. Cancer Rep (Hoboken) 2021;:e1387. [PMID: 33835729 DOI: 10.1002/cnr2.1387] [Reference Citation Analysis]
116 Butler OL, Mekhael MM, Ahmed A, Cuthbertson DJ, Pritchard DM. Frequency and Causes of False-Positive Elevated Plasma Concentrations of Fasting Gut Hormones in a Specialist Neuroendocrine Tumor Center. Front Endocrinol (Lausanne) 2020;11:606264. [PMID: 33391185 DOI: 10.3389/fendo.2020.606264] [Reference Citation Analysis]
117 Gallo M, Ruggeri RM, Muscogiuri G, Pizza G, Faggiano A, Colao A; NIKE Group. Diabetes and pancreatic neuroendocrine tumours: Which interplays, if any? Cancer Treat Rev 2018;67:1-9. [PMID: 29746922 DOI: 10.1016/j.ctrv.2018.04.013] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
118 O'Dorisio TM, Harris AG, O'Dorisio MS. Evolution of Neuroendocrine Tumor Therapy. Surg Oncol Clin N Am 2020;29:145-63. [PMID: 32151353 DOI: 10.1016/j.soc.2019.11.002] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
119 Krug S, Garbe J, König S, Ungewiss H, Michl P, Rinke A, Schrader J. Professional Assessment of the Impact of COVID-19 on Handling NET Patients. J Clin Med 2020;9:E3633. [PMID: 33187393 DOI: 10.3390/jcm9113633] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
120 Paganelli G, Sansovini M, Nicolini S, Grassi I, Ibrahim T, Amadori E, Di Iorio V, Monti M, Scarpi E, Bongiovanni A, Altini M, Urso L, Cittanti C, Matteucci F, Severi S. 177Lu-PRRT in advanced gastrointestinal neuroendocrine tumors: 10-year follow-up of the IRST phase II prospective study. Eur J Nucl Med Mol Imaging 2021;48:152-60. [PMID: 32472437 DOI: 10.1007/s00259-020-04873-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
121 Shi H, Jiang C, Zhang Q, Qi C, Yao H, Lin R. Clinicopathological heterogeneity between primary and metastatic sites of gastroenteropancreatic neuroendocrine neoplasm. Diagn Pathol 2020;15:108. [PMID: 32917216 DOI: 10.1186/s13000-020-01030-x] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
122 Scalorbi F, Argiroffi G, Baccini M, Gherardini L, Fuoco V, Prinzi N, Pusceddu S, Garanzini EM, Centonze G, Kirienko M, Seregni E, Milione M, Maccauro M. Application of FLIC model to predict adverse events onset in neuroendocrine tumors treated with PRRT. Sci Rep 2021;11:19490. [PMID: 34593940 DOI: 10.1038/s41598-021-99048-8] [Reference Citation Analysis]
123 Sappenfield R, Gonzalez IA, Cao D, Chatterjee D. Well-differentiated rectal neuroendocrine tumors: analysis of histology, including insulinoma-associated protein 1 expression, and biologic behavior, involving a large cohort of 94 cases. Hum Pathol 2020;104:66-72. [PMID: 32763255 DOI: 10.1016/j.humpath.2020.07.021] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
124 Mirvis E, Toumpanakis C, Mandair D, Gnanasegaran G, Caplin M, Navalkissoor S. Efficacy and tolerability of peptide receptor radionuclide therapy (PRRT) in advanced metastatic bronchial neuroendocrine tumours (NETs). Lung Cancer 2020;150:70-5. [DOI: 10.1016/j.lungcan.2020.10.005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
125 Delbeke D, Newman G, Deppen S, Shah C, Ndolo J, Shi C, Bailey CE, Jessop AC, Sandler MP. 68Ga-DOTATATE: Significance of Uptake in the Tail of the Pancreas in Patients Without Lesions. Clin Nucl Med 2019;44:851-4. [PMID: 31524686 DOI: 10.1097/RLU.0000000000002757] [Reference Citation Analysis]
126 Sigfridsson J, Lindström E, Iyer V, Holstensson M, Velikyan I, Sundin A, Lubberink M. Prospective data-driven respiratory gating of [68Ga]Ga-DOTATOC PET/CT. EJNMMI Res 2021;11:33. [PMID: 33788025 DOI: 10.1186/s13550-021-00775-w] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
127 Fields AC, Mccarty JC, Lu P, Vierra BM, Pak LM, Irani J, Goldberg JE, Bleday R, Chan J, Melnitchouk N. Colon Neuroendocrine Tumors: A New Lymph Node Staging Classification. Ann Surg Oncol 2019;26:2028-36. [DOI: 10.1245/s10434-019-07327-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
128 Hasegawa S, Kobayashi N, Okubo N, Tokuhisa M, Goto A, Kurita Y, Sato T, Hosono K, Endo I, Nakajima A, Ichikawa Y. Pathological Findings of the Host Immune Reaction in the Tumor Microenvironment of Gastroenteropancreatic Neuroendocrine Neoplasms. Intern Med 2021;60:977-83. [PMID: 33162477 DOI: 10.2169/internalmedicine.5648-20] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
129 Folkert IW, Sinnamon AJ, Concors SJ, Bennett BJ, Fraker DL, Mahmoud NN, Metz DC, Stashek KM, Roses RE. Grade is a Dominant Risk Factor for Metastasis in Patients with Rectal Neuroendocrine Tumors. Ann Surg Oncol 2020;27:855-63. [DOI: 10.1245/s10434-019-07848-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
130 Imam R, Chang Q, Black M, Yu C, Cao W. CD47 expression and CD163+ macrophages correlated with prognosis of pancreatic neuroendocrine tumor. BMC Cancer 2021;21:320. [PMID: 33765961 DOI: 10.1186/s12885-021-08045-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
131 Vida Navas EM, Martínez Lorca A, Sancho Gutiérrez A, Sanz Gómez L, Navarro Martínez T, Grande Pulido E, Carrato Mena A, Gajate Borau P. Case Report: Re-Treatment With Lu-DOTATATE in Neuroendocrine Tumors. Front Endocrinol (Lausanne) 2021;12:676973. [PMID: 33935979 DOI: 10.3389/fendo.2021.676973] [Reference Citation Analysis]
132 Kaçmaz E, Sarasqueta AF, van Eeden S, Dreijerink KMA, Klümpen HJ, Tanis PJ, van Dijkum EJMN, Engelsman AF. Update on Incidence, Prevalence, Treatment and Survival of Patients with Small Bowel Neuroendocrine Neoplasms in the Netherlands. World J Surg 2021;45:2482-91. [PMID: 33895862 DOI: 10.1007/s00268-021-06119-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
133 Lamarca A, Clouston H, Barriuso J, McNamara MG, Frizziero M, Mansoor W, Hubner RA, Manoharan P, O'Dwyer S, Valle JW. Follow-Up Recommendations after Curative Resection of Well-Differentiated Neuroendocrine Tumours: Review of Current Evidence and Clinical Practice. J Clin Med 2019;8:E1630. [PMID: 31590343 DOI: 10.3390/jcm8101630] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
134 Andre A, Squittieri N, Patil SB. Evaluation of the Octreotide Acetate Pen Injector and its Instructions for Use in a Formative Human Factors Study. Adv Ther 2021;38:3129-42. [PMID: 33948925 DOI: 10.1007/s12325-021-01739-1] [Reference Citation Analysis]
135 Jin XF, Spoettl G, Maurer J, Nölting S, Auernhammer CJ. Inhibition of Wnt/β-Catenin Signaling in Neuroendocrine Tumors in vitro: Antitumoral Effects. Cancers (Basel) 2020;12:E345. [PMID: 32033025 DOI: 10.3390/cancers12020345] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 9.0] [Reference Citation Analysis]
136 Baeg K, Harris C, Naparst MS, Ahn E, Thapi S, Martin J, Rustgi S, Mhango G, Wisnivesky J, Kim MK. Effect of treatment center volume on outcomes in gastroenteropancreatic neuroendocrine tumor patients. BMC Cancer 2021;21:146. [PMID: 33563241 DOI: 10.1186/s12885-021-07868-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
137 Berner AM, Pipinikas C, Ryan A, Dibra H, Moghul I, Webster A, Luong TV, Thirlwell C. Diagnostic Approaches to Neuroendocrine Neoplasms of Unknown Primary Site. Neuroendocrinology 2020;110:563-73. [PMID: 31658461 DOI: 10.1159/000504370] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
138 Maharjan CK, Ear PH, Tran CG, Howe JR, Chandrasekharan C, Quelle DE. Pancreatic Neuroendocrine Tumors: Molecular Mechanisms and Therapeutic Targets. Cancers (Basel) 2021;13:5117. [PMID: 34680266 DOI: 10.3390/cancers13205117] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
139 Zhou YJ, Wang QW, Zhang QW, Chen JN, Wang XY, Gao YJ, Li XB. Patterns of Lymph Node Metastasis in Patients With T1/T2 Gastroduodenal Neuroendocrine Neoplasms: Implications for Endoscopic Treatment. Front Endocrinol (Lausanne) 2021;12:658392. [PMID: 34122337 DOI: 10.3389/fendo.2021.658392] [Reference Citation Analysis]
140 Tian FX, Cai YQ, Zhuang LP, Chen MF, Xiu ZB, Zhang Y, Liu H, Liu ZH, Liu GP, Zeng C, Lin FL, Liu J, Huang ST, Zhang LZ, Lin HY. Clinicopathological features and prognosis of patients with gastric neuroendocrine tumors: A population-based study. Cancer Med. 2018;7:5359-5369. [PMID: 30311450 DOI: 10.1002/cam4.1683] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
141 Vijayvergia N, Dasari A. Targeted Therapies in the Management of Well-Differentiated Digestive and Lung Neuroendocrine Neoplasms. Curr Treat Options Oncol 2020;21:96. [PMID: 33029680 DOI: 10.1007/s11864-020-00794-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
142 Mintziras I, Keck T, Werner J, Fichtner-Feigl S, Wittel U, Senninger N, Vowinkel T, Köninger J, Anthuber M, Geißler B, Bartsch DK; StuDoQ|Pancreas Study Group of the German Society for General, Visceral Surgery (DGAV). Indications for resection and perioperative outcomes of surgery for pancreatic neuroendocrine neoplasms in Germany: an analysis of the prospective DGAV StuDoQ|Pancreas registry. Surg Today 2019;49:1013-21. [PMID: 31240463 DOI: 10.1007/s00595-019-01838-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
143 Bongiovanni A, Liverani C, Recine F, Fausti V, Mercatali L, Vagheggini A, Spadazzi C, Miserocchi G, Cocchi C, Di Menna G, De Vita A, Severi S, Nicolini S, Ibrahim T. Phase-II Trials of Pazopanib in Metastatic Neuroendocrine Neoplasia (mNEN): A Systematic Review and Meta-Analysis. Front Oncol 2020;10:414. [PMID: 32318336 DOI: 10.3389/fonc.2020.00414] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
144 Scott AT, Pelletier D, Maxwell JE, Sherman SK, Keck KJ, Li G, Dillon JS, O'Dorisio TM, Bellizzi AM, Howe JR. The Pancreas as a Site of Metastasis or Second Primary in Patients with Small Bowel Neuroendocrine Tumors. Ann Surg Oncol 2019;26:2525-32. [PMID: 31011904 DOI: 10.1245/s10434-019-07370-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
145 Ghobrial SN, Menda Y, Zamba GK, Mott SL, Gaimari-Varner K, Dick D, Dillon J, Howe JR, Graham M, Sunderland J, Bellizzi A, O'Dorisio TM, O'Dorisio MS. Prospective Analysis of the Impact of 68Ga-DOTATOC Positron Emission Tomography-Computerized Axial Tomography on Management of Pancreatic and Small Bowel Neuroendocrine Tumors. Pancreas 2020;49:1033-6. [PMID: 32769854 DOI: 10.1097/MPA.0000000000001625] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
146 Chen J, Yang Y, Liu Y, Kan H. Prognosis analysis of patients with pancreatic neuroendocrine tumors after surgical resection and the application of enucleation. World J Surg Oncol 2021;19:11. [PMID: 33436017 DOI: 10.1186/s12957-020-02115-z] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
147 Thomasian NM, Kamel IR, Bai HX. Machine intelligence in non-invasive endocrine cancer diagnostics. Nat Rev Endocrinol 2021. [PMID: 34754064 DOI: 10.1038/s41574-021-00543-9] [Reference Citation Analysis]
148 Kim J, Kim J, Oh EH, Ham NS, Hwang SW, Park SH, Ye BD, Byeon JS, Myung SJ, Yang SK, Hong SM, Yang DH. Anchoring the snare tip is a feasible endoscopic mucosal resection method for small rectal neuroendocrine tumors. Sci Rep 2021;11:12918. [PMID: 34155319 DOI: 10.1038/s41598-021-92462-y] [Reference Citation Analysis]
149 Cloyd JM, Ejaz A, Konda B, Makary MS, Pawlik TM. Neuroendocrine liver metastases: a contemporary review of treatment strategies.Hepatobiliary Surg Nutr. 2020;9:440-451. [PMID: 32832495 DOI: 10.21037/hbsn.2020.04.02] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
150 Cataldi C, Cerasari S, Poillucci G, Capaldi M, Scocchera F, Trombetta S, Fransvea P, Mazzarella-Farao R, Marini P. Metastatic retroperitoneal tumor from a non-functional neuroendocrine neoplasia of the left ethmoid-nose-orbitary region: Case report and short review of literature. Int J Surg Case Rep 2020;66:169-73. [PMID: 31862660 DOI: 10.1016/j.ijscr.2019.12.001] [Reference Citation Analysis]
151 Benson AB 3rd, Strosberg J, Joish VN, Dharba S, Sapre D, Lapuerta P. Clinical Benefits of Telotristat Ethyl in Patients With Neuroendocrine Tumors and Low Bowel Movement Frequency: An Observational Patient-Reported Outcomes Study. Pancreas 2020;49:408-12. [PMID: 32132510 DOI: 10.1097/MPA.0000000000001496] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
152 Wong L, Kanthasamy SV, Durairaj G, Thangaratnam RR. Neuroendocrine tumour masquerading as intussusception: A case report. Int J Surg Case Rep 2020;77:48-52. [PMID: 33137672 DOI: 10.1016/j.ijscr.2020.10.091] [Reference Citation Analysis]
153 Yuan B, Shi Y, Li Y, Tan H, Jiao P, Su W, Liu M, Qi Z, Tan H, Luo J. Ki-67 index of 5% could better predict the clinical prognosis of well-differentiated pancreatic neuroendocrine tumours. Jpn J Clin Oncol 2021:hyab144. [PMID: 34580725 DOI: 10.1093/jjco/hyab144] [Reference Citation Analysis]
154 Tirosh A, Killian JK, Petersen D, Zhu YJ, Walker RL, Blau JE, Nilubol N, Patel D, Agarwal SK, Weinstein LS, Meltzer P, Kebebew E. Distinct DNA Methylation Signatures in Neuroendocrine Tumors Specific for Primary Site and Inherited Predisposition. J Clin Endocrinol Metab 2020;105:dgaa477. [PMID: 32706863 DOI: 10.1210/clinem/dgaa477] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
155 Alevroudis E, Spei ME, Chatziioannou SN, Tsoli M, Wallin G, Kaltsas G, Daskalakis K. Clinical Utility of 18F-FDG PET in Neuroendocrine Tumors Prior to Peptide Receptor Radionuclide Therapy: A Systematic Review and Meta-Analysis. Cancers (Basel) 2021;13:1813. [PMID: 33920195 DOI: 10.3390/cancers13081813] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
156 Tanno L, Mayo D, Mills S, Takhar A, Cave J, Nolan L, Stedman B, Sundram FX, Abu Hilal M, Connor H, Pearce N, Armstrong T. Proactive multi-modality treatment of Pancreatic Neuroendocrine Tumours (PNETs): Potential survival benefits. Pancreatology 2018;18:304-12. [PMID: 29433805 DOI: 10.1016/j.pan.2017.12.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
157 Mayer K, Kiry S, Yordanova A, Ahmadzadehfar H, Gaertner FC, Bundschuh RA, Essler M, Gonzalez-Carmona MA, Strassburg CP, Matthaei H, Lingohr P, Bisht S, Brossart P, Feldmann G. Systemic Therapy of Neuroendocrine Neoplasia: Single Center Experience from a Cohort of 110 Consecutive Cases. Int J Endocrinol 2020;2020:1491475. [PMID: 32089680 DOI: 10.1155/2020/1491475] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
158 Yang L, Yu X, Yang Y. Autotaxin upregulated by STAT3 activation contributes to invasion in pancreatic neuroendocrine neoplasms. Endocr Connect 2018;7:1299-307. [PMID: 30352421 DOI: 10.1530/EC-18-0356] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
159 Martini I, Polici M, Zerunian M, Panzuto F, Rinzivillo M, Landolfi F, Magi L, Caruso D, Eid M, Annibale B, Laghi A, Iannicelli E. CT texture analysis of liver metastases in PNETs versus NPNETs: Correlation with histopathological findings. Eur J Radiol 2020;124:108812. [PMID: 31951893 DOI: 10.1016/j.ejrad.2020.108812] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
160 Boyar Cetinkaya R, Aagnes B, Myklebust TÅ, Thiis-Evensen E. Survival in neuroendocrine neoplasms; A report from a large Norwegian population-based study. Int J Cancer 2018;142:1139-47. [PMID: 29082524 DOI: 10.1002/ijc.31137] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
161 Mrzljak A, Kocman B, Skrtic A, Furac I, Popic J, Franusic L, Zunec R, Mayer D, Mikulic D. Liver re-transplantation for donor-derived neuroendocrine tumor: A case report. World J Clin Cases 2019; 7(18): 2794-2801 [PMID: 31616694 DOI: 10.12998/wjcc.v7.i18.2794] [Reference Citation Analysis]
162 Huynh L, Cai B, Cheng M, Lax A, Lejeune D, Duh MS, Kim MK. Analysis of Real-World Treatment Patterns, Healthcare Resource Utilization, and Costs Between Octreotide and Lanreotide Among Patients With Neuroendocrine Tumors. Pancreas 2019;48:1126-35. [DOI: 10.1097/mpa.0000000000001403] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
163 Zhang T, Choi S, Zhang T, Chen Z, Chi Y, Huang S, Xiang JZ, Du YN. miR-431 Promotes Metastasis of Pancreatic Neuroendocrine Tumors by Targeting DAB2 Interacting Protein, a Ras GTPase Activating Protein Tumor Suppressor. Am J Pathol 2020;190:689-701. [PMID: 31953039 DOI: 10.1016/j.ajpath.2019.11.007] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
164 Uri I, Grozinsky-Glasberg S. Current treatment strategies for patients with advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Clin Diabetes Endocrinol. 2018;4:16. [PMID: 30009041 DOI: 10.1186/s40842-018-0066-3] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 8.0] [Reference Citation Analysis]
165 Starr JS, Sonbol MB, Hobday TJ, Sharma A, Kendi AT, Halfdanarson TR. Peptide Receptor Radionuclide Therapy for the Treatment of Pancreatic Neuroendocrine Tumors: Recent Insights. Onco Targets Ther. 2020;13:3545-3555. [PMID: 32431509 DOI: 10.2147/ott.s202867] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
166 Johansson J, Andersson RE, Landerholm K, Redéen S. Incidence of Appendiceal Malignancies in Sweden Between 1970 and 2012. World J Surg 2020;44:4086-92. [PMID: 32885316 DOI: 10.1007/s00268-020-05758-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
167 Kjaer J, Stålberg P, Crona J, Welin S, Hellman P, Thornell A, Norlen O. Long-term outcome after resection and thermal hepatic ablation of pancreatic neuroendocrine tumour liver metastases. BJS Open 2021;5:zrab062. [PMID: 34291287 DOI: 10.1093/bjsopen/zrab062] [Reference Citation Analysis]
168 Ewang-emukowhate M, Nair D, Caplin M. The role of 5-hydroxyindoleacetic acid in neuroendocrine tumors: the journey so far. International Journal of Endocrine Oncology 2019;6:IJE17. [DOI: 10.2217/ije-2019-0001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
169 Yan J, Yu S, Jia C, Li M, Chen J. Molecular subtyping in pancreatic neuroendocrine neoplasms: New insights into clinical, pathological unmet needs and challenges. Biochim Biophys Acta Rev Cancer 2020;1874:188367. [PMID: 32339609 DOI: 10.1016/j.bbcan.2020.188367] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
170 Huang J, Chen J, Xu M, Zheng Y, Lin M, Huang G, Xie X, Xie X. Contrast-Enhanced Ultrasonography Findings Correlate with Pathologic Grades of Pancreatic Neuroendocrine Tumors. Ultrasound Med Biol 2021;47:2097-106. [PMID: 33934943 DOI: 10.1016/j.ultrasmedbio.2021.02.013] [Reference Citation Analysis]
171 Zheng Z, Chen C, Li B, Liu H, Zhou L, Zhang H, Zheng C, He X, Liu W, Hong T, Zhao Y. Biliary Neuroendocrine Neoplasms: Clinical Profiles, Management, and Analysis of Prognostic Factors. Front Oncol. 2019;9:38. [PMID: 30805307 DOI: 10.3389/fonc.2019.00038] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
172 Twito O, Paran H, Avital S, Kravtsov V, Rosenblum RC, Rotman-Pikielny P, Klein N. Temporal trends in incidence, evaluation and management of neuroendocrine neoplasms of the appendix: 14 years' experience. Am J Surg 2021;221:1000-4. [PMID: 33004142 DOI: 10.1016/j.amjsurg.2020.09.021] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
173 Kolarova T, Bouvier C. The Role of Patient Support Groups in Neuroendocrine Neoplasms. Curr Oncol Rep 2021;23:53. [PMID: 33754245 DOI: 10.1007/s11912-021-01046-6] [Reference Citation Analysis]
174 Weilin M, Xu H, Yang L, Wenqi C, Huanyu W, Wentao Z, Dayong J, Wenchuan W, Dansong W, Tiantao K, Lei Z, Wenhui L, Xuefeng X. Propensity score-matched analysis of clinical outcome after enucleation versus regular pancreatectomy in patients with small non-functional pancreatic neuroendocrine tumors. Pancreatology. 2020;20:169-176. [PMID: 31941586 DOI: 10.1016/j.pan.2019.12.007] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
175 Chakedis J, Beal EW, Lopez-aguiar AG, Poultsides G, Makris E, Rocha FG, Kanji Z, Weber S, Fisher A, Fields R, Krasnick BA, Idrees K, Marincola-smith P, Cho C, Beems M, Pawlik TM, Maithel SK, Schmidt CR, Dillhoff M. Surgery Provides Long-Term Survival in Patients with Metastatic Neuroendocrine Tumors Undergoing Resection for Non-Hormonal Symptoms. J Gastrointest Surg 2019;23:122-34. [DOI: 10.1007/s11605-018-3986-4] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
176 Zhang P, Li J, Li J, Zhang X, Zhou J, Wang X, Peng Z, Shen L, Lu M. Etoposide and cisplatin versus irinotecan and cisplatin as the first-line therapy for patients with advanced, poorly differentiated gastroenteropancreatic neuroendocrine carcinoma: A randomized phase 2 study. Cancer 2020;126 Suppl 9:2086-92. [PMID: 32293725 DOI: 10.1002/cncr.32750] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 10.0] [Reference Citation Analysis]
177 Herrera-Martínez AD, Hofland J, Hofland LJ, Brabander T, Eskens FALM, Gálvez Moreno MA, Luque RM, Castaño JP, de Herder WW, Feelders RA. Targeted Systemic Treatment of Neuroendocrine Tumors: Current Options and Future Perspectives. Drugs 2019;79:21-42. [PMID: 30560479 DOI: 10.1007/s40265-018-1033-0] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 11.0] [Reference Citation Analysis]
178 Zhong Q, Chen QY, Xie JW, Wang JB, Lin JX, Lu J, Cao LL, Lin M, Tu RH, Huang ZN, Lin JL, Li P, Zheng CH, Huang CM. Incidence trend and conditional survival estimates of gastroenteropancreatic neuroendocrine tumors: A large population-based study. Cancer Med. 2018;7:3521-3533. [PMID: 29873204 DOI: 10.1002/cam4.1598] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.7] [Reference Citation Analysis]
179 Chen HY, Zhang XY, Deng XY, Ge YL, Tang YQ, Cui H, Yang B, Pan Y, Shi D, Yu RS. Grade 3 Pancreatic Neuroendocrine Tumors on MDCT: Establishing a Diagnostic Model and Comparing Survival Against Pancreatic Ductal Adenocarcinoma. AJR Am J Roentgenol 2020;215:390-7. [PMID: 32432906 DOI: 10.2214/AJR.19.21921] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
180 van Treijen MJC, Korse CM, van Leeuwaarde RS, Saveur LJ, Vriens MR, Verbeek WHM, Tesselaar MET, Valk GD. Blood Transcript Profiling for the Detection of Neuroendocrine Tumors: Results of a Large Independent Validation Study. Front Endocrinol (Lausanne) 2018;9:740. [PMID: 30564197 DOI: 10.3389/fendo.2018.00740] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 8.0] [Reference Citation Analysis]
181 Laing E, Kiss N, Michael M, Gough K, Krishnasamy M. Investigating Nutrition-Related Complications and Quality of Life in Patients With Gastroenteropancreatic Neuroendocrine Tumors: Protocol for a Mixed-Methods Prospective Study. JMIR Res Protoc 2018;7:e11228. [PMID: 30567691 DOI: 10.2196/11228] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
182 Rudisile S, Gosewisch A, Wenter V, Unterrainer M, Böning G, Gildehaus FJ, Fendler WP, Auernhammer CJ, Spitzweg C, Bartenstein P, Todica A, Ilhan H. Salvage PRRT with 177Lu-DOTA-octreotate in extensively pretreated patients with metastatic neuroendocrine tumor (NET): dosimetry, toxicity, efficacy, and survival. BMC Cancer 2019;19:788. [PMID: 31395036 DOI: 10.1186/s12885-019-6000-y] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 11.5] [Reference Citation Analysis]
183 Barat M, Cottereau AS, Kedra A, Dermine S, Palmieri LJ, Coriat R, Dautry R, Tselikas L, Soyer P, Dohan A. The Role of Interventional Radiology for the Treatment of Hepatic Metastases from Neuroendocrine Tumor: An Updated Review. J Clin Med 2020;9:E2302. [PMID: 32698459 DOI: 10.3390/jcm9072302] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
184 Deleval N, Pesque L, Dieudonné A, Viry F, Hentic O, Lebtahi R, Ruszniewski P, de Mestier L. Prognostic impact of bone metastases detected by 18F-DOPA PET in patients with metastatic midgut neuroendocrine tumors. Eur Radiol 2021;31:4166-74. [PMID: 33247341 DOI: 10.1007/s00330-020-07554-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
185 Maggio I, Manuzzi L, Lamberti G, Ricci AD, Tober N, Campana D. Landscape and Future Perspectives of Immunotherapy in Neuroendocrine Neoplasia. Cancers (Basel) 2020;12:E832. [PMID: 32235636 DOI: 10.3390/cancers12040832] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 15.0] [Reference Citation Analysis]
186 Mollazadegan K, Welin S, Crona J. Systemic Treatment of Gastroenteropancreatic Neuroendocrine Carcinoma. Curr Treat Options Oncol 2021;22:68. [PMID: 34110508 DOI: 10.1007/s11864-021-00866-9] [Reference Citation Analysis]
187 Kim YI. Salvage peptide receptor radionuclide therapy in patients with progressive neuroendocrine tumors: a systematic review and meta-analysis. Nucl Med Commun 2021;42:451-8. [PMID: 33346603 DOI: 10.1097/MNM.0000000000001350] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
188 Manoharan P, Lamarca A, Navalkissoor S, Calero J, Chan PS, Julyan P, Sierra M, Caplin M, Valle J. Safety, tolerability and clinical implementation of 'ready-to-use' 68gallium-DOTA0-Tyr3-octreotide (68Ga-DOTATOC) (SomaKIT TOC) for injection in patients diagnosed with gastroenteropancreatic neuroendocrine tumours (GEP-NETs). ESMO Open 2020;5:e000650. [PMID: 32188715 DOI: 10.1136/esmoopen-2019-000650] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
189 Pathipati MP, Yohannan TK, Tian L, Hornbacker K, Benson JA, Berry GJ, Lui NS, Kunz PL, Padda SK. Examination of factors associated with lymph node metastases in lung carcinoids: Results from a single institution retrospective cohort study. Lung Cancer 2021;154:186-94. [PMID: 33551175 DOI: 10.1016/j.lungcan.2021.01.017] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
190 Desai H, Borges-Neto S, Wong TZ. Molecular Imaging and Therapy for Neuroendocrine Tumors. Curr Treat Options Oncol 2019;20:78. [PMID: 31468190 DOI: 10.1007/s11864-019-0678-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
191 Foubert F, Salimon M, Dumars C, Regenet N, Girot P, Venara A, Senellart H, Heymann MF, Matysiak-Budnik T, Touchefeu Y. Survival and prognostic factors analysis of 151 intestinal and pancreatic neuroendocrine tumors: a single center experience. J Gastrointest Oncol 2019;10:103-11. [PMID: 30788165 DOI: 10.21037/jgo.2018.09.13] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
192 Lu Y, Zhao Z, Wang J, Lv W, Lu L, Fu W, Li W. Safety and efficacy of combining capecitabine and temozolomide (CAPTEM) to treat advanced neuroendocrine neoplasms: A meta-analysis. Medicine (Baltimore) 2018;97:e12784. [PMID: 30313101 DOI: 10.1097/MD.0000000000012784] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 5.3] [Reference Citation Analysis]
193 Frilling A, Clift AK, Braat AJ, Alsafi A, Wasan HS, Al-nahhas A, Thomas R, Drymousis P, Habib N, Tait PN. Radioembolisation with 90Y microspheres for neuroendocrine liver metastases: an institutional case series, systematic review and meta-analysis. HPB 2019;21:773-83. [DOI: 10.1016/j.hpb.2018.12.014] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
194 Minczeles NS, Hofland J, de Herder WW, Brabander T. Strategies Towards Improving Clinical Outcomes of Peptide Receptor Radionuclide Therapy. Curr Oncol Rep 2021;23:46. [PMID: 33721105 DOI: 10.1007/s11912-021-01037-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
195 Scoville SD, Cloyd JM, Pawlik TM. New and emerging systemic therapy options for well-differentiated gastroenteropancreatic neuroendocrine tumors. Expert Opin Pharmacother. 2020;21:183-191. [PMID: 31760823 DOI: 10.1080/14656566.2019.1694003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
196 Legoux JL, Lombard-Bohas C, Brixi H, Le Malicot K, Lecomte T, Dahan L, Ruszniewski P, Mahamat-Abakar A, Etienne PL, Caroli-Bosc FX, Dominguez S, Paule B, Terrebonne E, Michel P, Lepage C, Choukroun G; for Streptotox-FFCD0906 investigators. Renal function in patients receiving streptozocin for locally advanced or metastatic digestive neuroendocrine tumours: results of the Streptotox-FFCD 0906 study. Clin Res Hepatol Gastroenterol 2021;45:101572. [PMID: 33751987 DOI: 10.1016/j.clinre.2020.10.014] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
197 Shi M, Zhou B. Clinical Characteristics and Prognostic Factors of Early-Onset Pancreatic Neuroendocrine Tumors. Cancer Control 2021;28:1073274820986827. [PMID: 33491476 DOI: 10.1177/1073274820986827] [Reference Citation Analysis]
198 Custodio A, Jimenez-Fonseca P, Carmona-Bayonas A, Gomez MJ, Del Olmo-García MI, Lorenzo I, Díaz JÁ, Canal N, De la Cruz G, Villabona C. Use of healthcare REsources and associated COsts in controlled versus uncontrolled carcinoid SYndrome in patients with neuroendocrine tumours: the RECOSY study. Clin Transl Oncol 2021;23:2046-56. [PMID: 34109562 DOI: 10.1007/s12094-021-02608-7] [Reference Citation Analysis]
199 Cukier M, Vergara R, Mendez-Rios JD, Castillo O, Barrera I, Tello E, El Achtar O, Loo Y, Tapia H, Perez G, Peña M. Neuroendocrine tumors in Panama: A nationwide database analysis. Mol Clin Oncol 2021;15:157. [PMID: 34178328 DOI: 10.3892/mco.2021.2319] [Reference Citation Analysis]
200 Gogna S, Samson D, Gachabayov M, Rojas A, Felsenreich DM, Koo D, Gu K, Quintero L, Miller KR, Azim A, Da Eric Dong X. Neuroendocrine neoplasms of the gallbladder: early detection and surgery is key to improved outcome. Langenbecks Arch Surg 2021. [PMID: 34236488 DOI: 10.1007/s00423-021-02256-z] [Reference Citation Analysis]
201 Chen X, Li B, Wang S, Yang B, Zhu L, Ma S, Wu J, He Q, Zhao J, Zheng Z, Li S, Wang T, Liang L. Efficacy and safety of endoscopic submucosal dissection for gastrointestinal neuroendocrine tumors: a 10-year data analysis of Northern China. Scandinavian Journal of Gastroenterology 2019;54:384-9. [DOI: 10.1080/00365521.2019.1588367] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
202 Xie JW, Lu J, Wang JB, Lin JX, Chen QY, Cao LL, Lin M, Tu RH, Huang ZN, Lin JL, Zheng CH, Li P, Huang CM. Prognostic factors for survival after curative resection of gastric mixed adenoneuroendocrine carcinoma: a series of 80 patients. BMC Cancer 2018;18:1021. [PMID: 30348122 DOI: 10.1186/s12885-018-4943-z] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 5.3] [Reference Citation Analysis]
203 Søreide JA, Kvaløy JT, Lea D, Sandvik OM, Al-Saiddi M, Haslerud TM, Garresori H, Karlsen LN, Gudlaugsson E, Søreide K. The overriding role of surgery and tumor grade for long-term survival in patients with gastroenteropancreatic neuroendocrine neoplasms: A population-based cohort study. Cancer Rep (Hoboken) 2021;:e1462. [PMID: 34105314 DOI: 10.1002/cnr2.1462] [Reference Citation Analysis]
204 Ruhwedel T, Rogasch JMM, Huang K, Jann H, Schatka I, Furth C, Amthauer H, Wetz C. The Prognostic Value of the De Ritis Ratio for Progression-Free Survival in Patients with NET Undergoing [177Lu]Lu-DOTATOC-PRRT: A Retrospective Analysis. Cancers (Basel) 2021;13:635. [PMID: 33562643 DOI: 10.3390/cancers13040635] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
205 Samsom KG, van Veenendaal LM, Valk GD, Vriens MR, Tesselaar MET, van den Berg JG. Molecular prognostic factors in small-intestinal neuroendocrine tumours. Endocr Connect 2019;8:906-22. [PMID: 31189127 DOI: 10.1530/EC-19-0206] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
206 Hanif A, Lee S, Gupta M, Chander A, Kannisto ED, Punnanitinont A, Fenstermaker R, Ciesielski M, Attwood K, Qiu J, Yendamuri S, Iyer R. Exploring the role of survivin in neuroendocrine neoplasms. Oncotarget 2020;11:2246-58. [PMID: 32577168 DOI: 10.18632/oncotarget.27631] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
207 Cong L, Wu W, Lou W, Wang J, Gu F, Qian J, Xu J, Bi F, Cai S, Tang C, He Y, Zhong J, Zhao Y. Gastroenteropancreatic neuroendocrine tumor registry study in China. Journal of Pancreatology 2018;1:35-8. [DOI: 10.1097/jp9.0000000000000005] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
208 Cavalcoli F, Pusceddu S, Zilli A, Tamagno G, Femia D, Prinzi N, Travers J, Consonni D, Ciafardini C, Conte D, Massironi S. Effects of low-dose aspirin on clinical outcome and disease progression in patients with gastroenteropancreatic neuroendocrine neoplasm. Scand J Gastroenterol 2019;54:1111-7. [PMID: 31454281 DOI: 10.1080/00365521.2019.1656773] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
209 Xu GH, Zou HW, Grossman AB. Difference in survival between right- versus left-sided colorectal neuroendocrine neoplasms. J Zhejiang Univ Sci B 2019;20:933-9. [PMID: 31595730 DOI: 10.1631/jzus.B1900210] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
210 Fust K, Maschio M, Kohli M, Singh S, Pritchard DM, Marteau F, Myrenfors P, Feuilly M. A Budget Impact Model of the Addition of Telotristat Ethyl Treatment to the Standard of Care in Patients with Uncontrolled Carcinoid Syndrome. PharmacoEconomics 2020;38:607-18. [DOI: 10.1007/s40273-020-00896-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
211 Kim YI, Yoo C, Oh SJ, Lee SJ, Kang J, Hwang HS, Hong SM, Ryoo BY, Ryu JS. Tumour-to-liver ratio determined by [68Ga]Ga-DOTA-TOC PET/CT as a prognostic factor of lanreotide efficacy for patients with well-differentiated gastroenteropancreatic-neuroendocrine tumours. EJNMMI Res 2020;10:63. [PMID: 32542576 DOI: 10.1186/s13550-020-00651-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
212 Grozinsky-Glasberg S, Alexandraki KI, Angelousi A, Chatzellis E, Sougioultzis S, Kaltsas G. Gastric Carcinoids. Endocrinol Metab Clin North Am. 2018;47:645-660. [PMID: 30098721 DOI: 10.1016/j.ecl.2018.04.013] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 6.7] [Reference Citation Analysis]
213 Remes SM, Leijon H, Vesterinen T, Louhimo J, Pulkkinen V, Ezer S, Kere J, Haglund C, Arola J. PCSK2 expression in neuroendocrine tumors points to a midgut, pulmonary, or pheochromocytoma-paraganglioma origin. APMIS 2020;128:563-72. [PMID: 32794589 DOI: 10.1111/apm.13071] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
214 Singhi AD, Klimstra DS. Well-differentiated pancreatic neuroendocrine tumours (PanNETs) and poorly differentiated pancreatic neuroendocrine carcinomas (PanNECs): concepts, issues and a practical diagnostic approach to high-grade (G3) cases. Histopathology. 2018;72:168-177. [PMID: 29239037 DOI: 10.1111/his.13408] [Cited by in Crossref: 43] [Cited by in F6Publishing: 41] [Article Influence: 14.3] [Reference Citation Analysis]
215 Lu X, Yan S, Koral KA, Chen Z. Surufatinib for the treatment of advanced extrapancreatic neuroendocrine tumors. Expert Rev Anticancer Ther 2021;21:917-26. [PMID: 34142932 DOI: 10.1080/14737140.2021.1944110] [Reference Citation Analysis]
216 Yang Z, Gao H, Lu J, Niu Z, Zhu H, Zong Y, Song X, Yang F, Zhou X. Comparison of clinical outcomes between enucleation and regular pancreatectomy in patients with non-functional pancreatic neuroendocrine tumors: a retrospective multicenter and propensity score-matched study. Jpn J Clin Oncol 2021;51:595-603. [PMID: 33395471 DOI: 10.1093/jjco/hyaa246] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
217 Barriuso J, Custodio A, Afonso R, Alonso V, Astudillo A, Capdevila J, García-Carbonero R, Grande E, Jimenez-Fonseca P, Marazuela M, Rodríguez-Antona C, Aller J. Prognostic and predictive biomarkers for somatostatin analogs, peptide receptor radionuclide therapy and serotonin pathway targets in neuroendocrine tumours. Cancer Treat Rev 2018;70:209-22. [PMID: 30292979 DOI: 10.1016/j.ctrv.2018.09.008] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
218 Scott AT, Breheny PJ, Keck KJ, Bellizzi AM, Dillon JS, O'Dorisio TM, Howe JR. Effective cytoreduction can be achieved in patients with numerous neuroendocrine tumor liver metastases (NETLMs). Surgery. 2019;165:166-175. [PMID: 30343949 DOI: 10.1016/j.surg.2018.04.070] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 9.3] [Reference Citation Analysis]
219 Gosain R, Ball S, Rana N, Groman A, Gage-Bouchard E, Dasari A, Mukherjee S. Geographic and demographic features of neuroendocrine tumors in the United States of America: A population-based study. Cancer 2020;126:792-9. [PMID: 31714595 DOI: 10.1002/cncr.32607] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
220 Partelli S, Muffatti F, Rancoita PMV, Andreasi V, Balzano G, Crippa S, Doglioni C, Rubini C, Zamboni G, Falconi M. The size of well differentiated pancreatic neuroendocrine tumors correlates with Ki67 proliferative index and is not associated with age. Digestive and Liver Disease 2019;51:735-40. [DOI: 10.1016/j.dld.2019.01.008] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
221 Chen L, Liu M, Zhang Y, Guo Y, Chen MH, Chen J. Genetic Characteristics of Colorectal Neuroendocrine Carcinoma: More Similar to Colorectal Adenocarcinoma. Clin Colorectal Cancer 2021;20:177-185.e13. [PMID: 33041225 DOI: 10.1016/j.clcc.2020.09.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
222 Han X, Yang J, Luo J, Chen P, Zhang Z, Alu A, Xiao Y, Ma X. Application of CT-Based Radiomics in Discriminating Pancreatic Cystadenomas From Pancreatic Neuroendocrine Tumors Using Machine Learning Methods. Front Oncol 2021;11:606677. [PMID: 34367940 DOI: 10.3389/fonc.2021.606677] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
223 Amer A, Wilson CH, Manas DM. Liver transplantation for unresectable malignancies: Beyond hepatocellular carcinoma. Eur J Surg Oncol 2019;45:2268-78. [PMID: 31387755 DOI: 10.1016/j.ejso.2019.07.024] [Reference Citation Analysis]
224 Yamaguchi T, Takahashi K, Yamada K, Bando H, Baba H, Ito M, Funahashi K, Ueno H, Fujita S, Hasegawa S, Sakai Y, Sugihara K. A nationwide, multi-institutional collaborative retrospective study of colorectal neuroendocrine tumors in Japan. Ann Gastroenterol Surg 2021;5:215-20. [PMID: 33860141 DOI: 10.1002/ags3.12403] [Reference Citation Analysis]
225 Hoskoppal D, Epstein JI, Gown AM, Arnold Egloff SA, Gordetsky JB, Shi CJ, Giannico GA. SATB2 protein expression by immunohistochemistry is a sensitive and specific marker of appendiceal and rectosigmoid well differentiated neuroendocrine tumours. Histopathology 2020;76:550-9. [DOI: 10.1111/his.14012] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
226 La Salvia A, Portigliatti Pomeri A, Persano I, Trevisi E, Parlagreco E, Colombi N, Brizzi MP, Picci RL, Oliva F. Serotoninergic brain dysfunction in neuroendocrine tumor patients: A scoping review. Compr Psychiatry 2021;109:152244. [PMID: 34120056 DOI: 10.1016/j.comppsych.2021.152244] [Reference Citation Analysis]
227 White BE, Mujica-Mota R, Snowsill T, Gamper EM, Srirajaskanthan R, Ramage JK. Evaluating cost-effectiveness in the management of neuroendocrine neoplasms. Rev Endocr Metab Disord 2021;22:647-63. [PMID: 33155118 DOI: 10.1007/s11154-020-09608-y] [Reference Citation Analysis]
228 Hofland J, de Herder WW, Kann PH. Turning Up the Heat: Endoscopic Ablation of Pancreatic Neuroendocrine Neoplasms. J Clin Endocrinol Metab 2019;104:5053-5. [PMID: 31058975 DOI: 10.1210/jc.2019-00954] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
229 Tarquini M, Ambrosio MR, Albertelli M, de Souza PB, Gafà R, Gagliardi I, Carnevale A, Franceschetti P, Zatelli MC. A tool to predict survival in stage IV entero-pancreatic NEN. J Endocrinol Invest 2021;44:1185-92. [PMID: 32892316 DOI: 10.1007/s40618-020-01404-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
230 Xu J, Shen L, Zhou Z, Li J, Bai C, Chi Y, Li Z, Xu N, Li E, Liu T, Bai Y, Yuan Y, Li X, Wang X, Chen J, Ying J, Yu X, Qin S, Yuan X, Zhang T, Deng Y, Xiu D, Cheng Y, Tao M, Jia R, Wang W, Li J, Fan S, Peng M, Su W. Surufatinib in advanced extrapancreatic neuroendocrine tumours (SANET-ep): a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol 2020;21:1500-12. [PMID: 32966811 DOI: 10.1016/S1470-2045(20)30496-4] [Cited by in Crossref: 21] [Cited by in F6Publishing: 9] [Article Influence: 21.0] [Reference Citation Analysis]
231 Wu L, Sahara K, Tsilimigras DI, Maithel SK, Poultsides GA, Rocha FG, Weber SM, Fields RC, Idrees K, Cho CS, Shen F, Pawlik TM; and other members of the U.S. Neuroendocrine Tumor Study Group. Therapeutic index of lymphadenectomy among patients with pancreatic neuroendocrine tumors: A multi‐institutional analysis. J Surg Oncol 2019;120:1080-6. [DOI: 10.1002/jso.25689] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 5.5] [Reference Citation Analysis]
232 Pollard JH, Menda Y, Zamba KD, Madsen M, O'Dorisio MS, O'Dorisio T, Bushnell D. Potential for Increasing Uptake of Radiolabeled 68Ga-DOTATOC and 123I-MIBG in Patients with Midgut Neuroendocrine Tumors Using a Histone Deacetylase Inhibitor Vorinostat. Cancer Biother Radiopharm 2021. [PMID: 34252288 DOI: 10.1089/cbr.2020.4633] [Reference Citation Analysis]
233 Gangi A, Anaya DA. Surgical Principles in the Management of Small Bowel Neuroendocrine Tumors. Curr Treat Options Oncol 2020;21:88. [PMID: 32862334 DOI: 10.1007/s11864-020-00784-2] [Reference Citation Analysis]
234 Wang XY, Chai NL, Linghu EQ, Qiu ST, Li LS, Zou JL, Xiang JY, Li XX. The outcomes of modified endoscopic mucosal resection and endoscopic submucosal dissection for the treatment of rectal neuroendocrine tumors and the value of endoscopic morphology classification in endoscopic resection. BMC Gastroenterol 2020;20:200. [PMID: 32586282 DOI: 10.1186/s12876-020-01340-w] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
235 Ge W, Zhou D, Zhu L, Song W, Wang W. Efficacy and Safety of Everolimus plus Somatostatin Analogues in Patients with Neuroendocrine Tumors. J Cancer 2018;9:4783-90. [PMID: 30588264 DOI: 10.7150/jca.25908] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
236 Hijioka S, Sakuma K, Aoki M, Mizuno N, Kuwahara T, Okuno N, Hara K, Yatabe Y. Clinical and in vitro studies of the correlation between MGMT and the effect of streptozocin in pancreatic NET. Cancer Chemother Pharmacol 2019;83:43-52. [PMID: 30310970 DOI: 10.1007/s00280-018-3700-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
237 Gluckman CR, Metz DC. Gastric Neuroendocrine Tumors (Carcinoids). Curr Gastroenterol Rep. 2019;21:13. [PMID: 30868284 DOI: 10.1007/s11894-019-0684-7] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 7.0] [Reference Citation Analysis]
238 Dasari A, Bergsland EK, Benson AB, Cai B, Huynh L, Totev T, Shea J, Duh MS, Neary MP, Dagohoy CG, Shih BE, Maurer VE, Chan J, Kulke MH. Treatment Patterns and Clinical Outcomes in Advanced Lung Neuroendocrine Tumors in Real-World Settings: A Multicenter Retrospective Chart Review Study. Oncologist 2019;24:1066-75. [PMID: 30610008 DOI: 10.1634/theoncologist.2018-0520] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
239 Do MY, Jang SI, Kang HP, Kim EJ, Lee KJ, Park GE, Lee SJ, Lee DK, Woo SM, Cho JH. Comparison of the Clinical Features and Outcomes of Gallbladder Neuroendocrine Carcinoma with Those of Adenocarcinoma: A Propensity Score-Matched Analysis. Cancers (Basel) 2021;13:4713. [PMID: 34572940 DOI: 10.3390/cancers13184713] [Reference Citation Analysis]
240 Cuny T, de Herder W, Barlier A, Hofland LJ. Role of the tumor microenvironment in digestive neuroendocrine tumors. Endocr Relat Cancer 2018;25:R519-44. [PMID: 30306777 DOI: 10.1530/ERC-18-0025] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
241 Pal SK, Miller MJ, Agarwal N, Chang SM, Chavez-macgregor M, Cohen E, Cole S, Dale W, Magid Diefenbach CS, Disis ML, Dreicer R, Graham DL, Henry NL, Jones J, Keedy V, Klepin HD, Markham MJ, Mittendorf EA, Rodriguez-galindo C, Sabel MS, Schilsky RL, Sznol M, Tap WD, Westin SN, Johnson BE. Clinical Cancer Advances 2019: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. JCO 2019;37:834-49. [DOI: 10.1200/jco.18.02037] [Cited by in Crossref: 42] [Cited by in F6Publishing: 18] [Article Influence: 21.0] [Reference Citation Analysis]
242 Zheng H, Zhao Y, He Q, Hao H, Tian Y, Zou B, Jiang L, Qiu X, Zhou Y, Li Z, Xu Y, Zhao G, Xue F, Li S, Fu W, Li Y, Zhou X, Li Y, Zhu Z, Chen J, Xu Z, Cai L, Li E, Li H, Xie J, Zheng C, Lu J, Li P, Huang C. Multi-institutional development and validation of a nomogram to predict recurrence after curative resection of gastric neuroendocrine/mixed adenoneuroendocrine carcinoma. Gastric Cancer 2021;24:503-14. [PMID: 32915373 DOI: 10.1007/s10120-020-01119-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
243 Treglia G, Goichot B, Giovanella L, Hindié E, Jha A, Pacak K, Taïeb D, Walter T, Imperiale A. Prognostic and predictive value of nuclear imaging in endocrine oncology. Endocrine 2020;67:9-19. [PMID: 31734779 DOI: 10.1007/s12020-019-02131-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
244 Thomas K, Voros BA, Meadows-Taylor M, Smeltzer MP, Griffin R, Boudreaux JP, Thiagarajan R, Woltering EA, Ramirez RA. Outcomes of Capecitabine and Temozolomide (CAPTEM) in Advanced Neuroendocrine Neoplasms (NENs). Cancers (Basel) 2020;12:E206. [PMID: 31947598 DOI: 10.3390/cancers12010206] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 13.0] [Reference Citation Analysis]
245 Ayabe RI, Wach M, Ruff S, Martin S, Diggs L, Wiemken T, Hinyard L, Davis JL, Luu C, Hernandez JM. Primary Gallbladder Neuroendocrine Tumors: Insights into a Rare Histology Using a Large National Database. Ann Surg Oncol 2019;26:3577-85. [PMID: 31102094 DOI: 10.1245/s10434-019-07440-6] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
246 Woltering EA, Voros BA, Beyer DT, Thiagarajan R, Ramirez RA, Mamikunian G, Boudreaux JP. Plasma Pancreastatin Predicts the Outcome of Surgical Cytoreduction in Neuroendocrine Tumors of the Small Bowel. Pancreas 2019;48:356-62. [PMID: 30768573 DOI: 10.1097/MPA.0000000000001263] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
247 Daskalakis K, Tsoli M, Angelousi A, Kassi E, Alexandraki KI, Kolomodi D, Kaltsas G, Koumarianou A. Anti-tumour activity of everolimus and sunitinib in neuroendocrine neoplasms. Endocr Connect. 2019;8:641-653. [PMID: 31026812 DOI: 10.1530/ec-19-0134] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
248 Alexandraki KI, Daskalakis K, Tsoli M, Grossman AB, Kaltsas GA. Endocrinological Toxicity Secondary to Treatment of Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NENs). Trends in Endocrinology & Metabolism 2020;31:239-55. [DOI: 10.1016/j.tem.2019.11.003] [Reference Citation Analysis]
249 Froelich MF, Schnitzer ML, Holzgreve A, Gassert FG, Gresser E, Overhoff D, Schwarze V, Fabritius MP, Nörenberg D, von Münchhausen N, Hokamp NG, Auernhammer CJ, Ilhan H, Todica A, Rübenthaler J. Cost-Effectiveness Analysis of 68Ga DOTA-TATE PET/CT, 111In-Pentetreotide SPECT/CT and CT for Diagnostic Workup of Neuroendocrine Tumors. Diagnostics (Basel) 2021;11:334. [PMID: 33670457 DOI: 10.3390/diagnostics11020334] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
250 Mao R, Li K, Cai JQ, Luo S, Turner M, Blazer D 3rd, Zhao H. Adjuvant Chemotherapy Versus Observation Following Resection for Patients With Nonmetastatic Poorly Differentiated Colorectal Neuroendocrine Carcinomas. Ann Surg. 2019;. [PMID: 31478977 DOI: 10.1097/sla.0000000000003562] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
251 Pusceddu S, Prinzi N, Raimondi A, Corti F, Buzzoni R, Di Bartolomeo M, Seregni E, Maccauro M, Coppa J, Milione M, Mazzaferro V, de Braud F. Entering the third decade of experience with octreotide LAR in neuroendocrine tumors: A review of current knowledge. Tumori 2019;105:113-20. [DOI: 10.1177/0300891618765362] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
252 Ren S, Qian L, Daniels MJ, Duan S, Chen R, Wang Z. Evaluation of contrast-enhanced computed tomography for the differential diagnosis of hypovascular pancreatic neuroendocrine tumors from chronic mass-forming pancreatitis. Eur J Radiol 2020;133:109360. [PMID: 33126171 DOI: 10.1016/j.ejrad.2020.109360] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
253 de Vries FE, Godthelp A, Spruit JR, Ruissen AM, Tesselaar MET, Boekhout AH. Coping with social consequences of disease-related symptoms in patients with a metastatic small intestinal neuroendocrine tumour: A qualitative study. J Neuroendocrinol 2021;33:e12956. [PMID: 33733525 DOI: 10.1111/jne.12956] [Reference Citation Analysis]
254 Isenberg-Grzeda E, MacGregor M, Matsoukas K, Chow N, Reidy-Lagunes D, Alici Y. Must antidepressants be avoided in patients with neuroendocrine tumors? Results of a systematic review. Palliat Support Care 2020;18:602-8. [PMID: 32036806 DOI: 10.1017/S147895152000005X] [Reference Citation Analysis]
255 Hu P, Bai J, Liu M, Xue J, Chen T, Li R, Kuai X, Zhao H, Li X, Tian Y, Sun W, Xiong Y, Tang Q. Trends of incidence and prognosis of gastric neuroendocrine neoplasms: a study based on SEER and our multicenter research. Gastric Cancer. 2020;23:591-599. [PMID: 32026156 DOI: 10.1007/s10120-020-01046-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 8.0] [Reference Citation Analysis]
256 Majmudar K, Quintero LD, Fuentes HE, Stocker S, Tafur AJ, Lee CJ, Talamonti M. Postoperative venous thromboembolism and mortality in patients with pancreatic surgery. J Surg Oncol 2019;120:494-500. [PMID: 31222842 DOI: 10.1002/jso.25589] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
257 Ricci C, Partelli S, Landoni L, Rinzivillo M, Ingaldi C, Andreasi V, Nessi C, Muffatti F, Fontana M, Tamburrino D, Deiro G, Alberici L, Campana D, Panzuto F, Bassi C, Falconi M, Casadei R. Sporadic non-functioning pancreatic neuroendocrine tumours: multicentre analysis. Br J Surg 2021;108:811-6. [PMID: 33724300 DOI: 10.1093/bjs/znaa141] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
258 Satapathy S, Mittal BR, Sood A, Sood A, Kapoor R, Gupta R, Khosla D. 177Lu-DOTATATE Plus Radiosensitizing Capecitabine Versus Octreotide Long-Acting Release as First-Line Systemic Therapy in Advanced Grade 1 or 2 Gastroenteropancreatic Neuroendocrine Tumors: A Single-Institution Experience. JCO Glob Oncol 2021;7:1167-75. [PMID: 34288699 DOI: 10.1200/GO.21.00103] [Reference Citation Analysis]
259 Sackstein PE, O'Neil DS, Neugut AI, Chabot J, Fojo T. Epidemiologic trends in neuroendocrine tumors: An examination of incidence rates and survival of specific patient subgroups over the past 20 years. Semin Oncol 2018;45:249-58. [PMID: 30348533 DOI: 10.1053/j.seminoncol.2018.07.001] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 7.0] [Reference Citation Analysis]
260 Hofland J, Zandee WT, de Herder WW. Role of biomarker tests for diagnosis of neuroendocrine tumours. Nat Rev Endocrinol. 2018;14:656-669. [PMID: 30158549 DOI: 10.1038/s41574-018-0082-5] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 15.5] [Reference Citation Analysis]
261 Zhu Y, Meng F, Fang H, Zhang Z, Wang L, Zheng W. Clinicopathologic characteristics and survival outcomes in neuroendocrine carcinoma of the ovary. Int J Gynecol Cancer 2020;30:207-12. [DOI: 10.1136/ijgc-2019-000746] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
262 Hallet J, Davis LE, Mahar AL, Isenberg-grzeda E, Bubis LD, Myrehaug S, Zhao H, Beyfuss K, Moody L, Law CHL, Coburn NG. Symptom Burden at the End of Life for Neuroendocrine Tumors: An Analysis of 2579 Prospectively Collected Patient-Reported Outcomes. Ann Surg Oncol 2019;26:2711-21. [DOI: 10.1245/s10434-019-07441-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
263 Beesley VL, Burge M, Dumbrava M, Callum J, Neale RE, Wyld DK. Perceptions of care and patient-reported outcomes in people living with neuroendocrine tumours. Support Care Cancer 2018;26:3153-61. [DOI: 10.1007/s00520-018-4166-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
264 Herring B, Whitt J, Aweda T, Ou J, Guenter R, Lapi S, Berry J, Chen H, Liu X, Rose JB, Jaskula-Sztul R. A growth model of neuroendocrine tumor surrogates and the efficacy of a novel somatostatin-receptor-guided antibody-drug conjugate: Perspectives on clinical response? Surgery 2020;167:197-203. [PMID: 31543319 DOI: 10.1016/j.surg.2019.04.073] [Reference Citation Analysis]
265 Nguyen AH, O'Leary MP, De Andrade JP, Ituarte PHG, Kessler J, Li D, Singh G, Chang S. Natural History of Renal Neuroendocrine Neoplasms: A NET by Any Other Name? Front Endocrinol (Lausanne) 2020;11:624251. [PMID: 33613455 DOI: 10.3389/fendo.2020.624251] [Reference Citation Analysis]
266 Boons G, Vandamme T, Ibrahim J, Roeyen G, Driessen A, Peeters D, Lawrence B, Print C, Peeters M, Van Camp G, Op de Beeck K. PDX1 DNA Methylation Distinguishes Two Subtypes of Pancreatic Neuroendocrine Neoplasms with a Different Prognosis. Cancers (Basel) 2020;12:E1461. [PMID: 32512761 DOI: 10.3390/cancers12061461] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
267 Sorbye H, Meyer LS, Mordal KE, Myhre S, Thiis-Evensen E. Patient reported symptoms, coping and quality of life during somatostatin analogue treatment for metastatic small- intestinal neuroendocrine tumours. Health Qual Life Outcomes 2020;18:188. [PMID: 32546236 DOI: 10.1186/s12955-020-01452-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
268 Wedin M, Mehta S, Angerås-Kraftling J, Wallin G, Daskalakis K. The Role of Serum 5-HIAA as a Predictor of Progression and an Alternative to 24-h Urine 5-HIAA in Well-Differentiated Neuroendocrine Neoplasms. Biology (Basel) 2021;10:76. [PMID: 33494283 DOI: 10.3390/biology10020076] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
269 Soldath P, Binderup T, Kjær A, Federspiel B, Langer SW, Knigge U, Petersen RH. Long-term survival and recurrence after resection of bronchopulmonary carcinoids: A single-center cohort study of 236 patients. Lung Cancer 2021;156:109-16. [PMID: 33940543 DOI: 10.1016/j.lungcan.2021.04.010] [Reference Citation Analysis]
270 Azoulay A, Cros J, Vullierme MP, de Mestier L, Couvelard A, Hentic O, Ruszniewski P, Sauvanet A, Vilgrain V, Ronot M. Morphological imaging and CT histogram analysis to differentiate pancreatic neuroendocrine tumor grade 3 from neuroendocrine carcinoma. Diagn Interv Imaging 2020;101:821-30. [PMID: 32709455 DOI: 10.1016/j.diii.2020.06.006] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
271 Zhang S, Tong YX, Zhang XH, Zhang YJ, Xu XS, Xiao AT, Chao TF, Gong JP. A novel and validated nomogram to predict overall survival for gastric neuroendocrine neoplasms. J Cancer 2019;10:5944-54. [PMID: 31762804 DOI: 10.7150/jca.35785] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
272 Cives M, Strosberg JR. Gastroenteropancreatic Neuroendocrine Tumors. CA: A Cancer Journal for Clinicians 2018;68:471-87. [DOI: 10.3322/caac.21493] [Cited by in Crossref: 110] [Cited by in F6Publishing: 98] [Article Influence: 36.7] [Reference Citation Analysis]
273 Li J, Liang L, Yu H, Shen Y, Hu Y, Hu D, Tang H, Li Z. Whole-tumor histogram analysis of non-Gaussian distribution DWI parameters to differentiation of pancreatic neuroendocrine tumors from pancreatic ductal adenocarcinomas. Magnetic Resonance Imaging 2019;55:52-9. [DOI: 10.1016/j.mri.2018.09.017] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
274 Prantesh J, Dorth J, Asa SL, Mohamed A. Nasopharyngeal neuroendocrine neoplasms: Systematic review of the literature and case presentation. J Neuroendocrinol 2021;33:e13005. [PMID: 34342078 DOI: 10.1111/jne.13005] [Reference Citation Analysis]
275 La Rosa S, Solcia E. New insights into the classification of gastric neuroendocrine tumours, expanding the spectrum of ECL-cell tumours related to hypergastrinaemia. Histopathology 2020;77:862-4. [PMID: 33190337 DOI: 10.1111/his.14226] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
276 Eads JR, Reidy-Lagunes D, Soares HP, Chan JA, Anthony LB, Halfdanarson TR, Naraev BG, Wolin EM, Halperin DM, Li D, Pommier RF, Zacks JS, Morse MA, Metz DC; from the Carcinoid Syndrome Control Collaborative. Differential Diagnosis of Diarrhea in Patients With Neuroendocrine Tumors. Pancreas 2020;49:1123-30. [PMID: 32991344 DOI: 10.1097/MPA.0000000000001658] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
277 Stevenson M, Lines KE, Thakker RV. Molecular Genetic Studies of Pancreatic Neuroendocrine Tumors: New Therapeutic Approaches. Endocrinol Metab Clin North Am 2018;47:525-48. [PMID: 30098714 DOI: 10.1016/j.ecl.2018.04.007] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
278 Herrera-martínez AD, Hofland LJ, Gálvez Moreno MA, Castaño JP, de Herder WW, Feelders RA. Neuroendocrine neoplasms: current and potential diagnostic, predictive and prognostic markers. Endocrine-Related Cancer 2019;26:R157-79. [DOI: 10.1530/erc-18-0354] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 6.5] [Reference Citation Analysis]
279 Shi M, Fan Z, Xu J, Yang J, Li Y, Gao C, Su P, Wang X, Zhan H. Gastroenteropancreatic neuroendocrine neoplasms G3: Novel insights and unmet needs. Biochim Biophys Acta Rev Cancer 2021;1876:188637. [PMID: 34678439 DOI: 10.1016/j.bbcan.2021.188637] [Reference Citation Analysis]
280 Buicko JL, Finnerty BM, Zhang T, Kim BJ, Fahey TJ, Nancy Du YC. Insights into the biology and treatment strategies of pancreatic neuroendocrine tumors. Ann Pancreat Cancer. 2019;2. [PMID: 31535089 DOI: 10.21037/apc.2019.06.02] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
281 Hiltunen N, Väyrynen JP, Böhm J, Helminen O. CD3+, CD8+, CD4+ and FOXP3+ T Cells in the Immune Microenvironment of Small Bowel Neuroendocrine Tumors. Diseases 2021;9:42. [PMID: 34208144 DOI: 10.3390/diseases9020042] [Reference Citation Analysis]
282 Dromain C, Loaiza-Bonilla A, Mirakhur B, Beveridge TJR, Fojo AT. Novel Tumor Growth Rate Analysis in the Randomized CLARINET Study Establishes the Efficacy of Lanreotide Depot/Autogel 120 mg with Prolonged Administration in Indolent Neuroendocrine Tumors. Oncologist 2021;26:e632-8. [PMID: 33393112 DOI: 10.1002/onco.13669] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
283 Howe JR, Merchant NB, Conrad C, Keutgen XM, Hallet J, Drebin JA, Minter RM, Lairmore TC, Tseng JF, Zeh HJ, Libutti SK, Singh G, Lee JE, Hope TA, Kim MK, Menda Y, Halfdanarson TR, Chan JA, Pommier RF. The North American Neuroendocrine Tumor Society Consensus Paper on the Surgical Management of Pancreatic Neuroendocrine Tumors. Pancreas. 2020;49:1-33. [PMID: 31856076 DOI: 10.1097/mpa.0000000000001454] [Cited by in Crossref: 56] [Cited by in F6Publishing: 23] [Article Influence: 56.0] [Reference Citation Analysis]
284 Liu Q, Polydorides AD. Diagnosis and prognostic significance of extramural venous invasion in neuroendocrine tumors of the small intestine. Mod Pathol 2020;33:2318-29. [PMID: 32514164 DOI: 10.1038/s41379-020-0585-1] [Reference Citation Analysis]
285 Pastorino L, Grillo F, Albertelli M, Ghiorzo P, Bruno W. Insights into Mechanisms of Tumorigenesis in Neuroendocrine Neoplasms. Int J Mol Sci 2021;22:10328. [PMID: 34638668 DOI: 10.3390/ijms221910328] [Reference Citation Analysis]
286 Aktypis C, Spei ME, Yavropoulou M, Wallin G, Koumarianou A, Kaltsas G, Kassi E, Daskalakis K. Cardiovascular Toxicities Secondary to Biotherapy and Molecular Targeted Therapies in Neuroendocrine Neoplasms: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials. Cancers (Basel) 2021;13:2159. [PMID: 33946147 DOI: 10.3390/cancers13092159] [Reference Citation Analysis]
287 Singh S, Bergsland EK, Card CM, Hope TA, Kunz PL, Laidley DT, Lawrence B, Leyden S, Metz DC, Michael M, Modahl LE, Myrehaug S, Padda SK, Pommier RF, Ramirez RA, Soulen M, Strosberg J, Sung A, Thawer A, Wei B, Xu B, Segelov E. Commonwealth Neuroendocrine Tumour Research Collaboration and the North American Neuroendocrine Tumor Society Guidelines for the Diagnosis and Management of Patients With Lung Neuroendocrine Tumors: An International Collaborative Endorsement and Update of the 2015 European Neuroendocrine Tumor Society Expert Consensus Guidelines. J Thorac Oncol. 2020;15:1577-1598. [PMID: 32663527 DOI: 10.1016/j.jtho.2020.06.021] [Cited by in Crossref: 10] [Cited by in F6Publishing: 15] [Article Influence: 10.0] [Reference Citation Analysis]
288 Han D, Li YL, Zhou ZW, Yin F, Chen J, Liu F, Shi YF, Wang W, Zhang Y, Yu XJ, Xu JM, Yang RX, Tian C, Luo J, Tan HY. Clinicopathological characteristics and prognosis of 232 patients with poorly differentiated gastric neuroendocrine neoplasms. World J Gastroenterol 2021; 27(21): 2895-2909 [PMID: 34135560 DOI: 10.3748/wjg.v27.i21.2895] [Reference Citation Analysis]
289 Colquhoun SD. Neuroendocrine tumors with hepatic metastases: A review of evolving treatment options. Liver Research 2018;2:92-9. [DOI: 10.1016/j.livres.2018.08.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
290 Dawod M, Gordoa TA, Cives M, De Mestier L, Crona J, Spada F, Oberg K, Pavel M, Lamarca A. Antiproliferative Systemic Therapies for Metastatic Small Bowel Neuroendocrine Tumours. Curr Treat Options Oncol 2021;22:73. [PMID: 34185197 DOI: 10.1007/s11864-021-00863-y] [Reference Citation Analysis]
291 Juškys R, Poškus E, Beiša A, Gumbys L, Jocius D, Meškauskas R, Strupas K. High-grade well-differentiated neuroendocrine tumour of the cecum diagnosed following incisional hernia repair: a case report. Acta Med Litu 2020;27:17-24. [PMID: 32577092 DOI: 10.6001/actamedica.v27i1.4262] [Reference Citation Analysis]
292 Modlin IM, Kidd M, Oberg K, Falconi M, Filosso PL, Frilling A, Malczewska A, Salem R, Toumpanakis C, Laskaratos FM, Partelli S, Roffinella M, von Arx C, Kudla BK, Bodei L, Drozdov IA, Kitz A. Early Identification of Residual Disease After Neuroendocrine Tumor Resection Using a Liquid Biopsy Multigenomic mRNA Signature (NETest). Ann Surg Oncol 2021. [PMID: 34008138 DOI: 10.1245/s10434-021-10021-1] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
293 Li G, Tian ML, Bing YT, Yuan CH, Xiu DR. Impact of a Prior Nonpancreatic Malignancy on Survival Outcomes of Patients With Stage IV Pancreatic Neuroendocrine Tumor: A Population-Based and Propensity Score Matching Study. Pancreas 2020;49:1090-8. [PMID: 32833943 DOI: 10.1097/MPA.0000000000001630] [Reference Citation Analysis]
294 Li Y, Wu ZQ, Xu Q, Goyal H, Xu HG. Development and Validation of Novel Nomograms Using Serum Tumor Markers for the Prediction of Preoperative Histologic Grades in Gastroenteropancreatic Neuroendocrine Tumors. Front Oncol 2021;11:681149. [PMID: 34109127 DOI: 10.3389/fonc.2021.681149] [Reference Citation Analysis]
295 Puccini A, Battaglin F, Lenz HJ. Management of Advanced Small Bowel Cancer. Curr Treat Options Oncol 2018;19:69. [PMID: 30397729 DOI: 10.1007/s11864-018-0592-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
296 Leyden S, Kolarova T, Bouvier C, Caplin M, Conroy S, Davies P, Dureja S, Falconi M, Ferolla P, Fisher G, Goldstein G, Hicks RJ, Lawrence B, Majima Y, Metz DC, O'Toole D, Ruszniewski P, Wiedenmann B, Hollander R; International Neuroendocrine Cancer Alliance (INCA). Unmet needs in the international neuroendocrine tumor (NET) community: Assessment of major gaps from the perspective of patients, patient advocates and NET health care professionals. Int J Cancer 2020;146:1316-23. [PMID: 31509608 DOI: 10.1002/ijc.32678] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
297 Farooqui ZA, Chauhan A. Neuroendocrine Tumors in Pediatrics. Glob Pediatr Health 2019;6:2333794X19862712. [PMID: 31384627 DOI: 10.1177/2333794X19862712] [Reference Citation Analysis]
298 Koffas A, Toumpanakis C. Comparative safety review of the current therapies for gastroenteropancreatic neuroendocrine tumors. Expert Opin Drug Saf 2021;20:321-34. [PMID: 33338383 DOI: 10.1080/14740338.2021.1867097] [Reference Citation Analysis]
299 Vinagre J, Pinheiro J, Martinho O, Reis RM, Preto J, Soares P, Lopes JM. A 30-Year Long-Term Experience in Appendix Neuroendocrine Neoplasms-Granting a Positive Outcome. Cancers (Basel) 2020;12:E1357. [PMID: 32466539 DOI: 10.3390/cancers12061357] [Reference Citation Analysis]
300 Chen Q, Chen J, Huang Z, Zhao H, Cai J. Comparable survival benefit of local excision versus radical resection for 10- to 20-mm rectal neuroendocrine tumors. Eur J Surg Oncol 2021:S0748-7983(21)00779-4. [PMID: 34753616 DOI: 10.1016/j.ejso.2021.10.029] [Reference Citation Analysis]
301 Xie S, Li L, Wang X, Li L. Development and validation of a nomogram for predicting the overall survival of patients with gastroenteropancreatic neuroendocrine neoplasms. Medicine (Baltimore) 2021;100:e24223. [PMID: 33466202 DOI: 10.1097/MD.0000000000024223] [Reference Citation Analysis]
302 Zhou H, Zhang Y, Wei X, Yang K, Tan W, Qiu Z, Li S, Chen Q, Song Y, Gao S. Racial disparities in pancreatic neuroendocrine tumors survival: a SEER study. Cancer Med 2017;6:2745-56. [PMID: 28980417 DOI: 10.1002/cam4.1220] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 4.8] [Reference Citation Analysis]
303 Gao Y, Moua T, Midthun DE, Mullon JJ, Decker PA, Ryu JH. Diagnostic Yield and Bleeding Complications Associated With Bronchoscopic Biopsy of Endobronchial Carcinoid Tumors. J Bronchology Interv Pulmonol 2020;27:184-9. [PMID: 31876538 DOI: 10.1097/LBR.0000000000000639] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
304 Maharjan CK, Umesalma S, Kaemmer CA, Muniz VP, Bauchle C, Mott SL, Zamba KD, Breheny P, Leidinger MR, Darbro BW, Stephens SB, Meyerholz DK, Quelle DE. RABL6A Promotes Pancreatic Neuroendocrine Tumor Angiogenesis and Progression In Vivo. Biomedicines 2021;9:633. [PMID: 34199469 DOI: 10.3390/biomedicines9060633] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
305 Zhang JY, Kunz PL. Making Sense of a Complex Disease: A Practical Approach to Managing Neuroendocrine Tumors. JCO Oncol Pract 2021;:OP2100240. [PMID: 34652954 DOI: 10.1200/OP.21.00240] [Reference Citation Analysis]
306 Tirosh A, Kebebew E. Genetic and epigenetic alterations in pancreatic neuroendocrine tumors. J Gastrointest Oncol 2020;11:567-77. [PMID: 32655936 DOI: 10.21037/jgo.2020.03.11] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
307 Ivanidze J, Roytman M, Sasson A, Skafida M, Fahey TJ 3rd, Osborne JR, Dutruel SP. Molecular imaging and therapy of somatostatin receptor positive tumors. Clin Imaging 2019;56:146-54. [PMID: 31121520 DOI: 10.1016/j.clinimag.2019.04.006] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 6.5] [Reference Citation Analysis]
308 Tran CG, Sherman SK, Scott AT, Ear PH, Chandrasekharan C, Bellizzi AM, Dillon JS, O'Dorisio TM, Howe JR. It Is Time to Rethink Biomarkers for Surveillance of Small Bowel Neuroendocrine Tumors. Ann Surg Oncol 2021;28:732-41. [PMID: 32656719 DOI: 10.1245/s10434-020-08784-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
309 Uri I, Avniel-Polak S, Gross DJ, Grozinsky-Glasberg S. Update in the Therapy of Advanced Neuroendocrine Tumors. Curr Treat Options Oncol 2017;18:72. [PMID: 29143892 DOI: 10.1007/s11864-017-0514-9] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
310 Rinzivillo M, De Felice I, Magi L, Annibale B, Panzuto F. Octreotide long-acting release (LAR) in combination with other therapies for treatment of neuroendocrine neoplasia: a systematic review. J Gastrointest Oncol 2021;12:845-55. [PMID: 34012671 DOI: 10.21037/jgo-20-292] [Reference Citation Analysis]
311 Kajtazi Y, Kaemmerer D, Sänger J, Schulz S, Lupp A. Somatostatin and chemokine CXCR4 receptor expression in pancreatic adenocarcinoma relative to pancreatic neuroendocrine tumours. J Cancer Res Clin Oncol 2019;145:2481-93. [PMID: 31451931 DOI: 10.1007/s00432-019-03011-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
312 Shi H, Zhang Q, Han C, Zhen D, Lin R. Variability of the Ki-67 proliferation index in gastroenteropancreatic neuroendocrine neoplasms - a single-center retrospective study. BMC Endocr Disord 2018;18:51. [PMID: 30055596 DOI: 10.1186/s12902-018-0274-y] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
313 Cheng YJ, Meng CT, Ying HY, Zhou JF, Yan XY, Gao X, Zhou N, Bai CM. Effect of Endostar combined with chemotherapy in advanced well-differentiated pancreatic neuroendocrine tumors. Medicine (Baltimore) 2018;97:e12750. [PMID: 30407280 DOI: 10.1097/MD.0000000000012750] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
314 Davis LM, Nicou N, Martin W, Corcoran B, Mulholland N, Srirajaskanthan R, Ramage J, Wendler O, Vivian G. Timing of peptide receptor radiotargeted therapy in relation to cardiac valve surgery for carcinoid heart disease in patients with neuroendocrine metastases and cardiac syndrome. A single-centre study from a centre of excellence. Nucl Med Commun 2020;41:575-81. [PMID: 32371675 DOI: 10.1097/MNM.0000000000001200] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
315 Wan L, Tu C, Qi L, Li Z. Survivorship and prognostic factors for pleomorphic liposarcoma: a population-based study. J Orthop Surg Res 2021;16:175. [PMID: 33663547 DOI: 10.1186/s13018-021-02327-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
316 Pu N, Habib JR, Bejjani M, Yin H, Nagai M, Chen J, Kinny-Köster B, Chen Q, Zhang J, Yu J, Wu W, Lou W. The effect of primary site, functional status and treatment modality on survival in gastroenteropancreatic neuroendocrine neoplasms with synchronous liver metastasis: a US population-based study. Ann Transl Med 2021;9:329. [PMID: 33708956 DOI: 10.21037/atm-20-5348] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
317 Półtorak-Szymczak G, Budlewski T, Furmanek MI, Wierzba W, Sklinda K, Walecki J, Mruk B. Radiological Imaging of Gastro-Entero-Pancreatic Neuroendocrine Tumors. The Review of Current Literature Emphasizing the Diagnostic Value of Chosen Imaging Methods. Front Oncol 2021;11:670233. [PMID: 34211845 DOI: 10.3389/fonc.2021.670233] [Reference Citation Analysis]
318 Centonze G, Biganzoli D, Prinzi N, Pusceddu S, Mangogna A, Tamborini E, Perrone F, Busico A, Lagano V, Cattaneo L, Sozzi G, Roz L, Biganzoli E, Milione M. Beyond Traditional Morphological Characterization of Lung Neuroendocrine Neoplasms: In Silico Study of Next-Generation Sequencing Mutations Analysis across the Four World Health Organization Defined Groups. Cancers (Basel) 2020;12:E2753. [PMID: 32987854 DOI: 10.3390/cancers12102753] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
319 Beyer L, Gosewisch A, Lindner S, Völter F, Mittlmeier LM, Tiling R, Brendel M, Cyran CC, Unterrainer M, Rübenthaler J, Auernhammer CJ, Spitzweg C, Böning G, Gildehaus FJ, Jurkschat K, Wängler C, Wängler B, Schirrmacher R, Wenter V, Todica A, Bartenstein P, Ilhan H. Dosimetry and optimal scan time of [18F]SiTATE-PET/CT in patients with neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2021. [PMID: 33928401 DOI: 10.1007/s00259-021-05351-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
320 Alì G, Di Stefano I, Poma AM, Ricci S, Proietti A, Davini F, Lucchi M, Melfi F, Fontanini G. Prevalence of Delta-Like Protein 3 in a Consecutive Series of Surgically Resected Lung Neuroendocrine Neoplasms. Front Oncol 2021;11:729765. [PMID: 34568063 DOI: 10.3389/fonc.2021.729765] [Reference Citation Analysis]
321 Jiménez-Fonseca P, Morales Del Burgo P, Alvarez-Manceñido F. Histologic and molecular features of small well-differentiated pancreatic neuroendocrine tumors associated with the development of liver metastases. Hepatobiliary Surg Nutr 2019;8:433-5. [PMID: 31489325 DOI: 10.21037/hbsn.2019.04.10] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
322 Li J, Lu J, Liang P, Li A, Hu Y, Shen Y, Hu D, Li Z. Differentiation of atypical pancreatic neuroendocrine tumors from pancreatic ductal adenocarcinomas: Using whole-tumor CT texture analysis as quantitative biomarkers. Cancer Med 2018;7:4924-31. [PMID: 30151864 DOI: 10.1002/cam4.1746] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 8.0] [Reference Citation Analysis]
323 Gagliano T, Brancolini C. Targeting histone deacetylases for combination therapies in neuroendocrine tumors. Cancer Gene Ther 2021;28:547-50. [PMID: 33221822 DOI: 10.1038/s41417-020-00260-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
324 Wonn SM, Limbach KE, Pommier SJ, Ratzlaff AN, Leon EJ, McCully BH, Pommier RF. Outcomes of cytoreductive operations for peritoneal carcinomatosis with or without liver cytoreduction in patients with small bowel neuroendocrine tumors. Surgery 2021;169:168-74. [PMID: 32473829 DOI: 10.1016/j.surg.2020.03.030] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
325 Forero Molina MA, Garcia E, Gonzalez-Devia D, García-Duperly R, Vera A. A 17-year-old male with a Small Bowel Neuroendocrine Tumor: flushing differential diagnosis. World Allergy Organ J 2017;10:30. [PMID: 28904734 DOI: 10.1186/s40413-017-0161-4] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
326 Guo C, Zhuge X, Wang Z, Wang Q, Sun K, Feng Z, Chen X. Textural analysis on contrast-enhanced CT in pancreatic neuroendocrine neoplasms: association with WHO grade. Abdom Radiol (NY). 2019;44:576-585. [PMID: 30182253 DOI: 10.1007/s00261-018-1763-1] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 27.0] [Reference Citation Analysis]
327 Zhang T, Zhang Y, Liu X, Xu H, Chen C, Zhou X, Liu Y, Ma X. Application of Radiomics Analysis Based on CT Combined With Machine Learning in Diagnostic of Pancreatic Neuroendocrine Tumors Patient's Pathological Grades. Front Oncol 2020;10:521831. [PMID: 33643890 DOI: 10.3389/fonc.2020.521831] [Reference Citation Analysis]
328 Zou J, Chen S, Lian G, Li R, Li Y, Huang K, Chen Y. Prognostic and metastasis-related factors in colorectal neuroendocrine tumors: A cross-sectional study based on the Surveillance, Epidemiology and End Results. Oncol Lett 2019;18:5129-38. [PMID: 31612024 DOI: 10.3892/ol.2019.10876] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
329 Lin Z, Wang H, Zhang Y, Li G, Pi G, Yu X, Chen Y, Jin K, Chen L, Yang S, Zhu Y, Wu G, Chen J, Zhang T. Development and Validation of a Prognostic Nomogram to Guide Decision-Making for High-Grade Digestive Neuroendocrine Neoplasms. Oncologist 2020;25:e659-67. [PMID: 32297441 DOI: 10.1634/theoncologist.2019-0566] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
330 Pusceddu S, Barretta F, Trama A, Botta L, Milione M, Buzzoni R, De Braud F, Mazzaferro V, Pastorino U, Seregni E, Mariani L, Gatta G, Di Bartolomeo M, Femia D, Prinzi N, Coppa J, Panzuto F, Antonuzzo L, Bajetta E, Brizzi MP, Campana D, Catena L, Comber H, Dwane F, Fazio N, Faggiano A, Giuffrida D, Henau K, Ibrahim T, Marconcini R, Massironi S, Žakelj MP, Spada F, Tafuto S, Van Eycken E, Van der Zwan JM, Žagar T, Giacomelli L, Miceli R; NEPscore Working Group. A classification prognostic score to predict OS in stage IV well-differentiated neuroendocrine tumors. Endocr Relat Cancer 2018;25:607-18. [PMID: 29559553 DOI: 10.1530/ERC-17-0489] [Cited by in Crossref: 10] [Cited by in F6Publishing: 3] [Article Influence: 3.3] [Reference Citation Analysis]
331 Underwood PW, Riner AN, Neal D, Cameron ME, Yakovenko A, Reddy S, Rose JB, Hughes SJ, Trevino JG. It's more than just cancer biology: Health disparities in patients with pancreatic neuroendocrine tumors. J Surg Oncol 2021. [PMID: 34499741 DOI: 10.1002/jso.26667] [Reference Citation Analysis]
332 Giraldi L, Vecchioni A, Carioli G, Bilotta M, La Rosa S, Imperatori A, Volante M, Brizzi MP, Inzani F, Petrone G, Schinzari G, Bianchi A, Margaritora S, Alfieri S, La Vecchia C, Boccia S, Rindi G. Risk factors for pancreas and lung neuroendocrine neoplasms: a case-control study. Endocrine 2021;71:233-41. [PMID: 32869113 DOI: 10.1007/s12020-020-02464-5] [Reference Citation Analysis]
333 Ptasnuka M, Ozolins A, Narbuts Z, Truskovs A, Sperga M, Plaudis H. Epidemiological Data and Treatment of Gastroenteropancreatic Neuroendocrine Neoplasms: Insights From Tertiary Referral Hospitals in Latvia. World J Surg 2020;44:585-93. [PMID: 31605174 DOI: 10.1007/s00268-019-05219-0] [Reference Citation Analysis]
334 Anthony LB, Kulke MH, Caplin ME, Bergsland E, Öberg K, Pavel M, Hörsch D, Warner RRP, O'Dorisio TM, Dillon JS, Lapuerta P, Kassler-Taub K, Jiang W. Long-Term Safety Experience with Telotristat Ethyl Across Five Clinical Studies in Patients with Carcinoid Syndrome. Oncologist 2019;24:e662-70. [PMID: 30651397 DOI: 10.1634/theoncologist.2018-0236] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
335 Sobotka LA, Hake T, Kelly C, Mousa L. Metastatic neuroendocrine carcinoma presenting as multifocal liver lesions with elevated alpha-fetoprotein. Clin Case Rep. 2019;7:251-253. [PMID: 30847183 DOI: 10.1002/ccr3.1956] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
336 Lim JY, Pommier RF. Clinical Features, Management, and Molecular Characteristics of Familial Small Bowel Neuroendocrine Tumors. Front Endocrinol (Lausanne) 2021;12:622693. [PMID: 33732215 DOI: 10.3389/fendo.2021.622693] [Reference Citation Analysis]
337 Alexandraki KI, Daskalakis K, Tsoli M, Grossman AB, Kaltsas GA. Endocrinological Toxicity Secondary to Treatment of Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NENs). Trends Endocrinol Metab 2020;31:239-55. [PMID: 31839442 DOI: 10.1016/j.tem.2019.11.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
338 Alwan H, La Rosa S, Andreas Kopp P, Germann S, Maspoli-Conconi M, Sempoux C, Bulliard JL. Incidence trends of lung and gastroenteropancreatic neuroendocrine neoplasms in Switzerland. Cancer Med 2020;9:9454-61. [PMID: 33078908 DOI: 10.1002/cam4.3524] [Reference Citation Analysis]
339 Pavel ME, Phan AT, Wolin EM, Mirakhur B, Liyanage N, Pitman Lowenthal S, Fisher GA Jr, Vinik AI; CLARINET Study Investigators. Effect of Lanreotide Depot/Autogel on Urinary 5-Hydroxyindoleacetic Acid and Plasma Chromogranin A Biomarkers in Nonfunctional Metastatic Enteropancreatic Neuroendocrine Tumors. Oncologist 2019;24:463-74. [PMID: 30355775 DOI: 10.1634/theoncologist.2018-0217] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
340 Laird AM, Libutti SK. Management of Other Gastric and Duodenal Neuroendocrine Tumors. Surg Oncol Clin N Am 2020;29:253-66. [PMID: 32151359 DOI: 10.1016/j.soc.2019.11.009] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
341 Tanno L, Pea A, Nykänen T, Prasad P, Tuncer C, Marchegiani G, Robinson S. Role of Pre-operative Inflammatory Markers as Predictors of Lymph Node Positivity and Disease Recurrence in Well-Differentiated Pancreatic Neuroendocrine Tumours: Pancreas2000 Research and Educational Program (Course 9). Front Med (Lausanne) 2020;7:346. [PMID: 32850881 DOI: 10.3389/fmed.2020.00346] [Reference Citation Analysis]
342 Li YF, Zhang QQ, Wang WL. Clinicopathological Characteristics and Survival Outcomes of Primary Hepatic Neuroendocrine Tumor: A Surveillance, Epidemiology, and End Results (SEER) Population-Based Study. Med Sci Monit 2020;26:e923375. [PMID: 32651994 DOI: 10.12659/MSM.923375] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
343 Xu SS, Li H, Li TJ, Li S, Xia HY, Long J, Wu CT, Wang WQ, Zhang WH, Gao HL, Han X, Ye LY, Lin X, Xu HX, Yu XJ, Liu L. Neutrophil Extracellular Traps and Macrophage Extracellular Traps Predict Postoperative Recurrence in Resectable Nonfunctional Pancreatic Neuroendocrine Tumors. Front Immunol 2021;12:577517. [PMID: 34084158 DOI: 10.3389/fimmu.2021.577517] [Reference Citation Analysis]
344 Sun Z, Li D, Wu H, Hou B. Tumour stem cell markers CD133 and CD44 are useful prognostic factors after surgical resection of pancreatic neuroendocrine tumours. Oncol Lett 2020;20:341. [PMID: 33123252 DOI: 10.3892/ol.2020.12204] [Reference Citation Analysis]
345 Felder S, Jann H, Arsenic R, Denecke T, Prasad V, Knappe-Drzikova B, Maasberg S, Wiedenmann B, Pavel M, Pascher A, Pape UF. Gastric neuroendocrine neoplasias: manifestations and comparative outcomes. Endocr Relat Cancer 2019;26:751-63. [PMID: 31272081 DOI: 10.1530/ERC-18-0582] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
346 Sun S, Wang W, He C. Cardiovascular Mortality Risk among Patients with Gastroenteropancreatic Neuroendocrine Neoplasms: A Registry-Based Analysis. Oxid Med Cell Longev 2021;2021:9985814. [PMID: 34257826 DOI: 10.1155/2021/9985814] [Reference Citation Analysis]
347 Muffatti F, Partelli S, Cirocchi R, Andreasi V, Mapelli P, Picchio M, Gianolli L, Falconi M. Combined 68Ga-DOTA-peptides and 18F-FDG PET in the diagnostic work-up of neuroendocrine neoplasms (NEN). Clin Transl Imaging 2019;7:181-8. [DOI: 10.1007/s40336-019-00328-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
348 Rinke A, Auernhammer CJ, Bodei L, Kidd M, Krug S, Lawlor R, Marinoni I, Perren A, Scarpa A, Sorbye H, Pavel ME, Weber MM, Modlin I, Gress TM. Treatment of advanced gastroenteropancreatic neuroendocrine neoplasia, are we on the way to personalised medicine? Gut 2021;70:1768-81. [PMID: 33692095 DOI: 10.1136/gutjnl-2020-321300] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
349 Waseem N, Aparici CM, Kunz PL. Evaluating the Role of Theranostics in Grade 3 Neuroendocrine Neoplasms. J Nucl Med 2019;60:882-91. [PMID: 30850504 DOI: 10.2967/jnumed.118.217851] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
350 Assi HA, Hornbacker K, Shaheen S, Wittenberg T, Silberman R, Kunz PL. Rapid Progression After 177Lu-DOTATATE in Patients With Neuroendocrine Tumors. Pancreas 2021;50:890-4. [PMID: 34398071 DOI: 10.1097/MPA.0000000000001841] [Reference Citation Analysis]
351 De Rycke O, Védie AL, Guarneri G, Nin F, De Flori C, Hentic O, Idri S, Sauvanet A, Rebours V, Cros J, Couvelard A, Ruszniewski P, de Mestier L. O-positive blood type is associated with prolonged recurrence-free survival following curative resection of pancreatic neuroendocrine tumors. Pancreatology 2020;20:1718-22. [PMID: 33032924 DOI: 10.1016/j.pan.2020.09.014] [Reference Citation Analysis]
352 Waked B, De Maeyer F, Carton S, Pieter-Jan C, Vandamme T, Verslype C, Demetter P, Borbath I, Van Eycken L, Hoorens A, Geboes K, Van Damme N, Ribeiro S. Quality of pathology reporting and adherence to guidelines in rectal neuroendocrine neoplasms: a Belgian national study. Acta Clin Belg 2021;:1-9. [PMID: 34607538 DOI: 10.1080/17843286.2021.1985806] [Reference Citation Analysis]
353 Hackeng WM, Schelhaas W, Morsink FHM, Heidsma CM, van Eeden S, Valk GD, Vriens MR, Heaphy CM, Nieveen van Dijkum EJM, Offerhaus GJA, Dreijerink KMA, Brosens LAA. Alternative Lengthening of Telomeres and Differential Expression of Endocrine Transcription Factors Distinguish Metastatic and Non-metastatic Insulinomas. Endocr Pathol 2020;31:108-18. [PMID: 32103422 DOI: 10.1007/s12022-020-09611-8] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 11.0] [Reference Citation Analysis]
354 Kole C, Charalampakis N, Vailas M, Tolia M, Sotiropoulou M, Tsakatikas S, Kouris NI, Tsoli M, Koumarianou A, Karamouzis MV, Schizas D. Immunotherapy for gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): a 2021 update. Cancer Immunol Immunother 2021. [PMID: 34471940 DOI: 10.1007/s00262-021-03046-8] [Reference Citation Analysis]
355 Zheng M, Li Y, Li T, Zhang L, Zhou L. Resection of the primary tumor improves survival in patients with gastro-entero-pancreatic neuroendocrine neoplasms with liver metastases: A SEER-based analysis. Cancer Med 2019;8:5128-36. [PMID: 31328428 DOI: 10.1002/cam4.2431] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
356 Mirallas O, Saoudi N, Gómez-Puerto D, Riveiro-Barciela M, Merino X, Auger C, Landolfi S, Blanco L, Garcia-Burillo A, Molero X, Salcedo-Allende MT, Capdevila J. Acquired hepatocerebral degeneration in a metastatic neuroendocrine tumor long-term survivor — an update on neuroendocrine neoplasm’s treatment: A case report. World J Hepatol 2021; 13(5): 611-619 [PMID: 34131474 DOI: 10.4254/wjh.v13.i5.611] [Reference Citation Analysis]
357 Hauser H, Gerson DS, Reidy-Lagunes D, Raj N. Systemic Therapies for Metastatic Pancreatic Neuroendocrine Tumors. Curr Treat Options Oncol. 2019;20:87. [PMID: 31776785 DOI: 10.1007/s11864-019-0690-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
358 Frizziero M, Durand A, Taboada RG, Zaninotto E, Luchini C, Chakrabarty B, Hervieu V, Claro LCL, Zhou C, Cingarlini S, Milella M, Walter T, Riechelmann RS, Lamarca A, Hubner RA, Mansoor W, Valle JW, McNamara MG. Is the Morphological Subtype of Extra-Pulmonary Neuroendocrine Carcinoma Clinically Relevant? Cancers (Basel) 2021;13:4152. [PMID: 34439308 DOI: 10.3390/cancers13164152] [Reference Citation Analysis]
359 Hayes AR, Chan DLH, Chan BA, Pavlakis N. The quality of clinical trials in neuroendocrine tumours; have we learnt from our mistakes? An evaluation of phase II and phase III clinical trials. J Neuroendocrinol 2021;:e13015. [PMID: 34397130 DOI: 10.1111/jne.13015] [Reference Citation Analysis]
360 Muscogiuri G, Altieri B, Albertelli M, Dotto A, Modica R, Barrea L, Fanciulli G, Feola T, Baldelli R, Ruggeri RM, Gallo M, Guarnotta V, Malandrino P, Messina E, Venneri MA, Giannetta E, Ferone D, Colao A, Faggiano A; NIKE group. Epidemiology of pancreatic neuroendocrine neoplasms: a gender perspective. Endocrine 2020;69:441-50. [PMID: 32468269 DOI: 10.1007/s12020-020-02331-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
361 Ding X, Tian S, Hu J, Wang G, Yu X, Fu D, Yuan Y, Wang L, Wang Z. Risk and prognostic nomograms for colorectal neuroendocrine neoplasm with liver metastasis: a population-based study. Int J Colorectal Dis 2021;36:1915-27. [PMID: 34061225 DOI: 10.1007/s00384-021-03920-y] [Reference Citation Analysis]
362 Dasari A, Joish VN, Perez-olle R, Dharba S, Balaji K, Halperin DM. Work productivity burden and indirect costs associated with carcinoid syndrome diarrhea. Expert Review of Pharmacoeconomics & Outcomes Research 2020;20:507-11. [DOI: 10.1080/14737167.2019.1660646] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
363 Ouvrard E, Chevalier E, Addeo P, Sahakian N, Detour J, Goichot B, Bachellier P, Karcher G, Taïeb D, Imperiale A. Intraindividual comparison of 18 F-FDOPA and 68 Ga-DOTATOC PET/CT detection rate for metastatic assessment in patients with ileal neuroendocrine tumours. Clin Endocrinol (Oxf) 2021;94:66-73. [PMID: 32790887 DOI: 10.1111/cen.14312] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
364 Scott AT, Howe JR. Management of Small Bowel Neuroendocrine Tumors. Surg Oncol Clin N Am 2020;29:223-41. [PMID: 32151357 DOI: 10.1016/j.soc.2019.11.006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
365 Popa O, Taban SM, Pantea S, Plopeanu AD, Barna RA, Cornianu M, Pascu AA, Dema ALC. The new WHO classification of gastrointestinal neuroendocrine tumors and immunohistochemical expression of somatostatin receptor 2 and 5. Exp Ther Med 2021;22:1179. [PMID: 34475969 DOI: 10.3892/etm.2021.10613] [Reference Citation Analysis]
366 Naraev BG, Ramirez RA, Kendi AT, Halfdanarson TR. Peptide Receptor Radionuclide Therapy for Patients With Advanced Lung Carcinoids. Clin Lung Cancer. 2019;20:e376-e392. [PMID: 30910575 DOI: 10.1016/j.cllc.2019.02.007] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 7.5] [Reference Citation Analysis]
367 Auernhammer CJ, Spitzweg C, Angele MK, Boeck S, Grossman A, Nölting S, Ilhan H, Knösel T, Mayerle J, Reincke M, Bartenstein P. Advanced neuroendocrine tumours of the small intestine and pancreas: clinical developments, controversies, and future strategies. Lancet Diabetes Endocrinol 2018;6:404-15. [PMID: 29229497 DOI: 10.1016/S2213-8587(17)30401-1] [Cited by in Crossref: 34] [Cited by in F6Publishing: 21] [Article Influence: 8.5] [Reference Citation Analysis]
368 Yu F, Fu J, Zhang C, Wu W, Ai S, Yao X, Meng Q, Huang Y, Lu G, Wang F, Qu W. Use of Chromogranin A for Monitoring Patients With Pancreatic Neuroendocrine Neoplasms. Pancreas 2021;50:882-9. [PMID: 34347728 DOI: 10.1097/MPA.0000000000001852] [Reference Citation Analysis]
369 Liu M, Popa EC, Finnerty BM, Fahey TJ 3rd, Zarnegar R. Clinicopathological Features of Gastroesophageal Neuroendocrine Neoplasms. Curr Gastroenterol Rep 2020;22:50. [PMID: 32797314 DOI: 10.1007/s11894-020-00788-w] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
370 Aoki T, Kubota K, Kiritani S, Arita J, Morizane C, Masui T, Kudo A, Komoto I, Hatano E, Ito T, Osamura RY, Unno M, Uemoto S, Kokudo N; Japanese Neuroendocrine Tumor Society (JNETS). Survey of surgical resections for neuroendocrine liver metastases: A project study of the Japan Neuroendocrine Tumor Society (JNETS). J Hepatobiliary Pancreat Sci 2021;28:489-97. [PMID: 33792204 DOI: 10.1002/jhbp.956] [Reference Citation Analysis]
371 Casey RT, Valk GD, Schalin-Jäntti C, Grossman AB, Thakker RV. ENDOCRINOLOGY IN THE TIME OF COVID-19: Clinical management of neuroendocrine neoplasms (NENs). Eur J Endocrinol 2020;183:G79-88. [PMID: 32554825 DOI: 10.1530/EJE-20-0424] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
372 Rozenblum L, Mokrane FZ, Yeh R, Sinigaglia M, Besson F, Seban RD, Chougnet CN, Revel-Mouroz P, Zhao B, Otal P, Schwartz LH, Dercle L. The role of multimodal imaging in guiding resectability and cytoreduction in pancreatic neuroendocrine tumors: focus on PET and MRI. Abdom Radiol (NY) 2019;44:2474-93. [PMID: 30980115 DOI: 10.1007/s00261-019-01994-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
373 Chablaney S, Zator ZA, Kumta NA. Diagnosis and Management of Rectal Neuroendocrine Tumors. Clin Endosc. 2017;50:530-536. [PMID: 29207857 DOI: 10.5946/ce.2017.134] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
374 Guan M, He I, Luu M, David J, Gong J, Placencio-Hickok VR, Reznik RS, Tuli R, Hendifar AE. Palliative Radiation Therapy for Bone Metastases in Neuroendocrine Neoplasms. Adv Radiat Oncol 2019;4:513-9. [PMID: 31360808 DOI: 10.1016/j.adro.2019.03.014] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
375 Vesterinen T, Salmenkivi K, Mustonen H, Kuopio T, Lappi-Blanco E, Paavonen T, Vainio P, Knuuttila A, Carpén O, Haglund C, Arola J. Performance of Finnish biobanks in nationwide pulmonary carcinoid tumour research. Virchows Arch 2020;476:273-83. [PMID: 31385069 DOI: 10.1007/s00428-019-02625-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
376 Pavel M, Öberg K, Falconi M, Krenning EP, Sundin A, Perren A, Berruti A; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2020;31:844-60. [PMID: 32272208 DOI: 10.1016/j.annonc.2020.03.304] [Cited by in Crossref: 86] [Cited by in F6Publishing: 83] [Article Influence: 86.0] [Reference Citation Analysis]
377 Imperiale A, Poncet G, Addeo P, Ruhland E, Roche C, Battini S, Cicek AE, Chenard MP, Hervieu V, Goichot B, Bachellier P, Walter T, Namer IJ. Metabolomics of Small Intestine Neuroendocrine Tumors and Related Hepatic Metastases. Metabolites. 2019;9. [PMID: 31835679 DOI: 10.3390/metabo9120300] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
378 Avniel-Polak S, Leibowitz G, Doviner V, Gross DJ, Grozinsky-Glasberg S. Combining chloroquine with RAD001 inhibits tumor growth in a NEN mouse model. Endocr Relat Cancer 2018;25:677-86. [PMID: 29636368 DOI: 10.1530/ERC-18-0121] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
379 Chen L, Guo Y, Zhang Y, Liu M, Zhang Y, Lin Y, Chen MH, Chen J. Development of a novel scoring system based on endoscopic appearance for management of rectal neuroendocrine tumors. Endoscopy 2021;53:702-9. [PMID: 32992347 DOI: 10.1055/a-1274-0161] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
380 van Rees JM, Elferink MAG, Tanis PJ, de Wilt JHW, Burger JWA, Verhoef C. The incidence, treatment and survival of patients with rare types of rectal malignancies in the Netherlands: A population-based study between 1989 and 2018. Eur J Cancer 2021;152:183-92. [PMID: 34118528 DOI: 10.1016/j.ejca.2021.04.036] [Reference Citation Analysis]
381 Inzani F, Rindi G. Introduction to neuroendocrine neoplasms of the digestive system: definition and classification. Pathologica 2021;113:1-4. [PMID: 33686304 DOI: 10.32074/1591-951X-227] [Reference Citation Analysis]
382 Altieri B, Barrea L, Modica R, Muscogiuri G, Savastano S, Colao A, Faggiano A. Nutrition and neuroendocrine tumors: An update of the literature. Rev Endocr Metab Disord 2018;19:159-67. [PMID: 30267297 DOI: 10.1007/s11154-018-9466-z] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 8.0] [Reference Citation Analysis]
383 Kasai Y, Hirose K, Corvera CU, Kim GE, Hope TA, Shih BE, Harun N, Kim M, Warren RS, Bergsland EK, Nakakura EK. Residual tumor volume discriminates prognosis after surgery for neuroendocrine liver metastasis. J Surg Oncol 2019;121:330-6. [DOI: 10.1002/jso.25811] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
384 Becker A, Schalin-Jäntti C, Itkonen O. Comparison of Serum and Urinary 5-Hydroxyindoleacetic Acid as Biomarker for Neuroendocrine Neoplasms. J Endocr Soc 2021;5:bvab106. [PMID: 34195530 DOI: 10.1210/jendso/bvab106] [Reference Citation Analysis]
385 Concors SJ, Sinnamon AJ, Ecker BL, Metz DC, Vollmer CM, Fraker DL, Roses RE. The impact of surgery for metastatic pancreatic neuroendocrine tumor: a contemporary evaluation matching for chromogranin a level. HPB (Oxford) 2020;22:83-90. [PMID: 31239188 DOI: 10.1016/j.hpb.2019.05.011] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
386 Katz LH, Levi Z, Twig G, Kark JD, Leiba A, Derazne E, Liphshiz I, Keinan-Boker L, Eisenstein S, Afek A. Risk factors associated with gastroenteropancreatic neuroendocrine tumors in a cohort of 2.3 million Israeli adolescents. Int J Cancer 2018;143:1876-83. [PMID: 29744856 DOI: 10.1002/ijc.31589] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
387 April-Monn SL, Andreasi V, Schiavo Lena M, Sadowski MC, Kim-Fuchs C, Buri MC, Ketkar A, Maire R, Di Domenico A, Schrader J, Muffatti F, Doglioni C, Partelli S, Falconi M, Perren A, Marinoni I. EZH2 Inhibition as New Epigenetic Treatment Option for Pancreatic Neuroendocrine Neoplasms (PanNENs). Cancers (Basel) 2021;13:5014. [PMID: 34638497 DOI: 10.3390/cancers13195014] [Reference Citation Analysis]
388 Scott AT, Howe JR. Evaluation and Management of Neuroendocrine Tumors of the Pancreas. Surg Clin North Am 2019;99:793-814. [PMID: 31255207 DOI: 10.1016/j.suc.2019.04.014] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 8.0] [Reference Citation Analysis]
389 Hu Y, Ye Z, Wang F, Qin Y, Xu X, Yu X, Ji S. Role of Somatostatin Receptor in Pancreatic Neuroendocrine Tumor Development, Diagnosis, and Therapy. Front Endocrinol (Lausanne) 2021;12:679000. [PMID: 34093445 DOI: 10.3389/fendo.2021.679000] [Reference Citation Analysis]
390 Xu R, Zhou B, Hu P, Xue B, Gu D, Li X, Tang Q. Development and validation of prognostic nomograms for patients with colon neuroendocrine neoplasms. World J Surg Oncol 2021;19:233. [PMID: 34364382 DOI: 10.1186/s12957-021-02338-8] [Reference Citation Analysis]
391 Hackeng WM, Brosens LAA, Kim JY, O'Sullivan R, Sung YN, Liu TC, Cao D, Heayn M, Brosnan-Cashman J, An S, Morsink FHM, Heidsma CM, Valk GD, Vriens MR, Nieveen van Dijkum E, Offerhaus GJA, Dreijerink KMA, Zeh H, Zureikat AH, Hogg M, Lee K, Geller D, Marsh JW, Paniccia A, Ongchin M, Pingpank JF, Bahary N, Aijazi M, Brand R, Chennat J, Das R, Fasanella KE, Khalid A, McGrath K, Sarkaria S, Singh H, Slivka A, Nalesnik M, Han X, Nikiforova MN, Lawlor RT, Mafficini A, Rusev B, Corbo V, Luchini C, Bersani S, Pea A, Cingarlini S, Landoni L, Salvia R, Milione M, Milella M, Scarpa A, Hong SM, Heaphy CM, Singhi AD. Non-functional pancreatic neuroendocrine tumours: ATRX/DAXX and alternative lengthening of telomeres (ALT) are prognostically independent from ARX/PDX1 expression and tumour size. Gut 2021:gutjnl-2020-322595. [PMID: 33849943 DOI: 10.1136/gutjnl-2020-322595] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
392 Inzani F, Petrone G, Rindi G. The New World Health Organization Classification for Pancreatic Neuroendocrine Neoplasia. Endocrinol Metab Clin North Am. 2018;47:463-470. [PMID: 30098710 DOI: 10.1016/j.ecl.2018.04.008] [Cited by in Crossref: 71] [Cited by in F6Publishing: 70] [Article Influence: 23.7] [Reference Citation Analysis]
393 Keutgen XM, Schadde E, Pommier RF, Halfdanarson TR, Howe JR, Kebebew E. Metastatic neuroendocrine tumors of the gastrointestinal tract and pancreas: A surgeon's plea to centering attention on the liver. Semin Oncol 2018;45:232-5. [PMID: 30318110 DOI: 10.1053/j.seminoncol.2018.07.002] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
394 Fehrenbach U, Xin S, Hartenstein A, Auer TA, Dräger F, Froböse K, Jann H, Mogl M, Amthauer H, Geisel D, Denecke T, Wiedenmann B, Penzkofer T. Automatized Hepatic Tumor Volume Analysis of Neuroendocrine Liver Metastases by Gd-EOB MRI-A Deep-Learning Model to Support Multidisciplinary Cancer Conference Decision-Making. Cancers (Basel) 2021;13:2726. [PMID: 34072865 DOI: 10.3390/cancers13112726] [Reference Citation Analysis]
395 Kaçmaz E, Klümpen HJ, Bemelman WA, Nieveen van Dijkum EJM, Engelsman AF, Tanis PJ. Evaluating Nationwide Application of Minimally Invasive Surgery for Treatment of Small Bowel Neuroendocrine Neoplasms. World J Surg 2021;45:2463-70. [PMID: 33783584 DOI: 10.1007/s00268-021-06036-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
396 Berg Z, Koppula BR. 68Ga-DOTATATE Uptake by Cervicothoracic (Stellate) Ganglia. Clin Nucl Med 2019;44:810-1. [DOI: 10.1097/rlu.0000000000002731] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
397 Gabrielsen J, Girone G, Bennett B, Jung A. Long-Acting Somatostatin Analogue Safety Monitoring Protocol for Outpatients With Neuroendocrine Tumors. J Adv Pract Oncol 2019;10:646-59. [PMID: 33391850 DOI: 10.6004/jadpro.2019.10.7.2] [Reference Citation Analysis]
398 Clift AK, Frilling A. Liver-Directed Therapies for Neuroendocrine Neoplasms. Curr Oncol Rep 2021;23:44. [PMID: 33721122 DOI: 10.1007/s11912-021-01030-0] [Reference Citation Analysis]
399 Vesterinen T, Kuopio T, Ahtiainen M, Knuuttila A, Mustonen H, Salmenkivi K, Arola J, Haglund C. PD-1 and PD-L1 expression in pulmonary carcinoid tumors and their association to tumor spread. Endocr Connect 2019;8:1168-75. [PMID: 31299636 DOI: 10.1530/EC-19-0308] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
400 Bagge RO, Demir A, Karlsson J, Alaei-Mahabadi B, Einarsdottir BO, Jespersen H, Lindberg MF, Muth A, Nilsson LM, Persson M, Svensson JB, Söderberg EMV, de Krijger RR, Nilsson O, Larsson E, Stenman G, Nilsson JA. Mutational Signature and Transcriptomic Classification Analyses as the Decisive Diagnostic Tools for a Cancer of Unknown Primary. JCO Precis Oncol 2018;2:PO. [PMID: 32913988 DOI: 10.1200/PO.18.00002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
401 Goksu SY, Ozer M, Kazmi SMA, Sanford NN, Aguilera TA, Ahn C, Hsiehchen D, Sanjeevaiah A, Khosama L, Bleeker J, Atiq M, Beg MS. Distinct Clinical Characteristics in Young-Onset Pancreatic Neuroendocrine Tumor. Cancers (Basel) 2020;12:E2501. [PMID: 32899271 DOI: 10.3390/cancers12092501] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
402 Meoni G, Giommoni E, Petreni P, Pillozzi S, Mazzoni F, Pellegrini E, Brugia M, Lunghi A, Muto A, Antonuzzo L. Somatostatin analogs in pregnant patients with neuroendocrine tumor. Anti-Cancer Drugs 2020;31:1096-8. [DOI: 10.1097/cad.0000000000000967] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
403 Scott AT, Weitz M, Breheny PJ, Ear PH, Darbro B, Brown BJ, Braun TA, Li G, Umesalma S, Kaemmer CA, Maharjan CK, Quelle DE, Bellizzi AM, Chandrasekharan C, Dillon JS, O'Dorisio TM, Howe JR. Gene Expression Signatures Identify Novel Therapeutics for Metastatic Pancreatic Neuroendocrine Tumors. Clin Cancer Res 2020;26:2011-21. [PMID: 31937620 DOI: 10.1158/1078-0432.CCR-19-2884] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 12.0] [Reference Citation Analysis]
404 Acikgoz Y, Bal O, Dogan M. Albumin-to-Alkaline Phosphatase Ratio: Does It Predict Survival in Grade 1 and Grade 2 Neuroendocrine Tumors? Pancreas 2021;50:111-7. [PMID: 33370032 DOI: 10.1097/MPA.0000000000001720] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
405 Reed CT, Duma N, Halfdanarson T, Buckner J. Primary neuroendocrine carcinoma of the brain. BMJ Case Rep 2019;12:e230582. [PMID: 31537610 DOI: 10.1136/bcr-2019-230582] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
406 Gamboa AC, Liu Y, Lee RM, Zaidi MY, Staley CA, Russell MC, Cardona K, Sullivan PS, Maithel SK. A novel preoperative risk score to predict lymph node positivity for rectal neuroendocrine tumors: An NCDB analysis to guide operative technique. J Surg Oncol 2019;120:932-9. [PMID: 31448820 DOI: 10.1002/jso.25679] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
407 Gudmundsdottir H, Möller PH, Jonasson JG, Björnsson ES. Gastroenteropancreatic neuroendocrine tumors in Iceland: a population-based study. Scand J Gastroenterol 2019;54:69-75. [PMID: 30638086 DOI: 10.1080/00365521.2018.1553061] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
408 Matrood S, Apostolidis L, Schrader J, Krug S, Lahner H, Ramaswamy A, Librizzi D, Kender Z, Kröcher A, Kreutzfeldt S, Gress TM, Rinke A. Multicenter Analysis of Presacral Neuroendocrine Neoplasms-Clinicopathological Characterization and Treatment Outcomes of a Rare Disease. Front Endocrinol (Lausanne) 2021;12:709256. [PMID: 34690926 DOI: 10.3389/fendo.2021.709256] [Reference Citation Analysis]
409 Patanè E, Sgardello SD, Guendil B, Fournier I, Abbassi Z. Unexpected Finding of a Small Intestinal Neuroendocrine Tumor: A Case Report and Literature Review. Am J Case Rep 2020;21:e917759. [PMID: 31988272 DOI: 10.12659/AJCR.917759] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
410 Warsinggih, Liliyanto, Prihantono, Ariani GDW, Faruk M. Colorectal neuroendocrine tumors: A case series. Int J Surg Case Rep 2020;72:411-7. [PMID: 32563832 DOI: 10.1016/j.ijscr.2020.06.030] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
411 Pavel ME, Singh S, Strosberg JR, Bubuteishvili-pacaud L, Degtyarev E, Neary MP, Carnaghi C, Tomasek J, Wolin E, Raderer M, Lahner H, Valle JW, Pommier R, Van Cutsem E, Tesselaar MET, Fave GD, Buzzoni R, Hunger M, Eriksson J, Cella D, Ricci J, Fazio N, Kulke MH, Yao JC. Health-related quality of life for everolimus versus placebo in patients with advanced, non-functional, well-differentiated gastrointestinal or lung neuroendocrine tumours (RADIANT-4): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet Oncology 2017;18:1411-22. [DOI: 10.1016/s1470-2045(17)30471-0] [Cited by in Crossref: 39] [Cited by in F6Publishing: 22] [Article Influence: 9.8] [Reference Citation Analysis]
412 Cives M, Strosberg J, Al Diffalha S, Coppola D. Analysis of the immune landscape of small bowel neuroendocrine tumors. Endocr Relat Cancer 2019;26:119-30. [PMID: 30400003 DOI: 10.1530/ERC-18-0189] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 13.0] [Reference Citation Analysis]
413 Imaoka H, Sasaki M, Takahashi H, Hashimoto Y, Ohno I, Mitsunaga S, Watanabe K, Umemoto K, Kimura G, Suzuki Y, Kan M, Ikeda M. Alternate Endpoints for Phase II Trials in Advanced Neuroendocrine Tumors. Oncologist 2019;24:47-53. [PMID: 30072388 DOI: 10.1634/theoncologist.2017-0651] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
414 Espinosa-Olarte P, La Salvia A, Riesco-Martinez MC, Anton-Pascual B, Garcia-Carbonero R. Chemotherapy in NEN: still has a role? Rev Endocr Metab Disord 2021;22:595-614. [PMID: 33843007 DOI: 10.1007/s11154-021-09638-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
415 Cavalcanti E, Galleggiante V, Coletta S, Stasi E, Chieppa M, Armentano R, Serino G. Altered miRNAs Expression Correlates With Gastroenteropancreatic Neuroendocrine Tumors Grades. Front Oncol 2020;10:1187. [PMID: 32766159 DOI: 10.3389/fonc.2020.01187] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
416 Trinh VQ, Shi C, Ma C. Gastric neuroendocrine tumours from long-term proton pump inhibitor users are indolent tumours with good prognosis. Histopathology. 2020;77:865-876. [PMID: 32702178 DOI: 10.1111/his.14220] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
417 He R, Zhang W, Chen S, Liu Y, Yang W, Li J. Transcriptional Profiling Reveals the Regulatory Role of DNER in Promoting Pancreatic Neuroendocrine Neoplasms. Front Genet 2020;11:587402. [PMID: 33329729 DOI: 10.3389/fgene.2020.587402] [Reference Citation Analysis]
418 Alexandraki KI, Kaltsas G, Grozinsky-Glasberg S, Oleinikov K, Kos-Kudła B, Kogut A, Srirajaskanthan R, Pizanias M, Poulia KA, Ferreira C, Weickert MO, Daskalakis K. The effect of prophylactic surgery in survival and HRQoL in appendiceal NEN. Endocrine 2020;70:178-86. [PMID: 32524502 DOI: 10.1007/s12020-020-02356-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
419 Trikalinos NA, Chatterjee D, Lee J, Liu J, Williams G, Hawkins W, Hammill C. Accuracy of Grading in Pancreatic Neuroendocrine Neoplasms and Effect on Survival Estimates: An Institutional Experience. Ann Surg Oncol 2020;27:3542-50. [PMID: 32206954 DOI: 10.1245/s10434-020-08377-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
420 Lee L, Ito T, Jensen RT. Prognostic and predictive factors on overall survival and surgical outcomes in pancreatic neuroendocrine tumors: recent advances and controversies. Expert Rev Anticancer Ther. 2019;19:1029-1050. [PMID: 31738624 DOI: 10.1080/14737140.2019.1693893] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 6.5] [Reference Citation Analysis]
421 Bevilacqua A, Calabrò D, Malavasi S, Ricci C, Casadei R, Campana D, Baiocco S, Fanti S, Ambrosini V. A [68Ga]Ga-DOTANOC PET/CT Radiomic Model for Non-Invasive Prediction of Tumour Grade in Pancreatic Neuroendocrine Tumours. Diagnostics (Basel) 2021;11:870. [PMID: 34065981 DOI: 10.3390/diagnostics11050870] [Reference Citation Analysis]
422 Kong G, Grozinsky-glasberg S, Hofman MS, Akhurst T, Meirovitz A, Maimon O, Krausz Y, Godefroy J, Michael M, Gross DJ, Hicks RJ. Highly favourable outcomes with peptide receptor radionuclide therapy (PRRT) for metastatic rectal neuroendocrine neoplasia (NEN). Eur J Nucl Med Mol Imaging 2019;46:718-27. [DOI: 10.1007/s00259-018-4196-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
423 Tsoli M, Spei ME, Wallin G, Kaltsas G, Daskalakis K. Association of a Palliative Surgical Approach to Stage IV Pancreatic Neuroendocrine Neoplasms with Survival: A Systematic Review and Meta-Analysis. Cancers (Basel) 2020;12:E2246. [PMID: 32796714 DOI: 10.3390/cancers12082246] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
424 Mafficini A, Scarpa A. Genetics and Epigenetics of Gastroenteropancreatic Neuroendocrine Neoplasms. Endocr Rev 2019;40:506-36. [PMID: 30657883 DOI: 10.1210/er.2018-00160] [Cited by in Crossref: 60] [Cited by in F6Publishing: 55] [Article Influence: 30.0] [Reference Citation Analysis]
425 Santos AP, Santos AC, Castro C, Raposo L, Pereira SS, Torres I, Henrique R, Cardoso H, Monteiro MP. Visceral Obesity and Metabolic Syndrome Are Associated with Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors. Cancers (Basel) 2018;10:E293. [PMID: 30150555 DOI: 10.3390/cancers10090293] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
426 Li MX, Li QY, Xiao M, Wan DL, Chen XH, Zhou L, Xie HY, Zheng SS. Survival comparison between primary hepatic neuroendocrine neoplasms and primary pancreatic neuroendocrine neoplasms and the analysis on prognosis-related factors. Hepatobiliary Pancreat Dis Int 2019;18:538-45. [PMID: 30981633 DOI: 10.1016/j.hbpd.2019.03.009] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
427 Li G, Tian ML, Bing YT, Tao LY, Wang HY, Jiang B, Yuan CH, Xiu DR. Clinicopathological features and prognosis factors for survival in elderly patients with pancreatic neuroendocrine tumor: A STROBE-compliant article. Medicine (Baltimore) 2019;98:e14576. [PMID: 30882623 DOI: 10.1097/MD.0000000000014576] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
428 Sanli Y, Garg I, Kandathil A, Kendi T, Zanetti MJB, Kuyumcu S, Subramaniam RM. Neuroendocrine Tumor Diagnosis and Management: 68Ga-DOTATATE PET/CT. AJR Am J Roentgenol 2018;211:267-77. [PMID: 29975116 DOI: 10.2214/AJR.18.19881] [Cited by in Crossref: 37] [Cited by in F6Publishing: 12] [Article Influence: 12.3] [Reference Citation Analysis]
429 Grenader T, Pavel ME, Ruszniewski PB, Ćwikła JB, Phan AT, Raderer M, Sedláčková E, Cadiot G, Wolin EM, Capdevila J, Wall L, Rindi G, Truong Thanh XM, Caplin ME; CLARINET Study Group. Prognostic value of the neutrophil/lymphocyte ratio in enteropancreatic neuroendocrine tumors. Anticancer Drugs 2020;31:216-22. [PMID: 31977567 DOI: 10.1097/CAD.0000000000000909] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
430 Chatani PD, Aversa JG, McDonald JD, Khan TM, Keutgen XM, Nilubol N. Preoperative serum chromogranin-a is predictive of survival in locoregional jejuno-ileal small bowel neuroendocrine tumors. Surgery 2021;170:106-13. [PMID: 33814188 DOI: 10.1016/j.surg.2021.01.048] [Reference Citation Analysis]
431 Exarchou K, Howes N, Pritchard DM. Systematic review: management of localised low-grade upper gastrointestinal neuroendocrine tumours. Aliment Pharmacol Ther 2020;51:1247-67. [PMID: 32390152 DOI: 10.1111/apt.15765] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
432 Ramírez-Rentería C, Ferreira-Hermosillo A, Marrero-Rodríguez D, Taniguchi-Ponciano K, Melgar-Manzanilla V, Mercado M. An Update on Gastroenteropancreatic Neuroendocrine Neoplasms: From Mysteries to Paradigm Shifts. Arch Med Res 2020;51:765-76. [PMID: 32654882 DOI: 10.1016/j.arcmed.2020.06.018] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
433 Chan DL, Ulaner GA, Pattison D, Wyld D, Ladwa R, Kirchner J, Li BT, Lai WV, Pavlakis N, Roach PJ, Bailey DL. Dual PET Imaging in Bronchial Neuroendocrine Neoplasms: The NETPET Score as a Prognostic Biomarker. J Nucl Med 2021;62:1278-84. [PMID: 33579809 DOI: 10.2967/jnumed.120.257659] [Reference Citation Analysis]
434 Goksu SY, Ozer M, Beg MS, Sanford NN, Ahn C, Fangman BD, Goksu BB, Verma U, Sanjeevaiah A, Hsiehchen D, Jones AL, Kainthla R, Kazmi SM. Racial/Ethnic Disparities and Survival Characteristics in Non-Pancreatic Gastrointestinal Tract Neuroendocrine Tumors. Cancers (Basel) 2020;12:E2990. [PMID: 33076486 DOI: 10.3390/cancers12102990] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
435 Bruera G, Giuliani A, Romano L, Chiominto A, Di Sibio A, Mastropietro S, Cosenza P, Ricevuto E, Schietroma M, Carlei F; Oncology Network ASL1 Abruzzo. Poorly differentiated neuroendocrine rectal carcinoma with uncommon immune-histochemical features and clinical presentation with a subcutaneous metastasis, treated with first line intensive triplet chemotherapy plus bevacizumab FIr-B/FOx regimen: an experience of multidisciplinary management in clinical practice. BMC Cancer 2019;19:960. [PMID: 31619203 DOI: 10.1186/s12885-019-6214-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
436 Gonulal B, Bilgic Y, Akbulut S, Karabulut E, Samdanci ET. Management and Survival Analysis of Gastrointestinal Neuroendocrine Tumors by Different Tumor Characteristics: Tertiary Center Experience. J Gastrointest Cancer 2021. [PMID: 34524616 DOI: 10.1007/s12029-021-00709-8] [Reference Citation Analysis]
437 Duan X, Zhao M, Zhang S, Xu Z, Mi L, Shi J, Ma X, Liu Y, Li N, Yin X, Han X, Han G, Wang J, Xu J, Yin F. Effects of tumor distance from anal verge on survival outcomes for rectal NENs and lymphatic metastasis risk score for colorectal NENs. Int J Colorectal Dis 2020;35:1255-64. [PMID: 32314191 DOI: 10.1007/s00384-020-03596-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
438 Yoo C, Oh CR, Kim ST, Bae WK, Choi HJ, Oh DY, Lee MA, Ryoo BY. Systemic Treatment of Advanced Gastroenteropancreatic Neuroendocrine Tumors in Korea: Literature Review and Expert Opinion. Cancer Res Treat 2021;53:291-300. [PMID: 33421978 DOI: 10.4143/crt.2020.1233] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
439 Shen C, Gu D, Zhou S, Xu Y, Sarshekeh AM, Halperin D, Shih YT, Yao JC, Dasari A. Racial Differences in the Incidence and Survival of Patients With Neuroendocrine Tumors. Pancreas 2019;48:1373-9. [DOI: 10.1097/mpa.0000000000001431] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 3.5] [Reference Citation Analysis]
440 Kamiya M, Yamamoto N, Kamioka Y, Inoue H, Yotsumoto H, Murakawa M, Aoyama T, Washimi K, Kawachi K, Oshima T, Ueno M, Yukawa N, Rino Y, Masuda M, Morinaga S. Rapidly progressed neuroendocrine carcinoma in the extrahepatic bile duct: a case report and review of the literature. Surg Case Rep 2020;6:191. [PMID: 32748005 DOI: 10.1186/s40792-020-00945-3] [Reference Citation Analysis]
441 Lim LE, Chan DL, Thomas D, Du Y, Tincknell G, Kuchel A, Davis A, Bailey DL, Pavlakis N, Cehic G, Macdonald W, Wyld D, Segelov E. Australian experience of peptide receptor radionuclide therapy in lung neuroendocrine tumours. Oncotarget 2020;11:2636-46. [PMID: 32676165 DOI: 10.18632/oncotarget.27659] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
442 Ito T, Jensen RT. Perspectives on the current pharmacotherapeutic strategies for management of functional neuroendocrine tumor syndromes. Expert Opin Pharmacother 2021;22:685-93. [PMID: 33131345 DOI: 10.1080/14656566.2020.1845651] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
443 Saito K, Yamaoka Y, Shiomi A, Kagawa H, Hino H, Manabe S, Kato S, Hanaoka M. Short- and Long-Term Outcomes of Robotic Surgery for Rectal Neuroendocrine Tumor. Surg Innov 2021;:15533506211030436. [PMID: 34228945 DOI: 10.1177/15533506211030436] [Reference Citation Analysis]
444 Yan S, Liu T, Li Y, Zhu Y, Jiang J, Jiang L, Zhao H. Value of computed tomography evaluation in pathologic classification and prognosis prediction of gastric neuroendocrine tumors. Ann Transl Med 2019;7:545. [PMID: 31807527 DOI: 10.21037/atm.2019.09.114] [Reference Citation Analysis]
445 Milanetto AC, Fassan M, David A, Pasquali C. Serotonin-Secreting Neuroendocrine Tumours of the Pancreas. J Clin Med 2020;9:E1363. [PMID: 32384679 DOI: 10.3390/jcm9051363] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
446 Kendi AT, Halfdanarson TR, Packard A, Dundar A, Subramaniam RM. Therapy With 177Lu-DOTATATE: Clinical Implementation and Impact on Care of Patients With Neuroendocrine Tumors. AJR Am J Roentgenol. 2019;213:309-317. [PMID: 31039017 DOI: 10.2214/ajr.19.21123] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 4.5] [Reference Citation Analysis]
447 Rinzivillo M, De Felice I, Magi L, Annibale B, Panzuto F. Occurrence of exocrine pancreatic insufficiency in patients with advanced neuroendocrine tumors treated with somatostatin analogs. Pancreatology 2020;20:875-9. [DOI: 10.1016/j.pan.2020.06.007] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
448 Tirosh A, Nilubol N, Patel D, Kebebew E. Prognostic Utility of 24-Hour Urinary 5-HIAA Doubling Time in Patients With Neuroendocrine Tumors. Endocr Pract 2018;24:710-7. [PMID: 30084688 DOI: 10.4158/EP-2018-0022] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
449 de Mestier L, Lorenzo D, Fine C, Cros J, Hentic O, Walter T, Panis Y, Couvelard A, Cadiot G, Ruszniewski P. Endoscopic, transanal, laparoscopic, and transabdominal management of rectal neuroendocrine tumors. Best Practice & Research Clinical Endocrinology & Metabolism 2019;33:101293. [DOI: 10.1016/j.beem.2019.101293] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 7.5] [Reference Citation Analysis]
450 Fang L, Arvind D, Dowlati A, Mohamed A. Role of immunotherapy in gastro-enteropancreatic neuroendocrine neoplasms (gep-nens): Current advances and future directions. J Neuroendocrinol 2021;33:e12943. [PMID: 33724586 DOI: 10.1111/jne.12943] [Reference Citation Analysis]
451 Levy S, van Veenendaal LM, Korse CM, Breekveldt ECH, Verbeek WHM, Vriens MR, Kuhlmann KFD, van den Berg JG, Valk GD, Tesselaar MET. Survival in Patients with Neuroendocrine Tumours of the Small Intestine: Nomogram Validation and Predictors of Survival. J Clin Med 2020;9:E2502. [PMID: 32756529 DOI: 10.3390/jcm9082502] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
452 Partelli S, Landoni L, Andreasi V, Nessi C, Muffatti F, Crippa S, Cingarlini S, Bassi C, Falconi M. Pattern of disease recurrence and treatment after surgery for nonfunctioning well-differentiated pancreatic neuroendocrine tumors. Surgery 2020;168:816-24. [PMID: 32778411 DOI: 10.1016/j.surg.2020.06.034] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
453 Giovannini E, Giovacchini G, Borsò E, Lazzeri P, Riondato M, Leoncini R, Duce V, Ciarmiello A. [ 68 Ga]-Dota Peptide PET/CT in Neuroendocrine Tumors: Main Clinical Applications. CRP 2019;12:11-22. [DOI: 10.2174/1874471012666181212101244] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
454 Altieri B, Di Dato C, Modica R, Bottiglieri F, Di Sarno A, Pittaway JFH, Martini C, Faggiano A, Colao A. Bone Metabolism and Vitamin D Implication in Gastroenteropancreatic Neuroendocrine Tumors. Nutrients 2020;12:E1021. [PMID: 32276412 DOI: 10.3390/nu12041021] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
455 Velikyan I. (Radio)Theranostic Patient Management in Oncology Exemplified by Neuroendocrine Neoplasms, Prostate Cancer, and Breast Cancer. Pharmaceuticals (Basel) 2020;13:E39. [PMID: 32151049 DOI: 10.3390/ph13030039] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
456 Zheng K, Liu T, Zhao J, Meng P, Bian Y, Ni C, Wang H, Pan Y, Wu S, Jiang H, Jin G. Mutational landscape and potential therapeutic targets for sporadic pancreatic neuroendocrine tumors based on target next-generation sequencing. Exp Ther Med 2021;21:415. [PMID: 33747156 DOI: 10.3892/etm.2021.9859] [Reference Citation Analysis]
457 Gong P, Chen C, Wang Z, Zhang X, Hu W, Hu Z, Li X. Prognostic significance for colorectal carcinoid tumors based on the 8th edition TNM staging system. Cancer Med 2020;9:7979-87. [PMID: 32897004 DOI: 10.1002/cam4.3431] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
458 Saif MW, Fu J, Smith MH, Weinstein B, Relias V, Daly KP. Treatment with Lanreotide Depot Following Octreotide Long-Acting Release Among Patients with Gastroenteropancreatic Neuroendocrine Tumors. J Pancreat Cancer 2018;4:64-71. [PMID: 30788459 DOI: 10.1089/pancan.2018.0013] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
459 Mullangi S, Lekkala MR, Raghu Subramanian C, Nemer O, Singh J, Kichloo A, Moftakhar B. Incidental Finding of Squamous Cell Carcinoma on a 68Ga-DOTATATE PET Scan. J Investig Med High Impact Case Rep 2021;9:23247096211035232. [PMID: 34311624 DOI: 10.1177/23247096211035232] [Reference Citation Analysis]
460 Gordon LG, Elliott TM, Wakelin K, Leyden S, Leyden J, Michael M, Pavlakis N, Mumford J, Segelov E, Wyld DK. The Economic Impact on Australian Patients with Neuroendocrine Tumours. Patient 2020;13:363-73. [PMID: 32072460 DOI: 10.1007/s40271-020-00412-z] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
461 Satapathy S, Mittal BR, Sood A, Sood A, Kapoor R, Gupta R. Peptide Receptor Radionuclide Therapy as First-Line Systemic Treatment in Advanced Inoperable/Metastatic Neuroendocrine Tumors. Clin Nucl Med 2020;45:e393-9. [PMID: 32604121 DOI: 10.1097/RLU.0000000000003170] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
462 Liverani C, Bongiovanni A, Mercatali L, Pieri F, Spadazzi C, Miserocchi G, Di Menna G, Foca F, Ravaioli S, De Vita A, Cocchi C, Rossi G, Recine F, Ibrahim T. Diagnostic and Predictive Role of DLL3 Expression in Gastroenteropancreatic Neuroendocrine Neoplasms. Endocr Pathol 2021;32:309-17. [PMID: 33409812 DOI: 10.1007/s12022-020-09657-8] [Reference Citation Analysis]
463 Song Z, Wang S, Wu Y, Zhang J, Liu S. Prognostic Nomograms to Predict Overall Survival and Cancer-Specific Survival of Patients With Pancreatic Neuroendocrine Tumors: A Population-Based Study. Pancreas 2021;50:414-22. [PMID: 33835974 DOI: 10.1097/MPA.0000000000001779] [Reference Citation Analysis]
464 Curtin K, Cannon-Albright LA, VanDerslice J, Yu Z, Herget KA, Thota R, Neklason DW. Associations of Tobacco and Alcohol Use with Risk of Neuroendocrine Tumors of the Small Intestine in Utah. Cancer Epidemiol Biomarkers Prev 2019;28:1998-2004. [PMID: 31558509 DOI: 10.1158/1055-9965.EPI-19-0465] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
465 Ilhan H, Lindner S, Todica A, Cyran CC, Tiling R, Auernhammer CJ, Spitzweg C, Boeck S, Unterrainer M, Gildehaus FJ, Böning G, Jurkschat K, Wängler C, Wängler B, Schirrmacher R, Bartenstein P. Biodistribution and first clinical results of 18F-SiFAlin-TATE PET: a novel 18F-labeled somatostatin analog for imaging of neuroendocrine tumors. Eur J Nucl Med Mol Imaging 2020;47:870-80. [DOI: 10.1007/s00259-019-04501-6] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 10.5] [Reference Citation Analysis]
466 Zhang Z, Zhao X, Li Z, Wu Y, Liu Y, Li Z, Li G. Development of a nomogram model to predict survival outcomes in patients with primary hepatic neuroendocrine tumors based on SEER database. BMC Cancer 2021;21:567. [PMID: 34006241 DOI: 10.1186/s12885-021-08337-y] [Reference Citation Analysis]
467 Bertani E, Ravizza D, Milione M, Massironi S, Grana CM, Zerini D, Piccioli AN, Spinoglio G, Fazio N. Neuroendocrine neoplasms of rectum: A management update. Cancer Treat Rev. 2018;66:45-55. [PMID: 29684743 DOI: 10.1016/j.ctrv.2018.04.003] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 5.3] [Reference Citation Analysis]
468 Tacelli M, Petrone MC, Capurso G, Muffatti F, Andreasi V, Partelli S, Doglioni C, Falconi M, Arcidiacono PG. Diagnostic accuracy of EUS-FNA in the evaluation of pancreatic neuroendocrine neoplasms grading: Possible clinical impact of misclassification. Endosc Ultrasound 2021;10:372-80. [PMID: 34677159 DOI: 10.4103/EUS-D-20-00261] [Reference Citation Analysis]
469 Boons G, Vandamme T, Peeters M, Beyens M, Driessen A, Janssens K, Zwaenepoel K, Roeyen G, Van Camp G, Op de Beeck K. Cell-Free DNA From Metastatic Pancreatic Neuroendocrine Tumor Patients Contains Tumor-Specific Mutations and Copy Number Variations. Front Oncol 2018;8:467. [PMID: 30443491 DOI: 10.3389/fonc.2018.00467] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 3.7] [Reference Citation Analysis]
470 Singh S, Moody L, Chan DL, Metz DC, Strosberg J, Asmis T, Bailey DL, Bergsland E, Brendtro K, Carroll R, Cleary S, Kim M, Kong G, Law C, Lawrence B, McEwan A, McGregor C, Michael M, Pasieka J, Pavlakis N, Pommier R, Soulen M, Wyld D, Segelov E; Commonwealth Neuroendocrine Tumour Collaboration (CommNETS) Follow-up Working Group. Follow-up Recommendations for Completely Resected Gastroenteropancreatic Neuroendocrine Tumors. JAMA Oncol. 2018;4:1597-1604. [PMID: 30054622 DOI: 10.1001/jamaoncol.2018.2428] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 15.5] [Reference Citation Analysis]
471 Wetz C, Rogasch J, Genseke P, Schatka I, Furth C, Kreissl M, Jann H, Venerito M, Amthauer H. Asphericity of Somatostatin Receptor Expression in Neuroendocrine Tumors: An Innovative Predictor of Outcome in Everolimus Treatment? Diagnostics (Basel) 2020;10:E732. [PMID: 32971877 DOI: 10.3390/diagnostics10090732] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
472 Powers BD, Rothermel LD, Fleming JB, Strosberg JR, Anaya DA. A Survival Analysis of Patients with Localized, Asymptomatic Pancreatic Neuroendocrine Tumors: No Surgical Survival Benefit when Examining Appropriately Selected Outcomes. J Gastrointest Surg 2020;24:2773-9. [DOI: 10.1007/s11605-019-04433-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
473 Zhang X, Song J, Liu P, Mazid MA, Lu L, Shang Y, Wei Y, Gong P, Ma L. A modified M-stage classification based on the metastatic patterns of pancreatic neuroendocrine neoplasms: a population-based study. BMC Endocr Disord 2018;18:73. [PMID: 30340569 DOI: 10.1186/s12902-018-0301-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
474 Souche R, Hobeika C, Hain E, Gaujoux S. Surgical Management of Neuroendocrine Tumours of the Pancreas. J Clin Med. 2020;9. [PMID: 32947997 DOI: 10.3390/jcm9092993] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
475 Steinkraus K, Andresen JR, Clift AK, Liedke MO, Frilling A. Multifocal neuroendocrine tumour of the small bowel presenting as an incarcerated incisional hernia: a surgical challenge in a high-risk patient. J Surg Case Rep 2021;2021:rjab219. [PMID: 34150191 DOI: 10.1093/jscr/rjab219] [Reference Citation Analysis]
476 Anoshkin K, Vasilyev I, Karandasheva K, Shugay M, Kudryavtseva V, Egorov A, Gurevich L, Mironova A, Serikov A, Kutsev S, Strelnikov V. New Regions With Molecular Alterations in a Rare Case of Insulinomatosis: Case Report With Literature Review. Front Endocrinol (Lausanne) 2021;12:760154. [PMID: 34737724 DOI: 10.3389/fendo.2021.760154] [Reference Citation Analysis]
477 Carideo L, Prosperi D, Panzuto F, Magi L, Pratesi MS, Rinzivillo M, Annibale B, Signore A. Role of Combined [68Ga] Ga-DOTA-SST Analogues and [18F] FDG PET/CT in the Management of GEP-NENs: A Systematic Review. J Clin Med. 2019;8. [PMID: 31337043 DOI: 10.3390/jcm8071032] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 10.5] [Reference Citation Analysis]
478 Lamarca A, Mccallum L, Nuttall C, Barriuso J, Backen A, Frizziero M, Leon R, Mansoor W, Mcnamara MG, Hubner RA, Valle JW. Somatostatin analogue-induced pancreatic exocrine insufficiency in patients with neuroendocrine tumors: results of a prospective observational study. Expert Review of Gastroenterology & Hepatology 2018;12:723-31. [DOI: 10.1080/17474124.2018.1489232] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 6.3] [Reference Citation Analysis]
479 Barrea L, Altieri B, Muscogiuri G, Laudisio D, Annunziata G, Colao A, Faggiano A, Savastano S. Impact of Nutritional Status on Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) Aggressiveness. Nutrients 2018;10:E1854. [PMID: 30513732 DOI: 10.3390/nu10121854] [Cited by in Crossref: 33] [Cited by in F6Publishing: 27] [Article Influence: 11.0] [Reference Citation Analysis]
480 Haddad T, Fard-Esfahani A, Vali R. A review of pediatric neuroendocrine tumors, their detection, and treatment by radioisotopes. Nucl Med Commun 2021;42:21-31. [PMID: 33044400 DOI: 10.1097/MNM.0000000000001305] [Cited by in Crossref: 4] [Article Influence: 4.0] [Reference Citation Analysis]
481 Wei YL, Hua J, Liu XY, Hua XM, Sun C, Bai JA, Tang QY. LncNEN885 inhibits epithelial-mesenchymal transition by partially regulation of Wnt/β-catenin signalling in gastroenteropancreatic neuroendocrine neoplasms. Cancer Sci 2018;109:3139-48. [PMID: 30033597 DOI: 10.1111/cas.13747] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
482 Gharios J, Hain E, Dohan A, Prat F, Terris B, Bertherat J, Coriat R, Dousset B, Gaujoux S. Pre- and intraoperative diagnostic requirements, benefits and risks of minimally invasive and robotic surgery for neuroendocrine tumors of the pancreas. Best Pract Res Clin Endocrinol Metab. 2019;33:101294. [PMID: 31351817 DOI: 10.1016/j.beem.2019.101294] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
483 Garcia-Torralba E, Spada F, Lim KHJ, Jacobs T, Barriuso J, Mansoor W, McNamara MG, Hubner RA, Manoharan P, Fazio N, Valle JW, Lamarca A. Knowns and unknowns of bone metastases in patients with neuroendocrine neoplasms: A systematic review and meta-analysis. Cancer Treat Rev 2021;94:102168. [PMID: 33730627 DOI: 10.1016/j.ctrv.2021.102168] [Reference Citation Analysis]
484 Chow Z, Johnson J, Chauhan A, Izumi T, Cavnar M, Weiss H, Townsend CM Jr, Anthony L, Wasilchenko C, Melton ML, Schrader J, Evers BM, Rychahou P. PI3K/mTOR Dual Inhibitor PF-04691502 Is a Schedule-Dependent Radiosensitizer for Gastroenteropancreatic Neuroendocrine Tumors. Cells 2021;10:1261. [PMID: 34065268 DOI: 10.3390/cells10051261] [Reference Citation Analysis]
485 Hofland J, Kaltsas G, de Herder WW. Advances in the Diagnosis and Management of Well-Differentiated Neuroendocrine Neoplasms. Endocr Rev. 2020;41. [PMID: 31555796 DOI: 10.1210/endrev/bnz004] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 28.0] [Reference Citation Analysis]
486 Coriat R. Better Management for Neuroendocrine Neoplasms: A Complex Task Ahead. J Clin Med 2021;10:1859. [PMID: 33922910 DOI: 10.3390/jcm10091859] [Reference Citation Analysis]
487 Han X, Chen W, Chen P, Zhou W, Rong Y, Lv Y, Li JA, Ji Y, Chen W, Lou W, Xu X. Aberration of ARID1A Is Associated With the Tumorigenesis and Prognosis of Sporadic Nonfunctional Pancreatic Neuroendocrine Tumors. Pancreas 2020;49:514-23. [PMID: 32282764 DOI: 10.1097/MPA.0000000000001535] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
488 Raj N, Fazio N, Strosberg J. Biology and Systemic Treatment of Advanced Gastroenteropancreatic Neuroendocrine Tumors. American Society of Clinical Oncology Educational Book 2018. [DOI: 10.1200/edbk_200893] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
489 Shah S, Gosain R, Groman A, Gosain R, Dasari A, Halfdanarson TR, Mukherjee S. Incidence and Survival Outcomes in Patients with Lung Neuroendocrine Neoplasms in the United States. Cancers (Basel) 2021;13:1753. [PMID: 33916960 DOI: 10.3390/cancers13081753] [Reference Citation Analysis]
490 Allmark A, Brubaker ML. Small cell neuroendocrine carcinoma disguised as an external hemorrhoid. JAAPA 2021;34:35-9. [PMID: 34320538 DOI: 10.1097/01.JAA.0000742960.70174.8d] [Reference Citation Analysis]
491 Andreasi V, Muffatti F, Guarneri G, Falconi M, Partelli S. Surgical Principles in the Management of Pancreatic Neuroendocrine Neoplasms. Curr Treat Options Oncol. 2020;21:48. [PMID: 32350693 DOI: 10.1007/s11864-020-00736-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
492 Bartolini I, Bencini L, Risaliti M, Ringressi MN, Moraldi L, Taddei A. Current Management of Pancreatic Neuroendocrine Tumors: From Demolitive Surgery to Observation. Gastroenterol Res Pract 2018;2018:9647247. [PMID: 30140282 DOI: 10.1155/2018/9647247] [Cited by in Crossref: 8] [Cited by in F6Publishing: 12] [Article Influence: 2.7] [Reference Citation Analysis]
493 Kaemmer CA, Umesalma S, Maharjan CK, Moose DL, Narla G, Mott SL, Zamba GKD, Breheny P, Darbro BW, Bellizzi AM, Henry MD, Quelle DE. Development and comparison of novel bioluminescent mouse models of pancreatic neuroendocrine neoplasm metastasis. Sci Rep 2021;11:10252. [PMID: 33986468 DOI: 10.1038/s41598-021-89866-1] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
494 Guo C, Zhuge X, Wang Z, Wang Q, Sun K, Feng Z, Chen X. Textural analysis on contrast-enhanced CT in pancreatic neuroendocrine neoplasms: association with WHO grade. Abdom Radiol 2019;44:576-85. [DOI: 10.1007/s00261-018-1763-1] [Reference Citation Analysis]
495 Exarchou K, Kamieniarz L, Tsoli M, Victor A, Oleinikov K, Khan MS, Srirajaskanthan R, Mandair D, Grozinsky-Glasberg S, Kaltsas G, Howes N, Pritchard DM, Toumpanakis C. Is local excision sufficient in selected grade 1 or 2 type III gastric neuroendocrine neoplasms? Endocrine 2021. [PMID: 34120313 DOI: 10.1007/s12020-021-02775-1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
496 Herrera-Martínez AD, Gahete MD, Pedraza-Arevalo S, Sánchez-Sánchez R, Ortega-Salas R, Serrano-Blanch R, Luque RM, Gálvez-Moreno MA, Castaño JP. Clinical and functional implication of the components of somatostatin system in gastroenteropancreatic neuroendocrine tumors. Endocrine 2018;59:426-37. [PMID: 29196939 DOI: 10.1007/s12020-017-1482-3] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 4.8] [Reference Citation Analysis]
497 Koumarianou A, Alexandraki KI, Wallin G, Kaltsas G, Daskalakis K. Pathogenesis and Clinical Management of Mesenteric Fibrosis in Small Intestinal Neuroendocine Neoplasms: A Systematic Review. J Clin Med. 2020;9. [PMID: 32521677 DOI: 10.3390/jcm9061777] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
498 Jiang R, Hong X, Zhao Y, Wu W. Application of multiomics sequencing and advances in the molecular mechanisms of pancreatic neuroendocrine neoplasms. Cancer Lett 2021;499:39-48. [PMID: 33246093 DOI: 10.1016/j.canlet.2020.11.012] [Reference Citation Analysis]
499 Perri G, Prakash LR, Katz MHG. Pancreatic neuroendocrine tumors. Curr Opin Gastroenterol 2019;35:468-77. [PMID: 31306159 DOI: 10.1097/MOG.0000000000000571] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
500 Shen C, Dasari A, Gu D, Chu Y, Zhou S, Xu Y, Halperin D, Fu S, Yao JC, Shih YT. Costs of Cancer Care for Elderly Patients with Neuroendocrine Tumors. Pharmacoeconomics 2018;36:1005-13. [PMID: 29682693 DOI: 10.1007/s40273-018-0656-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
501 Wang M, Ding D, Qin T, Wang H, Liu Y, Liu J, Liu J, Zhang H, Zhao J, Wu CH, Javed A, Wolfgang C, Guo S, Chen Q, Zhao W, Shi W, Zhu F, Guo X, Li X, He R, Xu S, Edil B, Tien YW, Jin G, Zheng L, He J, Qin R; Minimally Invasive Pancreas Treatment Group in the Pancreatic Disease Branch of China's International Exchange and Promotion Association for Medicine and Healthcare. New staging classification for pancreatic neuroendocrine neoplasms combining TNM stage and WHO grade classification []. Cancer Lett 2021;518:207-13. [PMID: 34271105 DOI: 10.1016/j.canlet.2021.07.018] [Reference Citation Analysis]
502 Derks JL, Rijnsburger N, Hermans BCM, Moonen L, Hillen LM, von der Thüsen JH, den Bakker MA, van Suylen RJ, Speel EM, Dingemans AC. Clinical-Pathologic Challenges in the Classification of Pulmonary Neuroendocrine Neoplasms and Targets on the Horizon for Future Clinical Practice. J Thorac Oncol 2021:S1556-0864(21)02228-0. [PMID: 34139363 DOI: 10.1016/j.jtho.2021.05.020] [Reference Citation Analysis]
503 Ryan P, McBride A, Ray D, Pulgar S, Ramirez RA, Elquza E, Favaro JP, Dranitsaris G. Lanreotide vs octreotide LAR for patients with advanced gastroenteropancreatic neuroendocrine tumors: An observational time and motion analysis.J Oncol Pharm Pract. 2019;25:1425-1433. [PMID: 30924737 DOI: 10.1177/1078155219839458] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
504 Karls S, Gold R, Kravets S, Wang Y, Cheng S, Perez K, Chan J, Jacene H. Correlation of 68Ga-DOTATATE uptake on PET/CT with pathologic features of cellular proliferation in neuroendocrine neoplasms. Ann Nucl Med 2021;35:1066-77. [PMID: 34146243 DOI: 10.1007/s12149-021-01642-3] [Reference Citation Analysis]
505 McCarthy DM. Proton Pump Inhibitor Use, Hypergastrinemia, and Gastric Carcinoids-What Is the Relationship? Int J Mol Sci 2020;21:E662. [PMID: 31963924 DOI: 10.3390/ijms21020662] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 9.0] [Reference Citation Analysis]
506 Li MX, Wang HY, Yuan CH, Ma CL, Jiang B, Li L, Zhang L, Zhao H, Cai JQ, Xiu DR. The eighth version of American Joint Committee on Cancer nodal classification for high grade pancreatic neuroendocrine tumor should be generalized for the whole population with this disease. Medicine (Baltimore) 2020;99:e22089. [PMID: 32925749 DOI: 10.1097/MD.0000000000022089] [Reference Citation Analysis]
507 Miao DL, Song W, Qian J, Zhu ZG, Wu Q, Lv CG, Chen L. Development and Validation of a Nomogram for Predicting Overall Survival in Pancreatic NeuroendocrineTumors. Transl Oncol 2018;11:1097-103. [PMID: 30015262 DOI: 10.1016/j.tranon.2018.06.012] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
508 Debien V, Davidson G, Baltzinger P, Kurtz JE, Séverac F, Imperiale A, Pessaux P, Addeo P, Bachellier P, Su X, Davidson I, Chenard MP, Goichot B, Malouf GG. Involvement of Neutrophils in Metastatic Evolution of Pancreatic Neuroendocrine Tumors. Cancers (Basel) 2021;13:2771. [PMID: 34199561 DOI: 10.3390/cancers13112771] [Reference Citation Analysis]
509 Alese OB, Jiang R, Shaib W, Wu C, Akce M, Behera M, El-Rayes BF. High-Grade Gastrointestinal Neuroendocrine Carcinoma Management and Outcomes: A National Cancer Database Study. Oncologist. 2019;24:911-920. [PMID: 30482824 DOI: 10.1634/theoncologist.2018-0382] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
510 Song L, Zhai X, Yu S, Ma Y, Wang F, Yu X, Tao S, Lian Y, Yang M, Tao W, Fan Q. Clinical analysis of 547 patients with neuroendocrine tumors in a Chinese population: A single-center study. Cancer Med 2019;8:3729-37. [PMID: 31127690 DOI: 10.1002/cam4.2259] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
511 Malczewska A, Witkowska M, Makulik K, Bocian A, Walter A, Pilch-Kowalczyk J, Zajęcki W, Bodei L, Oberg KE, Kos-Kudła B. NETest liquid biopsy is diagnostic of small intestine and pancreatic neuroendocrine tumors and correlates with imaging. Endocr Connect 2019:EC-19-0030. [PMID: 30865931 DOI: 10.1530/EC-19-0030] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 7.5] [Reference Citation Analysis]
512 Camus B, Cottereau AS, Palmieri LJ, Dermine S, Tenenbaum F, Brezault C, Coriat R. Indications of Peptide Receptor Radionuclide Therapy (PRRT) in Gastroenteropancreatic and Pulmonary Neuroendocrine Tumors: An Updated Review. J Clin Med 2021;10:1267. [PMID: 33803817 DOI: 10.3390/jcm10061267] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
513 Chauhan A, Das S, Miller R, Luque L, Cheuvront SN, Cloud J, Tarter Z, Siddiqui F, Ramirez RA, Anthony L. Can an amino acid mixture alleviate gastrointestinal symptoms in neuroendocrine tumor patients? BMC Cancer 2021;21:580. [PMID: 34016080 DOI: 10.1186/s12885-021-08315-4] [Reference Citation Analysis]
514 Henfling M, Perren A, Schmitt AM, Saddig CM, Starke AA, Riedl RG, Versleijen-Jonkers YMH, Sprij-Mooij DM, Ramaekers FCS, Hofland L, Speel EM. The IGF pathway is activated in insulinomas but downregulated in metastatic disease. Endocr Relat Cancer 2018:ERC-18-0222. [PMID: 30021864 DOI: 10.1530/ERC-18-0222] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
515 Crown A, Rocha FG, Raghu P, Lin B, Funk G, Alseidi A, Hubka M, Rosales J, Lee M, Kennecke H. Impact of initial imaging with gallium‐68 dotatate PET/CT on diagnosis and management of patients with neuroendocrine tumors. J Surg Oncol 2020;121:480-5. [DOI: 10.1002/jso.25812] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 6.5] [Reference Citation Analysis]
516 Rizzo FM, Vesely C, Childs A, Marafioti T, Khan MS, Mandair D, Cives M, Ensell L, Lowe H, Akarca AU, Luong T, Caplin M, Toumpanakis C, Krell D, Thirlwell C, Silvestris F, Hartley JA, Meyer T. Circulating tumour cells and their association with bone metastases in patients with neuroendocrine tumours. Br J Cancer 2019;120:294-300. [PMID: 30636773 DOI: 10.1038/s41416-018-0367-4] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
517 Bouvier AM, Robaszkiewicz M, Jooste V, Cariou M, Drouillard A, Bouvier V, Nousbaum JB; French Network of Cancer Registries (FRANCIM). Trends in incidence of small bowel cancer according to histology: a population-based study. J Gastroenterol 2020;55:181-8. [PMID: 31630251 DOI: 10.1007/s00535-019-01636-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
518 Saif MW, Parikh R, Ray D, Kaye JA, Kurosky SK, Thomas K, Ramirez RA, Halfdanarson TR, Beveridge TJR, Mirakhur B, Nagar SP, Soares HP. Medical record review of transition to lanreotide following octreotide for neuroendocrine tumors. J Gastrointest Oncol 2019;10:674-87. [PMID: 31392048 DOI: 10.21037/jgo.2019.03.11] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
519 Pozas J, San Román M, Alonso-Gordoa T, Pozas M, Caracuel L, Carrato A, Molina-Cerrillo J. Targeting Angiogenesis in Pancreatic Neuroendocrine Tumors: Resistance Mechanisms. Int J Mol Sci 2019;20:E4949. [PMID: 31597249 DOI: 10.3390/ijms20194949] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
520 Picchia S, Terlizzo M, Bali MA. Radiological and histological findings of an asymptomatic ever-increasing neoplasm: The small bowel neuroendocrine tumor (NET). Curr Probl Cancer 2020;44:100495. [PMID: 31376987 DOI: 10.1016/j.currproblcancer.2019.07.001] [Reference Citation Analysis]
521 Assi HA, Padda SK. Latest advances in management of small cell lung cancer and other neuroendocrine tumors of the lung. Cancer Treatment and Research Communications 2020;23:100167. [DOI: 10.1016/j.ctarc.2020.100167] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
522 Vaghaiwalla T, Keutgen XM. Surgical Management of Pancreatic Neuroendocrine Tumors. Surg Oncol Clin N Am 2020;29:243-52. [PMID: 32151358 DOI: 10.1016/j.soc.2019.11.008] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
523 López-López Á, Godzien J, Soldevilla B, Gradillas A, López-Gonzálvez Á, Lens-Pardo A, La Salvia A, Del Carmen Riesco-Martínez M, García-Carbonero R, Barbas C. Oxidized lipids in the metabolic profiling of neuroendocrine tumors - Analytical challenges and biological implications. J Chromatogr A 2020;1625:461233. [PMID: 32709312 DOI: 10.1016/j.chroma.2020.461233] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
524 Moeckli B, Ivanics T, Claasen M, Toso C, Sapisochin G. Recent developments and ongoing trials in transplant oncology. Liver Int 2020;40:2326-44. [PMID: 33021344 DOI: 10.1111/liv.14621] [Reference Citation Analysis]
525 Patel N, Barbieri A, Gibson J. Neuroendocrine Tumors of the Gastrointestinal Tract and Pancreas.Surg Pathol Clin. 2019;12:1021-1044. [PMID: 31672292 DOI: 10.1016/j.path.2019.08.007] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 7.0] [Reference Citation Analysis]
526 Liu X, Chin W, Pan C, Zhang W, Yu J, Zheng S, Liu Y. Risk of malignancy and prognosis of sporadic resected small (≤2 cm) nonfunctional pancreatic neuroendocrine tumors. Gland Surg 2021;10:219-32. [PMID: 33633978 DOI: 10.21037/gs-20-582] [Reference Citation Analysis]
527 Lu Y, Li W, Mu S, Tao L, Yan G, Xiao E, Wang L, Li D. Predictive significance of tumor budding in postoperative liver metastasis of pancreatic neuroendocrine tumors. J Surg Oncol 2021;123:196-203. [PMID: 32996132 DOI: 10.1002/jso.26242] [Reference Citation Analysis]
528 Lesén E, Granfeldt D, Houchard A, Berthon A, Dinet J, Gabriel S, Björstad Å, Björholt I, Elf AK, Johanson V. Cost-of-illness of metastatic gastroenteropancreatic neuroendocrine tumours in Sweden-A population-based register-linkage study. Eur J Cancer Care (Engl) 2019;28:e12983. [PMID: 30652364 DOI: 10.1111/ecc.12983] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
529 Zhang Q, Huang J, He Y, Cao R, Shu J. Insulinoma-associated protein 1(INSM1) is a superior marker for the diagnosis of gastroenteropancreatic neuroendoerine neoplasms: a meta-analysis. Endocrine 2021. [PMID: 34021851 DOI: 10.1007/s12020-021-02754-6] [Reference Citation Analysis]
530 Kulke MH, Benson AB, Dasari A, Huynh L, Cai B, Totev T, Roesner N, Duh MS, Neary MP, Maurer VE, Shih BE, Dagohoy CG, Chan J, Bergsland EK. Real-World Treatment Patterns and Clinical Outcomes in Advanced Gastrointestinal Neuroendocrine Tumors (GI NET): A Multicenter Retrospective Chart Review Study. Oncologist 2019;24:1056-65. [PMID: 30606883 DOI: 10.1634/theoncologist.2018-0519] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
531 Merath K, Bagante F, Beal EW, Lopez-Aguiar AG, Poultsides G, Makris E, Rocha F, Kanji Z, Weber S, Fisher A, Fields R, Krasnick BA, Idrees K, Smith PM, Cho C, Beems M, Schmidt CR, Dillhoff M, Maithel SK, Pawlik TM. Nomogram predicting the risk of recurrence after curative-intent resection of primary non-metastatic gastrointestinal neuroendocrine tumors: An analysis of the U.S. Neuroendocrine Tumor Study Group. J Surg Oncol. 2018;117:868-878. [PMID: 29448303 DOI: 10.1002/jso.24985] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 6.0] [Reference Citation Analysis]
532 Bollard J, Patte C, Radkova K, Massoma P, Chardon L, Valantin J, Gadot N, Goddard I, Vercherat C, Hervieu V, Gouysse G, Poncet G, Scoazec JY, Walter T, Roche C. Neuropilin-2 contributes to tumor progression in preclinical models of small intestinal neuroendocrine tumors. J Pathol 2019;249:343-55. [PMID: 31257576 DOI: 10.1002/path.5321] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
533 Pastrián LG, Ruz-caracuel I, Gonzalez RS. Giant Primary Neuroendocrine Neoplasms of the Liver: Report of 2 Cases With Molecular Characterization. Int J Surg Pathol 2019;27:893-9. [DOI: 10.1177/1066896919855764] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
534 Spada F, Maisonneuve P, Fumagalli C, Marconcini R, Gelsomino F, Antonuzzo L, Campana D, Puliafito I, Rossi G, Faviana P, Messerini L, Barberis M, Fazio N. Temozolomide alone or in combination with capecitabine in patients with advanced neuroendocrine neoplasms: an Italian multicenter real-world analysis. Endocrine 2021;72:268-78. [PMID: 32700133 DOI: 10.1007/s12020-020-02421-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
535 Herrera-Martínez AD, van den Dungen R, Dogan-Oruc F, van Koetsveld PM, Culler MD, de Herder WW, Luque RM, Feelders RA, Hofland LJ. Effects of novel somatostatin-dopamine chimeric drugs in 2D and 3D cell culture models of neuroendocrine tumors. Endocr Relat Cancer 2019;26:585-99. [PMID: 30939452 DOI: 10.1530/ERC-19-0086] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
536 Koumarianou A, Pectasides D, Koliou GA, Dionysopoulos D, Kolomodi D, Poulios C, Skondra M, Sgouros J, Pentheroudakis G, Kaltsas G, Fountzilas G. Efficacy and Safety of First-Line Everolimus Therapy Alone or in Combination with Octreotide in Gastroenteropancreatic Neuroendocrine Tumors. A Hellenic Cooperative Oncology Group (HeCOG) Study. Biology (Basel) 2020;9:E51. [PMID: 32182791 DOI: 10.3390/biology9030051] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
537 Jackson T, Darwish M, Cho E, Nagatomo K, Osman H, Jeyarajah DR. 68Ga-DOTATATE PET/CT compared to standard imaging in metastatic neuroendocrine tumors: a more sensitive test to detect liver metastasis? Abdom Radiol (NY) 2021;46:3179-83. [PMID: 33665733 DOI: 10.1007/s00261-021-02990-4] [Reference Citation Analysis]
538 Adams JR, Ray D, Willmon R, Pulgar S, Dasari A. Living With Neuroendocrine Tumors: Assessment of Quality of Life Through a Mobile Application. JCO Clin Cancer Inform 2019;3:1-10. [PMID: 31283354 DOI: 10.1200/CCI.19.00025] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
539 Bharat A, Duncan F, Williams M. Novel Presentation of Pulmonary Atypical Carcinoid Tumor as Acute Pancreatitis. Cureus 2020;12:e11063. [PMID: 33224658 DOI: 10.7759/cureus.11063] [Reference Citation Analysis]
540 Hou X, Birkenfeld B, Piwowarska-Bilska H, Celler A. Patient-specific dosimetry of 99mTc-HYNIC-Tyr3-Octreotide in children. EJNMMI Phys 2017;4:24. [PMID: 29030760 DOI: 10.1186/s40658-017-0191-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
541 Dou D, Li XK, Xia QS, Chen YY, Li YL, Wang C, Qi ZR, Tan HY. Circulating miRNA-202-3p is a potential novel biomarker for diagnosis of type 1 gastric neuroendocrine neoplasms. BMC Gastroenterol 2021;21:188. [PMID: 33892648 DOI: 10.1186/s12876-021-01769-7] [Reference Citation Analysis]
542 Andreasi V, Partelli S, Manzoni M, Muffatti F, Colombo B, Corti A, Falconi M. Association between preoperative Vasostatin-1 and pathological features of aggressiveness in localized nonfunctioning pancreatic neuroendocrine tumors (NF-PanNET). Pancreatology 2019;19:57-63. [DOI: 10.1016/j.pan.2018.11.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
543 Deguelte S, de Mestier L, Hentic O, Cros J, Lebtahi R, Hammel P, Kianmanesh R. Preoperative imaging and pathologic classification for pancreatic neuroendocrine tumors. J Visc Surg 2018;155:117-25. [PMID: 29397338 DOI: 10.1016/j.jviscsurg.2017.12.008] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
544 Soczomski P, Jurecka-Lubieniecka B, Krzywon A, Cortez AJ, Zgliczynski S, Rogozik N, Oczko-Wojciechowska M, Pawlaczek A, Bednarczuk T, Jarzab B. A Direct Comparison of Patients With Hereditary and Sporadic Pancreatic Neuroendocrine Tumors: Evaluation of Clinical Course, Prognostic Factors and Genotype-Phenotype Correlations. Front Endocrinol (Lausanne) 2021;12:681013. [PMID: 34122352 DOI: 10.3389/fendo.2021.681013] [Reference Citation Analysis]
545 Park JH, Kim JH. Pathologic differential diagnosis of metastatic carcinoma in the liver. Clin Mol Hepatol 2019;25:12-20. [PMID: 30300991 DOI: 10.3350/cmh.2018.0067] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 5.7] [Reference Citation Analysis]
546 Ambrosini V, Kunikowska J, Baudin E, Bodei L, Bouvier C, Capdevila J, Cremonesi M, de Herder WW, Dromain C, Falconi M, Fani M, Fanti S, Hicks RJ, Kabasakal L, Kaltsas G, Lewington V, Minozzi S, Cinquini M, Öberg K, Oyen WJG, O'Toole D, Pavel M, Ruszniewski P, Scarpa A, Strosberg J, Sundin A, Taïeb D, Virgolini I, Wild D, Herrmann K, Yao J. Consensus on molecular imaging and theranostics in neuroendocrine neoplasms. Eur J Cancer 2021;146:56-73. [PMID: 33588146 DOI: 10.1016/j.ejca.2021.01.008] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
547 Ban X, Yan J, Yu S, Lu Z, Chang X, Jia C, Gao C, Shao H, Wu Y, Mao X, Zhang Y, Li Y, Chen J. High minichromosome maintenance protein 7 proliferation indices: a powerful predictor of progression in pancreatic neuroendocrine neoplasms without distant metastasis at the time of surgery. Hum Pathol 2019;85:101-11. [PMID: 30447299 DOI: 10.1016/j.humpath.2018.10.027] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
548 Thakur S, Daley B, Klubo-Gwiezdzinska J. The role of an anti-diabetic drug metformin in the treatment of endocrine tumors. J Mol Endocrinol 2019;63:R17-35. [PMID: 31307011 DOI: 10.1530/JME-19-0083] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 14.0] [Reference Citation Analysis]
549 Thomas KE, Boudreaux JP, Thiagarajan R, Marsala A, Voros BA, Ramirez RA. A Peptide Meets a Radionuclide to Combat a Rare Tumor. Ochsner J 2021;21:306-11. [PMID: 34566515 DOI: 10.31486/toj.20.0098] [Reference Citation Analysis]
550 Khetan P, Oyewole F, Wolin E, Kim MK, Divino CM. Prognostic Factors Associated With Progression for Advanced-Stage/G1 and G2 Small-Bowel Neuroendocrine Tumors After Multimodal Therapy: Experience From a Tertiary Referral Center. Pancreas 2020;49:509-13. [PMID: 32224719 DOI: 10.1097/MPA.0000000000001520] [Reference Citation Analysis]
551 Imaoka H, Sasaki M, Takahashi H, Hashimoto Y, Ohno I, Mitsunaga S, Watanabe K, Umemoto K, Kimura G, Suzuki Y, Ikeda M. Progression-free survival as a surrogate endpoint in advanced neuroendocrine neoplasms. Endocr Relat Cancer 2017;24:475-83. [PMID: 28684542 DOI: 10.1530/ERC-17-0197] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
552 Younan G. Pancreas Solid Tumors. Surg Clin North Am 2020;100:565-80. [PMID: 32402301 DOI: 10.1016/j.suc.2020.02.008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
553 Yang M, Zeng L, Ke NW, Tan CL, Tian BL, Liu XB, Xiang B, Zhang Y. World Health Organization grading classification for pancreatic neuroendocrine neoplasms: a comprehensive analysis from a large Chinese institution. BMC Cancer 2020;20:906. [PMID: 32962649 DOI: 10.1186/s12885-020-07356-5] [Reference Citation Analysis]
554 Weikert T, Maas OC, Haas T, Klarhöfer M, Bremerich J, Forrer F, Sauter AW, Sommer G. Early Prediction of Treatment Response of Neuroendocrine Hepatic Metastases after Peptide Receptor Radionuclide Therapy with 90Y-DOTATOC Using Diffusion Weighted and Dynamic Contrast-Enhanced MRI. Contrast Media Mol Imaging 2019;2019:1517208. [PMID: 31787860 DOI: 10.1155/2019/1517208] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
555 Vaghaiwalla T, Ruhle B, Memeh K, Angelos P, Kaplan E, Liao CY, Polite B, Keutgen X. Response rates in metastatic neuroendocrine tumors receiving peptide receptor radionuclide therapy and implications for future treatment strategies. Surgery 2021;169:162-7. [PMID: 32446596 DOI: 10.1016/j.surg.2020.04.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
556 Green P, Kebebew E. Clinical trial enrollment in patients with endocrine neoplasm: Parity achievable, but cancer type-specific. Am J Surg 2019;218:14-7. [PMID: 30862353 DOI: 10.1016/j.amjsurg.2019.02.019] [Reference Citation Analysis]
557 Viswanathan K, Borczuk AC, Siddiqui MT. Orthopedia homeobox protein (OTP) is a sensitive and specific marker for primary pulmonary carcinoid tumors in cytologic and surgical specimens. Journal of the American Society of Cytopathology 2019;8:39-46. [DOI: 10.1016/j.jasc.2018.09.004] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
558 de Hosson LD, Bouma G, Stelwagen J, van Essen H, de Bock GH, de Groot DJA, de Vries EGE, Walenkamp AME. Web-based personalised information and support for patients with a neuroendocrine tumour: randomised controlled trial. Orphanet J Rare Dis 2019;14:60. [PMID: 30819238 DOI: 10.1186/s13023-019-1035-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
559 Tokumaru Y, Matsuhashi N, Takahashi T, Imai H, Tanaka Y, Okumura N, Yamaguchi K, Yoshida K. Rectal neuroendocrine tumor developing lateral lymph node metastasis after curative resection: a case report. World J Surg Oncol 2020;18:74. [PMID: 32284069 DOI: 10.1186/s12957-020-01839-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
560 Figueira ERR, Ribeiro JF, Ribeiro TC, Jureidini R, Namur GN, Costa TN, Bacchella T, Cecconello I. Insights of Outcome after Resection of Small Nonfunctioning Neuroendocrine Pancreatic Tumors. Gastroenterol Res Pract 2021;2021:6650386. [PMID: 33986797 DOI: 10.1155/2021/6650386] [Reference Citation Analysis]
561 Delpassand ES, Ranganathan D, Wagh N, Shafie A, Gaber A, Abbasi A, Kjaer A, Tworowska I, Núñez R. 64Cu-DOTATATE PET/CT for Imaging Patients with Known or Suspected Somatostatin Receptor-Positive Neuroendocrine Tumors: Results of the First U.S. Prospective, Reader-Masked Clinical Trial. J Nucl Med 2020;61:890-6. [PMID: 31924723 DOI: 10.2967/jnumed.119.236091] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 12.0] [Reference Citation Analysis]
562 Pulvirenti A, Pea A, Chang DK, Jamieson NB. Clinical and Molecular Risk Factors for Recurrence Following Radical Surgery of Well-Differentiated Pancreatic Neuroendocrine Tumors. Front Med (Lausanne) 2020;7:385. [PMID: 32850899 DOI: 10.3389/fmed.2020.00385] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
563 Exner S, Schuldt C, Sachindra S, Du J, Heing-Becker I, Licha K, Wiedenmann B, Grötzinger C. AGTR1 Is Overexpressed in Neuroendocrine Neoplasms, Regulates Secretion and May Potentially Serve as a Target for Molecular Imaging and Therapy. Cancers (Basel) 2020;12:E3138. [PMID: 33120925 DOI: 10.3390/cancers12113138] [Reference Citation Analysis]
564 Ansquer C, Touchefeu Y, Faivre-Chauvet A, Leux C, Le Bras M, Régenet N, Fleury V, Maucherat B, Senellart H, Guyetant S, Carlier T, Scotet-Cérato E, Rauscher A, Frampas E, Kraeber-Bodéré F. Head-to-Head Comparison of 18F-DOPA PET/CT and 68Ga-DOTANOC PET/CT in Patients With Midgut Neuroendocrine Tumors. Clin Nucl Med 2021;46:181-6. [PMID: 33315677 DOI: 10.1097/RLU.0000000000003450] [Cited by in Crossref: 4] [Article Influence: 4.0] [Reference Citation Analysis]
565 Jin XF, Spöttl G, Maurer J, Nölting S, Auernhammer CJ. Antitumoral Activity of the MEK Inhibitor Trametinib (TMT212) Alone and in Combination with the CDK4/6 Inhibitor Ribociclib (LEE011) in Neuroendocrine Tumor Cells In Vitro. Cancers (Basel) 2021;13:1485. [PMID: 33807122 DOI: 10.3390/cancers13061485] [Reference Citation Analysis]
566 Naraev BG, Halland M, Halperin DM, Purvis AJ, OʼDorisio TM, Halfdanarson TR. Management of Diarrhea in Patients With Carcinoid Syndrome. Pancreas 2019;48:961-72. [PMID: 31425482 DOI: 10.1097/MPA.0000000000001384] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 12.0] [Reference Citation Analysis]
567 Trikalinos NA, Chatterjee D. ASO Author Reflections: Accuracy of Grading in Pancreatic Neuroendocrine Neoplasms and Effect on Survival Estimates: An Institutional Experience. Ann Surg Oncol 2020;27:3551-2. [PMID: 32253674 DOI: 10.1245/s10434-020-08424-7] [Reference Citation Analysis]
568 Low SK, Giannis D, Bahaie NS, Trong BLH, Moris D, Huy NT. Competing Mortality in Patients With Neuroendocrine Tumors. Am J Clin Oncol 2019;42:668-74. [PMID: 31343423 DOI: 10.1097/COC.0000000000000575] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
569 Frost M, Lines KE, Thakker RV. Current and emerging therapies for PNETs in patients with or without MEN1. Nat Rev Endocrinol 2018;14:216-27. [PMID: 29449689 DOI: 10.1038/nrendo.2018.3] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 8.7] [Reference Citation Analysis]
570 Soldevilla B, López-López A, Lens-Pardo A, Carretero-Puche C, Lopez-Gonzalvez A, La Salvia A, Gil-Calderon B, Riesco-Martinez MC, Espinosa-Olarte P, Sarmentero J, Rubio-Cuesta B, Rincón R, Barbas C, Garcia-Carbonero R. Comprehensive Plasma Metabolomic Profile of Patients with Advanced Neuroendocrine Tumors (NETs). Diagnostic and Biological Relevance. Cancers (Basel) 2021;13:2634. [PMID: 34072010 DOI: 10.3390/cancers13112634] [Reference Citation Analysis]
571 Fallahi B, Manafi-Farid R, Eftekhari M, Fard-Esfahani A, Emami-Ardekani A, Geramifar P, Akhlaghi M, Hashemi Taheri AP, Beiki D. Diagnostic fficiency of 68Ga-DOTATATE PET/CT as ompared to 99mTc-Octreotide SPECT/CT andonventional orphologic odalities in euroendocrine umors. Asia Ocean J Nucl Med Biol 2019;7:129-40. [PMID: 31380452 DOI: 10.22038/AOJNMB.2019.39392.1263] [Cited by in F6Publishing: 8] [Reference Citation Analysis]
572 Li Q, Chen Q, Chen J, Wang Z, Wang P, Zhao H, Zhao J. Prognostic nomogram for predicting long-term survival in bronchopulmonary carcinoid tumor patients receiving resection. Ann Transl Med 2021;9:1402. [PMID: 34733954 DOI: 10.21037/atm-21-1929] [Reference Citation Analysis]
573 Cen D, Liu H, Wan Z, Lin Z, Wang Y, Xu J, Liang Y. Clinicopathological features and survival for gallbladder NEN: a population-based study. Endocr Connect 2019;8:1273-81. [PMID: 31398710 DOI: 10.1530/EC-19-0124] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 3.5] [Reference Citation Analysis]
574 Buikhuisen WA, Steinbusch LC, Kodach LL, Tesselaar MET, Damhuis RAM. Risk of second primary malignancies among patients with carcinoid of the lung. Lung Cancer 2021;151:5-7. [PMID: 33278670 DOI: 10.1016/j.lungcan.2020.11.017] [Reference Citation Analysis]
575 Li J, Zhang X, He Q, Feng W, Ding L, Wang Z, Yu H, Chen Q, Lu N, Xu D, Cui J. Pancreatic neuroendocrine tumor producing vasopressin: A case report. Medicine (Baltimore) 2021;100:e27453. [PMID: 34622867 DOI: 10.1097/MD.0000000000027453] [Reference Citation Analysis]
576 Lindner S, Simmet M, Gildehaus FJ, Jurkschat K, Wängler C, Wängler B, Bartenstein P, Schirrmacher R, Ilhan H. Automated production of [18F]SiTATE on a Scintomics GRP™ platform for PET/CT imaging of neuroendocrine tumors. Nucl Med Biol 2020;88-89:86-95. [PMID: 32828007 DOI: 10.1016/j.nucmedbio.2020.07.008] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 8.0] [Reference Citation Analysis]
577 Chen K, Zhang W, Zhang Z, He Y, Liu Y, Yang X. Simple Vascular Architecture Classification in Predicting Pancreatic Neuroendocrine Tumor Grade and Prognosis. Dig Dis Sci 2018;63:3147-52. [DOI: 10.1007/s10620-018-5240-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
578 Wang TT, Lu J, Xu L, Wu H, Lin D, Wu Z, Xiao Y. Whole genome sequencing of colorectal neuroendocrine tumors and in-depth mutational analyses. Med Oncol 2020;37:56. [PMID: 32424617 DOI: 10.1007/s12032-020-01356-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
579 Chin JL, O'Toole D. Diagnosis and Management of Upper Gastrointestinal Neuroendocrine Tumors. Clin Endosc. 2017;50:520-529. [PMID: 29207862 DOI: 10.5946/ce.2017.181] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
580 Zhang XF, Lopez-Aguiar AG, Poultsides G, Makris E, Rocha F, Kanji Z, Weber S, Fields R, Krasnick BA, Idrees K, Smith PM, Cho C, Schmidt CR, Maithel SK, Pawlik TM; United States Neuroendocrine Tumor Study Group. Minimally invasive versus open distal pancreatectomy for pancreatic neuroendocrine tumors: An analysis from the U.S. neuroendocrine tumor study group. J Surg Oncol. 2019;120:231-240. [PMID: 31001868 DOI: 10.1002/jso.25481] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
581 Clement D, Ramage J, Srirajaskanthan R. Update on Pathophysiology, Treatment, and Complications of Carcinoid Syndrome. J Oncol 2020;2020:8341426. [PMID: 32322270 DOI: 10.1155/2020/8341426] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 9.0] [Reference Citation Analysis]
582 Niger M, Prisciandaro M, Antista M, Monica MAT, Cattaneo L, Prinzi N, Manglaviti S, Nichetti F, Brambilla M, Torchio M, Corti F, Pusceddu S, Coppa J, Mazzaferro V, de Braud F, Di Bartolomeo M. One size does not fit all for pancreatic cancers: A review on rare histologies and therapeutic approaches. World J Gastrointest Oncol 2020; 12(8): 833-849 [PMID: 32879662 DOI: 10.4251/wjgo.v12.i8.833] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
583 Cives M, Pelle’ E, Quaresmini D, Mandriani B, Tucci M, Silvestris F. The Role of Cytotoxic Chemotherapy in Well-Differentiated Gastroenteropancreatic and Lung Neuroendocrine Tumors. Curr Treat Options in Oncol 2019;20. [DOI: 10.1007/s11864-019-0669-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
584 MacFarlane AW 4th, Yeung HM, Alpaugh RK, Dulaimi E, Engstrom PF, Dasari A, Campbell KS, Vijayvergia N. Impacts of pembrolizumab therapy on immune phenotype in patients with high-grade neuroendocrine neoplasms. Cancer Immunol Immunother 2021;70:1893-906. [PMID: 33398390 DOI: 10.1007/s00262-020-02811-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
585 Alexandraki K, Angelousi A, Boutzios G, Kyriakopoulos G, Rontogianni D, Kaltsas G. Management of neuroendocrine tumors of unknown primary. Rev Endocr Metab Disord 2017;18:423-31. [PMID: 29199361 DOI: 10.1007/s11154-017-9437-9] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 5.7] [Reference Citation Analysis]
586 Gahete MD, Jimenez-Vacas JM, Alors-Perez E, Herrero-Aguayo V, Fuentes-Fayos AC, Pedraza-Arevalo S, Castaño JP, Luque RM. Mouse models in endocrine tumors. J Endocrinol 2018:JOE-18-0571. [PMID: 30475226 DOI: 10.1530/JOE-18-0571] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
587 Bai J, Tian Y, Liu F, Li X, Shao Y, Lu X, Wang J, Zhu G, Xue B, Liu M, Hu P, He N, Tang Q. Octreotide-Conjugated Core-Cross-Linked Micelles with pH/Redox Responsivity Loaded with Etoposide for Neuroendocrine Neoplasms Therapy and Bioimaging with Photoquenching Resistance. ACS Appl Mater Interfaces 2019;11:18111-22. [PMID: 31006230 DOI: 10.1021/acsami.9b01827] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
588 Xu J, Shen L, Bai C, Wang W, Li J, Yu X, Li Z, Li E, Yuan X, Chi Y, Yin Y, Lou W, Xu N, Bai Y, Zhang T, Xiu D, Wang X, Yuan Y, Chen J, Qin S, Jia R, Lu M, Cheng Y, Zhou Z, Li J, He J, Su W. Surufatinib in advanced pancreatic neuroendocrine tumours (SANET-p): a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol 2020;21:1489-99. [PMID: 32966810 DOI: 10.1016/S1470-2045(20)30493-9] [Cited by in Crossref: 19] [Cited by in F6Publishing: 9] [Article Influence: 19.0] [Reference Citation Analysis]
589 Effraimidis G, Knigge U, Rossing M, Oturai P, Rasmussen ÅK, Feldt-Rasmussen U. Multiple endocrine neoplasia type 1 (MEN-1) and neuroendocrine neoplasms (NENs). Semin Cancer Biol 2021:S1044-579X(21)00112-7. [PMID: 33905872 DOI: 10.1016/j.semcancer.2021.04.011] [Reference Citation Analysis]
590 Gillette AA, Babiarz CP, VanDommelen AR, Pasch CA, Clipson L, Matkowskyj KA, Deming DA, Skala MC. Autofluorescence Imaging of Treatment Response in Neuroendocrine Tumor Organoids. Cancers (Basel) 2021;13:1873. [PMID: 33919802 DOI: 10.3390/cancers13081873] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
591 Venable ER, Kerr SE, Lopes MBS, Jones KA, Bellizzi AM, Mounajjed T, Raghunathan A, Hamidi O, Halfdanarson TR, Ryder M, Graham RP. Liver metastases from pituitary carcinomas mimicking visceral well-differentiated neuroendocrine tumors: a series of four cases. Diagn Pathol 2020;15:81. [PMID: 32622369 DOI: 10.1186/s13000-020-00997-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
592 Kitada T, Masui T, Kasai Y, Uchida Y, Ogiso S, Ito T, Ishii T, Seo S, Katsuragawa H, Uemoto S. A subcentimeter duodenal neuroendocrine neoplasm with a liver metastasis upgraded to G3: a case report. Surg Case Rep 2021;7:72. [PMID: 33742297 DOI: 10.1186/s40792-021-01155-1] [Reference Citation Analysis]
593 de Mestier L, Védie AL, Faron M, Cros J, Rebours V, Hentic O, Do Cao C, Bardet P, Lévy P, Sauvanet A, Ruszniewski P, Hammel P. The Postoperative Occurrence or Worsening of Diabetes Mellitus May Increase the Risk of Recurrence in Resected Pancreatic Neuroendocrine Tumors. Neuroendocrinology 2020;110:967-76. [PMID: 31791037 DOI: 10.1159/000505158] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
594 Chauhan A, Farooqui Z, Murray LA, Weiss HL, War Myint Z, Raajasekar AKA, Evers BM, Arnold S, Anthony L. Capecitabine and Temozolomide in Neuroendocrine Tumor of Unknown Primary. J Oncol 2018;2018:3519247. [PMID: 29853889 DOI: 10.1155/2018/3519247] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
595 Mastoraki A, Schizas D, Papoutsi E, Ntella V, Kanavidis P, Sioulas A, Tsoli M, Charalampopoulos G, Vailas M, Felekouras E. Clinicopathological Data and Treatment Modalities for Pancreatic Somatostatinomas. In Vivo 2020;34:3573-82. [PMID: 33144470 DOI: 10.21873/invivo.12201] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
596 Larose LD, Vroman PJ, Musick SR, Beauvais AA. A Case Report: Insulinoma in a Military Pilot Detected by 68Ga-Dotatate PET/CT. Mil Med 2020;185:e1887-90. [PMID: 32617565 DOI: 10.1093/milmed/usaa100] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
597 Pettersson O, Fröss-Baron K, Crona J, Sundin A. Tumor Contrast-Enhancement for Monitoring of PRRT 177Lu-DOTATATE in Pancreatic Neuroendocrine Tumor Patients. Front Oncol 2020;10:193. [PMID: 32154181 DOI: 10.3389/fonc.2020.00193] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
598 Saravana-Bawan B, Bajwa A, Paterson J, McEwan AJB, McMullen TPW. Efficacy of 177Lu Peptide Receptor Radionuclide Therapy for the Treatment of Neuroendocrine Tumors: A Meta-analysis. Clin Nucl Med 2019;44:719-27. [PMID: 31205149 DOI: 10.1097/RLU.0000000000002646] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
599 Hendifar AE, Dhall D, Strosberg JR. The Evolving Treatment Algorithm for Advanced Neuroendocrine Neoplasms: Diversity and Commonalities Across Tumor Types. Oncologist 2019;24:54-61. [PMID: 30104288 DOI: 10.1634/theoncologist.2018-0187] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
600 Kövesdi A, Kurucz PA, Nyírő G, Darvasi O, Patócs A, Butz H. Circulating miRNA Increases the Diagnostic Accuracy of Chromogranin A in Metastatic Pancreatic Neuroendocrine Tumors. Cancers (Basel) 2020;12:E2488. [PMID: 32887459 DOI: 10.3390/cancers12092488] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
601 Chung HG, Goh MJ, Kim ER, Hong SN, Kim TJ, Chang DK, Kim YH. Recurrence pattern and surveillance strategy for rectal neuroendocrine tumors after endoscopic resection. J Gastroenterol Hepatol 2021;36:968-73. [PMID: 32864790 DOI: 10.1111/jgh.15231] [Reference Citation Analysis]
602 Heidsma CM, Tsilimigras DI, Rocha F, Abbott DE, Fields R, Poultsides GA, Cho CS, Lopez-Aguiar AG, Kanji Z, Fisher AV, Krasnick BA, Idrees K, Makris E, Beems M, van Eijck CHJ, Nieveen van Dijkum EJM, Maithel SK, Pawlik TM. Identifying Risk Factors and Patterns for Early Recurrence of Pancreatic Neuroendocrine Tumors: A Multi-Institutional Study. Cancers (Basel) 2021;13:2242. [PMID: 34067017 DOI: 10.3390/cancers13092242] [Reference Citation Analysis]
603 Chatterjee D, Trikalinos NA, Williams GA, Liu J, Hawkins WG, Hammill C. Intratumoral Fibrosis and Tumor Growth Pattern as Prognostic Factors in Optimally Resected Pancreatic Neuroendocrine Neoplasms: An Analysis of 168 Cases. Pancreas 2020;49:255-60. [PMID: 32011527 DOI: 10.1097/MPA.0000000000001478] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
604 Panzuto F, Massironi S, Partelli S, Campana D, Rinzivillo M, Invernizzi P, Andreasi V, Lamberti G, Falconi M. Gastro-entero-pancreatic neuroendocrine neoplasia: The rules for non-operative management. Surg Oncol 2020;35:141-8. [PMID: 32877883 DOI: 10.1016/j.suronc.2020.08.015] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
605 Kasai Y, Masui T, Nakakura EK, Nakano K, Sato A, Uchida Y, Yogo A, Nagai K, Anazawa T, Hope TA, Kim GE, Whitman J, Le BK, Takaori K, Bergsland EK, Hatano E, Uemoto S. Preoperative risk stratification of lymph node metastasis for non-functional pancreatic neuroendocrine neoplasm: An international dual-institutional study. Pancreatology 2021:S1424-3903(21)00608-6. [PMID: 34736838 DOI: 10.1016/j.pan.2021.10.005] [Reference Citation Analysis]
606 Antelo G, Hierro C, Fernández JP, Baena E, Bugés C, Layos L, Manzano JL, Caro M, Mesia R. Rectal neuroendocrine carcinoma: case report of a rare entity and perspective review of promising agents. Drugs Context 2020;9:2020-2-4. [PMID: 32477420 DOI: 10.7573/dic.2020-2-4] [Reference Citation Analysis]
607 Kalshetty A, Ramaswamy A, Ostwal V, Basu S. Resistant functioning and/or progressive symptomatic metastatic gastroenteropancreatic neuroendocrine tumors: efficacy of 177Lu-DOTATATE peptide receptor radionuclide therapy in this setting. Nuclear Medicine Communications 2018;39:1143-9. [DOI: 10.1097/mnm.0000000000000926] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
608 Lamarca A, Frizziero M, Barriuso J, McNamara MG, Hubner RA, Valle JW. Urgent need for consensus: international survey of clinical practice exploring use of platinum-etoposide chemotherapy for advanced extra-pulmonary high grade neuroendocrine carcinoma (EP-G3-NEC). Clin Transl Oncol. 2019;21:950-953. [PMID: 30506132 DOI: 10.1007/s12094-018-1996-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
609 Watanabe A, Yip L, Hamilton TD, Loree JM, Stuart HC. Tumour grade and primary site predict patterns of recurrence and survival in patients with resected gastroenteropancreatic neuroendocrine tumors. Am J Surg 2021;221:1141-9. [PMID: 33795127 DOI: 10.1016/j.amjsurg.2021.03.027] [Reference Citation Analysis]
610 Halperin DM, Lee JJ, Ng CS, Strosberg JR, Estrella JS, Dagohoy CG, Dasari A, Yao JC. A Phase II Trial of Ziv-Aflibercept in Patients With Advanced Pancreatic Neuroendocrine Tumors. Pancreas 2019;48:381-6. [PMID: 30768575 DOI: 10.1097/MPA.0000000000001258] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
611 Haider M, Das S, Al-Toubah T, Pelle E, El-Haddad G, Strosberg J. Somatostatin receptor radionuclide therapy in neuroendocrine tumors. Endocr Relat Cancer 2021;28:R81-93. [PMID: 33608483 DOI: 10.1530/ERC-20-0360] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
612 Baudin E, Caplin M, Garcia-Carbonero R, Fazio N, Ferolla P, Filosso PL, Frilling A, de Herder WW, Hörsch D, Knigge U, Korse CM, Lim E, Lombard-Bohas C, Pavel M, Scoazec JY, Sundin A, Berruti A;  ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Lung and thymic carcinoids: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.Ann Oncol. 2021;32:439-451. [PMID: 33482246 DOI: 10.1016/j.annonc.2021.01.003] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 8.0] [Reference Citation Analysis]
613 Parghane RV, Ostwal V, Ramaswamy A, Bhandare M, Chaudhari V, Talole S, Shrikhande SV, Basu S. Long-term outcome of "Sandwich" chemo-PRRT: a novel treatment strategy for metastatic neuroendocrine tumors with both FDG- and SSTR-avid aggressive disease. Eur J Nucl Med Mol Imaging 2021;48:913-23. [PMID: 32876706 DOI: 10.1007/s00259-020-05004-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
614 Muscogiuri G, Barrea L, Feola T, Gallo M, Messina E, Venneri MA, Faggiano A, Colao A; NIKE (Neuroendocrine Tumors, Innovation inKnowledge and Education) Group. Pancreatic Neuroendocrine Neoplasms: Does Sex Matter? Trends Endocrinol Metab 2020;31:631-41. [PMID: 32223919 DOI: 10.1016/j.tem.2020.02.010] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
615 Shah CP, Mramba LK, Bishnoi R, Unnikrishnan A, Duff JM, Chandana SR. Survival trends of metastatic small intestinal neuroendocrine tumor: a population-based analysis of SEER database. J Gastrointest Oncol 2019;10:869-77. [PMID: 31602324 DOI: 10.21037/jgo.2019.05.02] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
616 Raj N, Shah R, Stadler Z, Mukherjee S, Chou J, Untch B, Li J, Kelly V, Saltz LB, Mandelker D, Ladanyi M, Berger MF, Klimstra DS, Reidy-Lagunes D, Osoba M. Real-Time Genomic Characterization of Metastatic Pancreatic Neuroendocrine Tumors Has Prognostic Implications and Identifies Potential Germline Actionability. JCO Precis Oncol 2018;2018. [PMID: 30687805 DOI: 10.1200/PO.17.00267] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 4.7] [Reference Citation Analysis]
617 Wu Z, Wang Z, Zheng Z, Bi J, Wang X, Feng Q. Risk Factors for Lymph Node Metastasis and Survival Outcomes in Colorectal Neuroendocrine Tumors. Cancer Manag Res 2020;12:7151-64. [PMID: 32848469 DOI: 10.2147/CMAR.S256723] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
618 Baretti M, Zhu Q, Zahurak M, Bhaijee F, Xu H, Engle EL, Kotte A, Pawlik TM, Anders RA, De Jesus-Acosta A. Prognostic Implications of the Immune Tumor Microenvironment in Patients With Pancreatic and Gastrointestinal Neuroendocrine Tumors. Pancreas 2021;50:719-26. [PMID: 34016898 DOI: 10.1097/MPA.0000000000001831] [Reference Citation Analysis]
619 Ho K, Fleseriu M, Kaiser U, Salvatori R, Brue T, Lopes MB, Kunz P, Molitch M, Camper SA, Gadelha M, Syro LV, Laws E, Reincke M, Nishioka H, Grossman A, Barkan A, Casanueva F, Wass J, Mamelak A, Katznelson L, van der Lely AJ, Radovick S, Bidlingmaier M, Boguszewski M, Bollerslev J, Hoffman AR, Oyesiku N, Raverot G, Ben-Shlomo A, Fowkes R, Shimon I, Fukuoka H, Pereira AM, Greenman Y, Heaney AP, Gurnell M, Johannsson G, Osamura RY, Buchfelder M, Zatelli MC, Korbonits M, Chanson P, Biermasz N, Clemmons DR, Karavitaki N, Bronstein MD, Trainer P, Melmed S. Pituitary Neoplasm Nomenclature Workshop: Does Adenoma Stand the Test of Time? J Endocr Soc 2021;5:bvaa205. [PMID: 33604494 DOI: 10.1210/jendso/bvaa205] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
620 Lu L, Shang Y, Zechner D, Mullins CS, Linnebacher M, Zhang X, Gong P. Development and Validation of a Score for Screening Suicide of Patients With Neuroendocrine Neoplasms. Front Psychiatry 2021;12:638152. [PMID: 34177643 DOI: 10.3389/fpsyt.2021.638152] [Reference Citation Analysis]
621 Hallet J, Davis LE, Mahar AL, Law CHL, Isenberg-Grzeda E, Bubis LD, Singh S, Myrehaug S, Zhao H, Beyfuss K, Moody L, Coburn NG. Patterns of Symptoms Burden in Neuroendocrine Tumors: A Population-Based Analysis of Prospective Patient-Reported Outcomes. Oncologist 2019;24:1384-94. [PMID: 31270268 DOI: 10.1634/theoncologist.2019-0112] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
622 Yadav D, Ballal S, Yadav MP, Tripathi M, Roesch F, Bal C. Evaluation of [68Ga]Ga-DATA-TOC for imaging of neuroendocrine tumours: comparison with [68Ga]Ga-DOTA-NOC PET/CT. Eur J Nucl Med Mol Imaging 2020;47:860-9. [PMID: 31754796 DOI: 10.1007/s00259-019-04611-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
623 Scarpa A. The landscape of molecular alterations in pancreatic and small intestinal neuroendocrine tumours. Ann Endocrinol (Paris) 2019;80:153-8. [PMID: 31072588 DOI: 10.1016/j.ando.2019.04.010] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 11.5] [Reference Citation Analysis]
624 Noor M, Huber AR, Cates JMM, Gonzalez RS. Risk factors for progression of appendiceal neuroendocrine tumours: low-stage tumours <5 mm appear to be overwhelmingly indolent and may merit a separate designation. Histopathology 2021;79:416-26. [PMID: 33754384 DOI: 10.1111/his.14369] [Reference Citation Analysis]
625 Öberg K. Management of functional neuroendocrine tumors of the pancreas. Gland Surg 2018;7:20-7. [PMID: 29629316 DOI: 10.21037/gs.2017.10.08] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 8.0] [Reference Citation Analysis]
626 Gonzalez RS. Diagnosis and Management of Gastrointestinal Neuroendocrine Neoplasms. Surg Pathol Clin 2020;13:377-97. [PMID: 32773190 DOI: 10.1016/j.path.2020.04.002] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
627 Lee MR, Harris C, Baeg KJ, Aronson A, Wisnivesky JP, Kim MK. Incidence Trends of Gastroenteropancreatic Neuroendocrine Tumors in the United States. Clin Gastroenterol Hepatol. 2018;. [PMID: 30580091 DOI: 10.1016/j.cgh.2018.12.017] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 4.7] [Reference Citation Analysis]
628 Colao A, de Nigris F, Modica R, Napoli C. Clinical Epigenetics of Neuroendocrine Tumors: The Road Ahead. Front Endocrinol (Lausanne) 2020;11:604341. [PMID: 33384663 DOI: 10.3389/fendo.2020.604341] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
629 Silva DJ, Dos Santos J, Vaz AP, Mesquita A. Rectal mixed adenoneuroendocrine carcinoma: Case report. Medicine (Baltimore) 2021;100:e27348. [PMID: 34622834 DOI: 10.1097/MD.0000000000027348] [Reference Citation Analysis]
630 Zaidi MY, Lopez-Aguiar AG, Switchenko JM, Lipscomb J, Andreasi V, Partelli S, Gamboa AC, Lee RM, Poultsides GA, Dillhoff M, Rocha FG, Idrees K, Cho CS, Weber SM, Fields RC, Staley CA 3rd, Falconi M, Maithel SK. A Novel Validated Recurrence Risk Score to Guide a Pragmatic Surveillance Strategy After Resection of Pancreatic Neuroendocrine Tumors: An International Study of 1006 Patients. Ann Surg 2019;270:422-33. [PMID: 31283562 DOI: 10.1097/SLA.0000000000003461] [Cited by in Crossref: 22] [Cited by in F6Publishing: 10] [Article Influence: 22.0] [Reference Citation Analysis]
631 Özdirik B, Jann H, Bischoff P, Fehrenbach U, Tacke F, Roderburg C, Wiedenmann B. PD-L1 - inhibitors in neuroendocrine neoplasia: Results from a real-life study. Medicine (Baltimore) 2021;100:e23835. [PMID: 33429744 DOI: 10.1097/MD.0000000000023835] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
632 Gatto F, Barbieri F, Arvigo M, Thellung S, Amarù J, Albertelli M, Ferone D, Florio T. Biological and Biochemical Basis of the Differential Efficacy of First and Second Generation Somatostatin Receptor Ligands in Neuroendocrine Neoplasms. Int J Mol Sci 2019;20:E3940. [PMID: 31412614 DOI: 10.3390/ijms20163940] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
633 Babazadeh NT, Schlund DJ, Cornelius T, Singh JS, Tierney JF, Chen M, Keutgen XM. Should 68Ga-DOTATATE PET/CT be Performed Routinely in Patients with Neuroendocrine Tumors Before Surgical Resection? World J Surg 2020;44:604-11. [DOI: 10.1007/s00268-019-05216-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
634 Das S, Al-Toubah T, El-Haddad G, Strosberg J. 177Lu-DOTATATE for the treatment of gastroenteropancreatic neuroendocrine tumors. Expert Rev Gastroenterol Hepatol 2019;13:1023-31. [PMID: 31652074 DOI: 10.1080/17474124.2019.1685381] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
635 Carnie LE, Lamarca A, Vaughan K, Kapacee ZA, McCallum L, Backen A, Barriuso J, McNamara MG, Hubner RA, Abraham M, Valle JW. Prospective observational study of prevalence, assessment and treatment of pancreatic exocrine insufficiency in patients with inoperable pancreatic malignancy (PANcreatic cancer Dietary Assessment (PanDA): a study protocol. BMJ Open 2021;11:e042067. [PMID: 33986039 DOI: 10.1136/bmjopen-2020-042067] [Reference Citation Analysis]
636 Kasai Y, Mahuron K, Hirose K, Corvera CU, Kim GE, Hope TA, Shih BE, Warren RS, Bergsland EK, Nakakura EK. A novel stratification of mesenteric mass involvement as a predictor of challenging mesenteric lymph node dissection by minimally invasive approach for ileal neuroendocrine tumors. J Surg Oncol 2020;122:204-11. [PMID: 32291778 DOI: 10.1002/jso.25930] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
637 Nuñez-Valdovinos B, Carmona-Bayonas A, Jimenez-Fonseca P, Capdevila J, Castaño-Pascual Á, Benavent M, Pi Barrio JJ, Teule A, Alonso V, Custodio A, Marazuela M, Segura Á, Beguiristain A, Llanos M, Martinez Del Prado MP, Diaz-Perez JA, Castellano D, Sevilla I, Lopez C, Alonso T, Garcia-Carbonero R. Neuroendocrine Tumor Heterogeneity Adds Uncertainty to the World Health Organization 2010 Classification: Real-World Data from the Spanish Tumor Registry (R-GETNE). Oncologist 2018;23:422-32. [PMID: 29330208 DOI: 10.1634/theoncologist.2017-0364] [Cited by in Crossref: 29] [Cited by in F6Publishing: 31] [Article Influence: 9.7] [Reference Citation Analysis]
638 Gurevich LE, Proshchina AE, Voronkova IA, Ashevskaya VE, Korosteleva PA, Dolzhansky OV. [Differential diagnostic value of the expression of the transcription factor PDX-1 in neuroendocrine and non-neuroendocrine tumors of the pancreas and other organs]. Arkh Patol 2019;81:11-21. [PMID: 31626200 DOI: 10.17116/patol20198105111] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
639 Mehlis K, Witte J, Surmann B, Kudlich M, Apostolidis L, Walther J, Jäger D, Greiner W, Winkler EC. The patient-level effect of the cost of Cancer care - financial burden in German Cancer patients. BMC Cancer 2020;20:529. [PMID: 32503459 DOI: 10.1186/s12885-020-07028-4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 9.0] [Reference Citation Analysis]
640 La Salvia A, Brizzi MP, Trevisi E, Parisi F, Muratori L, Atzeni F, Di Maio M, Scagliotti GV. Carcinoid heart failure in a duodenal neuroendocrine tumor: role of cardiac surgery in a challenging patient and brief review of the literature. Acta Oncol 2020;59:315-9. [PMID: 31583924 DOI: 10.1080/0284186X.2019.1672891] [Reference Citation Analysis]
641 Ferolla P, Brizzi MP, Meyer T, Mansoor W, Mazieres J, Do Cao C, Léna H, Berruti A, Damiano V, Buikhuisen W, Grønbæk H, Lombard-Bohas C, Grohé C, Minotti V, Tiseo M, De Castro J, Reed N, Gislimberti G, Singh N, Stankovic M, Öberg K, Baudin E. Efficacy and safety of long-acting pasireotide or everolimus alone or in combination in patients with advanced carcinoids of the lung and thymus (LUNA): an open-label, multicentre, randomised, phase 2 trial. Lancet Oncol 2017;18:1652-64. [PMID: 29074099 DOI: 10.1016/S1470-2045(17)30681-2] [Cited by in Crossref: 52] [Cited by in F6Publishing: 28] [Article Influence: 13.0] [Reference Citation Analysis]
642 Wang S, Zhang J, Liu S, Zhang J. The prognostic analysis of different metastatic patterns in pancreatic neuroendocrine tumors patients: A population based analysis. Medicine (Baltimore) 2019;98:e17773. [PMID: 31689842 DOI: 10.1097/MD.0000000000017773] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
643 Weich A, Rogoll D, Gawlas S, Mayer L, Weich W, Pongracz J, Kudlich T, Meining A, Scheurlen M. Wnt/β-Catenin Signaling Regulates CXCR4 Expression and [68Ga] Pentixafor Internalization in Neuroendocrine Tumor Cells. Diagnostics (Basel) 2021;11:367. [PMID: 33671498 DOI: 10.3390/diagnostics11020367] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
644 Andreasi V, Partelli S, Muffatti F, Manzoni MF, Capurso G, Falconi M. Update on gastroenteropancreatic neuroendocrine tumors. Dig Liver Dis. 2021;53:171-182. [PMID: 32912771 DOI: 10.1016/j.dld.2020.08.031] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
645 Fazio N, Cella CA, Del Re M, Laffi A, Rubino M, Zagami P, Spada F. Pharmacodynamics, clinical findings and approval status of current and emerging tyrosine-kinase inhibitors for pancreatic neuroendocrine tumors. Expert Opin Drug Metab Toxicol. 2019;15:993-1004. [PMID: 31794273 DOI: 10.1080/17425255.2019.1700951] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
646 Zhang Z, Mäkinen N, Kasai Y, Kim GE, Diosdado B, Nakakura E, Meyerson M. Patterns of chromosome 18 loss of heterozygosity in multifocal ileal neuroendocrine tumors. Genes Chromosomes Cancer 2020;59:535-9. [PMID: 32291827 DOI: 10.1002/gcc.22850] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
647 Tran CG, Scott AT, Li G, Sherman SK, Ear PH, Howe JR. Metastatic pancreatic neuroendocrine tumors have decreased somatostatin expression and increased Akt signaling. Surgery 2021;169:155-61. [PMID: 32611516 DOI: 10.1016/j.surg.2020.04.034] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
648 Weber M, Kessler L, Schaarschmidt B, Fendler WP, Lahner H, Antoch G, Umutlu L, Herrmann K, Rischpler C. Textural analysis of hybrid DOTATOC-PET/MRI and its association with histological grading in patients with liver metastases from neuroendocrine tumors. Nucl Med Commun 2020;41:363-9. [PMID: 31977752 DOI: 10.1097/MNM.0000000000001150] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
649 Capurso G, Gaujoux S, Pescatori LC, Panzuto F, Panis Y, Pilozzi E, Terris B, de Mestier L, Prat F, Rinzivillo M, Coriat R, Coulevard A, Delle Fave G, Ruszniewski P. The ENETS TNM staging and grading system accurately predict prognosis in patients with rectal NENs. Dig Liver Dis 2019;51:1725-30. [PMID: 31405587 DOI: 10.1016/j.dld.2019.07.011] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
650 Malczewska A, Kos-Kudła B, Kidd M, Drozdov I, Bodei L, Matar S, Oberg K, Modlin IM. The clinical applications of a multigene liquid biopsy (NETest) in neuroendocrine tumors. Adv Med Sci 2020;65:18-29. [PMID: 31841822 DOI: 10.1016/j.advms.2019.10.002] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
651 DePalo DK, Lee RM, Lopez-Aguiar AG, Gamboa AC, Rocha F, Poultsides G, Dillhoff M, Fields RC, Idrees K, Nathan H, Abbott D, Maithel SK, Russell MC; other members of the United States Neuroendocrine Tumor Study Group. Interaction of race and pathology for neuroendocrine tumors: Epidemiology, natural history, or racial disparity? J Surg Oncol 2019;120:919-25. [PMID: 31385621 DOI: 10.1002/jso.25662] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
652 Paik WH, Lee SH, Jang S. Future Perspectives on Endoscopic Ultrasonography-Guided Therapy for Pancreatic Neoplasm. Clin Endosc 2018;51:229-34. [PMID: 29774696 DOI: 10.5946/ce.2018.063] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
653 Hou T, Gan Q, Joseph CT, Sun X, Gong Y. Insulinoma-associated protein 1 immunostaining for various types of neuroendocrine tumors on FNA smears. Cancer Cytopathol 2020;128:725-32. [PMID: 32573984 DOI: 10.1002/cncy.22310] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
654 Bu X, Wang X, Wei L, Liu J, Chen M. The Risk of Second Primary Malignancies in Patients With Lung Neuroendocrine Tumors: A Population-Based Study on SEER Database. Curr Probl Cancer 2020;44:100613. [PMID: 32563531 DOI: 10.1016/j.currproblcancer.2020.100613] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
655 Li G, Tian ML, Bing YT, Wang HY, Yuan CH, Xiu DR. Nomograms predict survival outcomes for distant metastatic pancreatic neuroendocrine tumor: A population based STROBE compliant study. Medicine (Baltimore) 2020;99:e19593. [PMID: 32221079 DOI: 10.1097/MD.0000000000019593] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
656 Massironi S, Campana D, Pusceddu S, Albertelli M, Faggiano A, Panzuto F, Smiroldo V, Andreasi V, Rossi RE, Maggio I, Torchio M, Dotto A, Modica R, Rinzivillo M, Carnaghi C, Partelli S, Fanetti I, Lamberti G, Corti F, Ferone D, Colao A, Annibale B, Invernizzi P, Falconi M; ItaNet (Italian Association for Neuroendocrine Tumours) Study Group. Second primary neoplasms in patients with lung and gastroenteropancreatic neuroendocrine neoplasms: Data from a retrospective multi-centric study. Dig Liver Dis 2021;53:367-74. [PMID: 33645508 DOI: 10.1016/j.dld.2020.09.031] [Reference Citation Analysis]
657 Krug S, Damm M, Garbe J, König S, Schmitz RL, Michl P, Schrader J, Rinke A. Finding the Appropriate Therapeutic Strategy in Patients with Neuroendocrine Tumors of the Pancreas: Guideline Recommendations Meet the Clinical Reality. J Clin Med 2021;10:3023. [PMID: 34300189 DOI: 10.3390/jcm10143023] [Reference Citation Analysis]
658 Saleh M, Bhosale PR, Yano M, Itani M, Elsayes AK, Halperin D, Bergsland EK, Morani AC. New frontiers in imaging including radiomics updates for pancreatic neuroendocrine neoplasms.Abdom Radiol (NY). 2020;. [PMID: 33095312 DOI: 10.1007/s00261-020-02833-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
659 Zhang J, Song Q, Cai L, Xie Y, Chen Y. The efficacy of 177Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) in patients with metastatic neuroendocrine tumours: a systematic review and meta-analysis. J Cancer Res Clin Oncol 2020;146:1533-43. [PMID: 32281025 DOI: 10.1007/s00432-020-03181-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
660 Tsoli M, Chatzellis E, Koumarianou A, Kolomodi D, Kaltsas G. Current best practice in the management of neuroendocrine tumors. Ther Adv Endocrinol Metab. 2019;10:2042018818804698. [PMID: 30800264 DOI: 10.1177/2042018818804698] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
661 Liu Q, Zang J, Sui H, Ren J, Guo H, Wang H, Wang R, Jacobson O, Zhang J, Cheng Y, Zhu Z, Chen X. Peptide Receptor Radionuclide Therapy of Late-Stage Neuroendocrine Tumor Patients with Multiple Cycles of 177Lu-DOTA-EB-TATE. J Nucl Med 2021;62:386-92. [PMID: 32826319 DOI: 10.2967/jnumed.120.248658] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
662 Satapathy S, Bhattacharya A, Sood A, Kapoor R, Gupta R, Sood A, Sharma P, Khosla D, Mittal BR. Hematological Markers as Predictors of Treatment Outcomes with Lu-177 DOTATATE in Patients with Advanced Neuroendocrine Tumors. Cancer Biother Radiopharm 2021. [PMID: 34185573 DOI: 10.1089/cbr.2021.0053] [Reference Citation Analysis]
663 Ramage J, Naraev BG, Halfdanarson TR. Peptide receptor radionuclide therapy for patients with advanced pancreatic neuroendocrine tumors. Seminars in Oncology 2018;45:236-48. [DOI: 10.1053/j.seminoncol.2018.08.004] [Cited by in Crossref: 26] [Cited by in F6Publishing: 20] [Article Influence: 8.7] [Reference Citation Analysis]
664 Arakelyan J, Zohrabyan D, Philip PA. Molecular profile of pancreatic neuroendocrine neoplasms (PanNENs): Opportunities for personalized therapies. Cancer 2021;127:345-53. [PMID: 33270905 DOI: 10.1002/cncr.33354] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
665 Chandrasekharan C. Medical Management of Gastroenteropancreatic Neuroendocrine Tumors. Surg Oncol Clin N Am 2020;29:293-316. [PMID: 32151362 DOI: 10.1016/j.soc.2019.11.004] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
666 Alexandraki KI, Tsoli M, Kyriakopoulos G, Angelousi A, Nikolopoulos G, Kolomodi D, Kaltsas GA. Current concepts in the diagnosis and management of neuroendocrine neoplasms of unknown primary origin. Minerva Endocrinol 2019;44:378-86. [PMID: 30991795 DOI: 10.23736/S0391-1977.19.03012-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
667 Oleinikov K, Avniel-Polak S, Gross DJ, Grozinsky-Glasberg S. Carcinoid Syndrome: Updates and Review of Current Therapy. Curr Treat Options Oncol 2019;20:70. [PMID: 31286272 DOI: 10.1007/s11864-019-0671-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
668 Chatani PD, Agarwal SK, Sadowski SM. Molecular Signatures and Their Clinical Utility in Pancreatic Neuroendocrine Tumors. Front Endocrinol (Lausanne) 2020;11:575620. [PMID: 33537001 DOI: 10.3389/fendo.2020.575620] [Reference Citation Analysis]
669 Fujii Y, Kobayashi K, Kimura S, Uehara S, Miyai H, Takiguchi S. Indications for lateral lymph node dissection in patients with rectal neuroendocrine tumors: A case report and review of the literature. Mol Clin Oncol 2021;14:80. [PMID: 33758661 DOI: 10.3892/mco.2021.2242] [Reference Citation Analysis]
670 La Salvia A, Espinosa-Olarte P, Riesco-Martinez MDC, Anton-Pascual B, Garcia-Carbonero R. Targeted Cancer Therapy: What's New in the Field of Neuroendocrine Neoplasms? Cancers (Basel) 2021;13:1701. [PMID: 33916707 DOI: 10.3390/cancers13071701] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
671 Tirosh A, Killian JK, Zhu YJ, Petersen D, Walling J, Mor-Cohen R, Neychev V, Stevenson H, Keutgen XM, Patel D, Nilubol N, Meltzer P, Kebebew E. ONCOGENE PANEL SEQUENCING ANALYSIS IDENTIFIES CANDIDATE ACTIONABLE GENES IN ADVANCED WELL-DIFFERENTIATED GASTROENTEROPANCREATIC NEUROENDOCRINE TUMORS. Endocr Pract 2019;25:580-8. [PMID: 30865533 DOI: 10.4158/EP-2018-0603] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
672 Vandamme T, Beyens M, Boons G, Schepers A, Kamp K, Biermann K, Pauwels P, De Herder WW, Hofland LJ, Peeters M, Van Camp G, Op de Beeck K. Hotspot DAXX, PTCH2 and CYFIP2 mutations in pancreatic neuroendocrine neoplasms. Endocrine-Related Cancer 2019;26:1-12. [DOI: 10.1530/erc-18-0120] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
673 Primavesi F, Klieser E, Cardini B, Marsoner K, Fröschl U, Thalhammer S, Fischer I, Hauer A, Urbas R, Kiesslich T, Neureiter D, Zitt M, Klug R, Wundsam H, Sellner F, Karner J, Függer R, Cakar-Beck F, Kornprat P, Öfner D, Stättner S; ASSO pNEN Study Group. Exploring the surgical landscape of pancreatic neuroendocrine neoplasia in Austria: Results from the ASSO pNEN study group. Eur J Surg Oncol 2019;45:198-206. [PMID: 30262324 DOI: 10.1016/j.ejso.2018.08.016] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
674 Deguelte S, Perrier M, Hammoutene C, Cadiot G, Kianmanesh R. Surgery and Perioperative Management in Small Intestinal Neuroendocrine Tumors. J Clin Med. 2020;9. [PMID: 32708330 DOI: 10.3390/jcm9072319] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
675 Liberini V, Huellner MW, Grimaldi S, Finessi M, Thuillier P, Muni A, Pellerito RE, Papotti MG, Piovesan A, Arvat E, Deandreis D. The Challenge of Evaluating Response to Peptide Receptor Radionuclide Therapy in Gastroenteropancreatic Neuroendocrine Tumors: The Present and the Future. Diagnostics (Basel) 2020;10:E1083. [PMID: 33322819 DOI: 10.3390/diagnostics10121083] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
676 Sitani K, Parghane RV, Talole S, Basu S. Long-term outcome of indigenous 177Lu-DOTATATE PRRT in patients with Metastatic Advanced Neuroendocrine Tumours: a single institutional observation in a large tertiary care setting. Br J Radiol 2021;94:20201041. [PMID: 33095671 DOI: 10.1259/bjr.20201041] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
677 Weidner TK, Kidwell JT, Glasgow AE, Menias CO, Ahn DH, Pai RK, Heigh RI, Mishra N. Small Intestine Neuroendocrine Tumor in a Patient With MUTYH Adenomatous Polyposis-Case Report and SEER Analysis. Clin Colorectal Cancer 2018;17:e545-8. [PMID: 29843990 DOI: 10.1016/j.clcc.2018.05.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
678 Scoville SD, Xourafas D, Ejaz AM, Tsung A, Pawlik T, Cloyd JM. Contemporary indications for and outcomes of hepatic resection for neuroendocrine liver metastases. World J Gastrointest Surg 2020; 12(4): 159-170 [PMID: 32426095 DOI: 10.4240/wjgs.v12.i4.159] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
679 Ricci C, Campana D, Casadei C, Ingaldi C, Ambrosini V, Pagano N, Santini D, Mosconi C, Brighi N, Alberici L, Minni F, Casadei R. A cure model survival analysis of patients affected by small intestinal neuroendocrine neoplasms: the Bologna ENETS center experience. Endocrine 2019;64:702-7. [PMID: 30796689 DOI: 10.1007/s12020-019-01870-8] [Reference Citation Analysis]
680 Tran CG, Sherman SK, Chandrasekharan C, Howe JR. Surgical Management of Neuroendocrine Tumor Liver Metastases. Surg Oncol Clin N Am 2021;30:39-55. [PMID: 33220808 DOI: 10.1016/j.soc.2020.08.001] [Reference Citation Analysis]
681 Inzani F, Petrone G, Fadda G, Rindi G. Cyto-histology in NET: what is necessary today and what is the future? Rev Endocr Metab Disord 2017;18:381-91. [PMID: 28871510 DOI: 10.1007/s11154-017-9428-x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
682 Mosenia A, Ward C, Yee A, Qorbani A, Corvera C. Multifocal pancreatic PPoma in the setting of MEN1: Case report and review of literature. Int J Surg Case Rep 2021;83:106008. [PMID: 34118524 DOI: 10.1016/j.ijscr.2021.106008] [Reference Citation Analysis]
683 Barriuso J, Lamarca A. Clinical and Translational Research Challenges in Neuroendocrine Tumours. Curr Med Chem 2020;27:4823-39. [PMID: 32031064 DOI: 10.2174/0929867327666200207120725] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
684 Das S, Dasari A. Epidemiology, Incidence, and Prevalence of Neuroendocrine Neoplasms: Are There Global Differences? Curr Oncol Rep 2021;23:43. [PMID: 33719003 DOI: 10.1007/s11912-021-01029-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
685 Luley K, Gebauer J, Gebauer N, Tharun L, Buchmann I, Barkhausen J, von Bubnoff N, Lindner K, Keck T, Lehnert H, Schmid SM. [Gastroenteropancreatic neuroendocrine neoplasms-Heterogeneity, management and perspectives of treatment and research]. Internist (Berl). 2020;61:875-890. [PMID: 32676723 DOI: 10.1007/s00108-020-00832-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
686 Malczewska A, Frampton AE, Mato Prado M, Ameri S, Dabrowska AF, Zagorac S, Clift AK, Kos-Kudła B, Faiz O, Stebbing J, Castellano L, Frilling A. Circulating MicroRNAs in Small-bowel Neuroendocrine Tumors: A Potential Tool for Diagnosis and Assessment of Effectiveness of Surgical Resection. Ann Surg 2021;274:e1-9. [PMID: 31373926 DOI: 10.1097/SLA.0000000000003502] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
687 Ribeiro S, De Maeyer F, De Man M, Carton S, Cuyle PJ, Verslype C, Borbath I, Demetter P, Van Damme N, Van Eycken L, Vandamme T, Hoorens A, Geboes K. Lessons learned about appendiceal neuroendocrine neoplasms from data analysis of the Belgian Cancer Registry 2010-2015. Acta Gastroenterol Belg 2021;84:458-66. [PMID: 34599571 DOI: 10.51821/84.3.011] [Reference Citation Analysis]
688 Lindner S, Wängler C, Bailey JJ, Jurkschat K, Bartenstein P, Wängler B, Schirrmacher R. Radiosynthesis of [18F]SiFAlin-TATE for clinical neuroendocrine tumor positron emission tomography. Nat Protoc 2020;15:3827-43. [DOI: 10.1038/s41596-020-00407-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
689 Stier MW, Chapman CG, Shamah S, Donboli K, Yassan L, Waxman I, Siddiqui UD. Endoscopic resection is more effective than biopsy or EUS to detect residual rectal neuroendocrine tumor. Endosc Int Open 2021;9:E4-8. [PMID: 33403229 DOI: 10.1055/a-1300-1017] [Reference Citation Analysis]
690 Heaphy CM, VandenBussche CJ. Prognostic biomarkers in pancreatic neuroendocrine tumors. Cancer Cytopathol 2021. [PMID: 34242496 DOI: 10.1002/cncy.22457] [Reference Citation Analysis]
691 Woltering EA, Voros BA, Thiagarajan R, Beyer DT, Ramirez RA, Wang YZ, Mamikunian G, Boudreaux JP. Plasma Neurokinin A Levels Predict Survival in Well-Differentiated Neuroendocrine Tumors of the Small Bowel. Pancreas 2018;47:843-8. [PMID: 29939909 DOI: 10.1097/MPA.0000000000001092] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
692 Cai B, Broder MS, Chang E, Yan T, Metz DC. Predictive factors associated with carcinoid syndrome in patients with gastrointestinal neuroendocrine tumors. World J Gastroenterol 2017; 23(40): 7283-7291 [PMID: 29142475 DOI: 10.3748/wjg.v23.i40.7283] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
693 Xia Y, Zeng C, Zhao Y, Zhang X, Li Z, Chen Y. Comparative evaluation of 68Ga-labelled TATEs: the impact of chelators on imaging. EJNMMI Res 2020;10:36. [PMID: 32297029 DOI: 10.1186/s13550-020-00620-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
694 Albers MB, Almquist M, Bergenfelz A, Nordenström E. Complications of surgery for gastro-entero-pancreatic neuroendocrine neoplasias. Langenbecks Arch Surg 2020;405:137-43. [PMID: 32291468 DOI: 10.1007/s00423-020-01869-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
695 Ida H, Honma Y, Hirano H, Shoji H, Iwasa S, Okita N, Takashima A, Kato K, Fukuda T, Boku N. Clinical outcomes of patients with G1/G2 neuroendocrine tumors arising from foregut or hindgut treated with somatostatin analogs: a retrospective study. Invest New Drugs 2019;37:573-8. [PMID: 30267338 DOI: 10.1007/s10637-018-0669-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
696 Adant S, Shah GM, Beauregard J. Combination treatments to enhance peptide receptor radionuclide therapy of neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2020;47:907-21. [DOI: 10.1007/s00259-019-04499-x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
697 Saavedra C, Barriuso J, McNamara MG, Valle JW, Lamarca A. Spotlight on telotristat ethyl for the treatment of carcinoid syndrome diarrhea: patient selection and reported outcomes. Cancer Manag Res 2019;11:7537-56. [PMID: 31496810 DOI: 10.2147/CMAR.S181439] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
698 Kobayashi N, Wild D, Kaul F, Shimamura T, Takano S, Takeda Y, Okubo N, Suzuki A, Tokuhisa M, Ichikawa Y. Retrospective study of peptide receptor radionuclide therapy for Japanese patients with advanced neuroendocrine tumors. J Hepatobiliary Pancreat Sci 2021. [PMID: 34174175 DOI: 10.1002/jhbp.1014] [Reference Citation Analysis]
699 Clift AK, Frilling A. Liver transplantation and multivisceral transplantation in the management of patients with advanced neuroendocrine tumours. World J Gastroenterol 2018; 24(20): 2152-2162 [PMID: 29853733 DOI: 10.3748/wjg.v24.i20.2152] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
700 Dong DH, Zhang XF, Lopez-Aguiar AG, Poultsides G, Makris E, Rocha F, Kanji Z, Weber S, Fisher A, Fields R, Krasnick BA, Idrees K, Smith PM, Cho C, Beems M, Dillhoff M, Maithel SK, Pawlik TM. Resection of pancreatic neuroendocrine tumors: defining patterns and time course of recurrence. HPB (Oxford) 2020;22:215-23. [PMID: 31235429 DOI: 10.1016/j.hpb.2019.05.020] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
701 Zhang MY, He D, Zhang S. Pancreatic neuroendocrine tumors G3 and pancreatic neuroendocrine carcinomas: Differences in basic biology and treatment. World J Gastrointest Oncol 2020; 12(7): 705-718 [PMID: 32864039 DOI: 10.4251/wjgo.v12.i7.705] [Cited by in CrossRef: 1] [Article Influence: 1.0] [Reference Citation Analysis]
702 Fernandez CJ, Agarwal M, Pottakkat B, Haroon NN, George AS, Pappachan JM. Gastroenteropancreatic neuroendocrine neoplasms: A clinical snapshot. World J Gastrointest Surg 2021; 13(3): 231-255 [PMID: 33796213 DOI: 10.4240/wjgs.v13.i3.231] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
703 Wang Y, Zhang Y, Lin H, Xu M, Zhou X, Zhuang J, Yang Y, Chen B, Liu X, Guan G. Risk factors for lymph node metastasis in rectal neuroendocrine tumors: A recursive partitioning analysis based on multicenter data. J Surg Oncol 2021. [PMID: 34291822 DOI: 10.1002/jso.26615] [Reference Citation Analysis]
704 Tolomeo A, Lopopolo G, Dimiccoli V, Perioli L, Modoni S, Scilimati A. Impact of 68Ga-DOTATOC PET/CT in comparison to 111In-Octreotide SPECT/CT in management of neuro-endocrine tumors: A case report. Medicine (Baltimore) 2020;99:e19162. [PMID: 32049844 DOI: 10.1097/MD.0000000000019162] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
705 Kiesewetter B, Raderer M. How I treat neuroendocrine tumours. ESMO Open 2020;5:e000811. [PMID: 32817134 DOI: 10.1136/esmoopen-2020-000811] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
706 Mafficini A, Scarpa A. Genomic landscape of pancreatic neuroendocrine tumours: the International Cancer Genome Consortium. J Endocrinol 2018;236:R161-7. [PMID: 29321190 DOI: 10.1530/JOE-17-0560] [Cited by in Crossref: 34] [Cited by in F6Publishing: 21] [Article Influence: 11.3] [Reference Citation Analysis]
707 Kuai L, Zhang Y, Luo Y, Li W, Li XD, Zhang HP, Liu TY, Yin SY, Li B. Prognostic Nomogram for Liver Metastatic Colon Cancer Based on Histological Type, Tumor Differentiation, and Tumor Deposit: A TRIPOD Compliant Large-Scale Survival Study. Front Oncol 2021;11:604882. [PMID: 34712601 DOI: 10.3389/fonc.2021.604882] [Reference Citation Analysis]
708 Stankard M, Soule E, Matteo J. Inferior Vena Cava Syndrome as a Manifestation of Metastatic Carcinoid Tumor. Gastrointest Tumors 2021;8:138-43. [PMID: 34307313 DOI: 10.1159/000514113] [Reference Citation Analysis]
709 Lamarca A, Cives M, de Mestier L, Crona J, Spada F, Öberg K, Pavel M, Alonso-Gordoa T. Advanced small-bowel well-differentiated neuroendocrine tumours: An international survey of practice on 3rd-line treatment. World J Gastroenterol 2021; 27(10): 976-989 [PMID: 33776367 DOI: 10.3748/wjg.v27.i10.976] [Reference Citation Analysis]
710 Cai JS, Chen HY, Lu YF, Yu RS. A prognostic nomogram in patients with distant metastasis of pancreatic neuroendocrine tumors: a population-based study. Future Oncol 2020;16:4369-79. [PMID: 31802701 DOI: 10.2217/fon-2019-0545] [Reference Citation Analysis]
711 Boons G, Vandamme T, Peeters M, Van Camp G, Op de Beeck K. Clinical applications of (epi)genetics in gastroenteropancreatic neuroendocrine neoplasms: Moving towards liquid biopsies. Rev Endocr Metab Disord 2019;20:333-51. [DOI: 10.1007/s11154-019-09508-w] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
712 Baghdadi A, Ghadimi M, Mirpour S, Hazhirkarzar B, Motaghi M, Pawlik TM, Kamel IR. Imaging neuroendocrine tumors: Characterizing the spectrum of radiographic findings. Surg Oncol 2021;37:101529. [PMID: 33549952 DOI: 10.1016/j.suronc.2021.101529] [Reference Citation Analysis]
713 Santiago-Naranjo KC, Ilaiwy A. Pulmonary carcinoid presenting with persistent pneumothorax. BMJ Case Rep 2019;12:e231083. [PMID: 31712234 DOI: 10.1136/bcr-2019-231083] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
714 Yozgat A, Kekilli M, Altay M. Time to give up traditional methods for the management of gastrointestinal neuroendocrine tumours. World J Clin Cases 2021; 9(29): 8627-8646 [PMID: 34734042 DOI: 10.12998/wjcc.v9.i29.8627] [Reference Citation Analysis]
715 Goretzki PE, Mogl MT, Akca A, Pratschke J. Curative and palliative surgery in patients with neuroendocrine tumors of the gastro-entero-pancreatic (GEP) tract. Rev Endocr Metab Disord 2018;19:169-78. [DOI: 10.1007/s11154-018-9469-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
716 Perez K, Chan J. Treatment of Gastroenteropancreatic Neuroendocrine Tumors. Surgical Pathology Clinics 2019;12:1045-53. [DOI: 10.1016/j.path.2019.08.011] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
717 Schmitz RL, Weissbach J, Kleilein J, Bell J, Hüttelmaier S, Viol F, Clauditz T, Grabowski P, Laumen H, Rosendahl J, Michl P, Schrader J, Krug S. Targeting HDACs in Pancreatic Neuroendocrine Tumor Models. Cells 2021;10:1408. [PMID: 34204116 DOI: 10.3390/cells10061408] [Reference Citation Analysis]
718 Leng A, Zhong N, He S, Liu Y, Yang M, Jiao J, Xu W, Yang X, Xiao J. Symptomatic spinal metastases from neuroendocrine neoplasms: surgical outcomes and prognostic analysis. Clin Neurol Neurosurg 2021;207:106710. [PMID: 34298351 DOI: 10.1016/j.clineuro.2021.106710] [Reference Citation Analysis]
719 Yao JC, Oh DY, Qian J, Park YS, Herbst F, Ridolfi A, Izquierdo M, Ito T, Jia L, Komoto I, Sriuranpong V, Shimada Y. Everolimus for the treatment of advanced gastrointestinal or lung nonfunctional neuroendocrine tumors in East Asian patients: a subgroup analysis of the RADIANT-4 study. Onco Targets Ther 2019;12:1717-28. [PMID: 30881026 DOI: 10.2147/OTT.S182259] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
720 Robelin P, Hadoux J, Forestier J, Planchard D, Hervieu V, Berdelou A, Scoazec JY, Valette PJ, Leboulleux S, Ducreux M, Lombard-Bohas C, Baudin E, Walter T. Characterization, Prognosis, and Treatment of Patients With Metastatic Lung Carcinoid Tumors. J Thorac Oncol 2019;14:993-1002. [PMID: 30771520 DOI: 10.1016/j.jtho.2019.02.002] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 7.0] [Reference Citation Analysis]
721 Rustgi SD, Oh A, Yang JY, Kang D, Wolin E, Kong CY, Hur C, Kim MK. Initiation of Somatostatin analogues for neuroendocrine tumor patients: a cost-effectiveness analysis. BMC Cancer 2021;21:597. [PMID: 34030646 DOI: 10.1186/s12885-021-08306-5] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
722 Das S, Dasari A. Novel therapeutics for patients with well-differentiated gastroenteropancreatic neuroendocrine tumors. Ther Adv Med Oncol 2021;13:17588359211018047. [PMID: 34093744 DOI: 10.1177/17588359211018047] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
723 Lee DY, Kim YI. Prognostic Value of Maximum Standardized Uptake Value in 68Ga-Somatostatin Receptor Positron Emission Tomography for Neuroendocrine Tumors: A Systematic Review and Meta-analysis. Clin Nucl Med 2019;44:777-83. [PMID: 31283601 DOI: 10.1097/RLU.0000000000002694] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 5.5] [Reference Citation Analysis]
724 Rübenthaler J, Auernhammer C, Harun I, Ricke J, Cyran CC. [Neuroendocrine tumors of the stomach, duodenum and pancreas : Value of (hybrid) radiological diagnostics]. Radiologe 2019;59:961-7. [PMID: 31515568 DOI: 10.1007/s00117-019-00593-1] [Reference Citation Analysis]
725 Darden C, Price M, Ray D, Goldstein G, Goss D, Bennett L, Garbinsky D, Thota R. Patients' satisfaction with long-acting injectable somatostatin analog therapy for neuroendocrine tumors. J Patient Rep Outcomes 2021;5:82. [PMID: 34491454 DOI: 10.1186/s41687-021-00355-5] [Reference Citation Analysis]
726 Elias E, Ardalan A, Lindberg M, Reinsbach SE, Muth A, Nilsson O, Arvidsson Y, Larsson E. Independent somatic evolution underlies clustered neuroendocrine tumors in the human small intestine. Nat Commun 2021;12:6367. [PMID: 34737276 DOI: 10.1038/s41467-021-26581-5] [Reference Citation Analysis]
727 Liao T, Su T, Huang L, Li B, Feng LH. Development and validation of a novel nomogram for predicting survival rate in pancreatic neuroendocrine neoplasms. Scand J Gastroenterol 2021;:1-6. [PMID: 34592854 DOI: 10.1080/00365521.2021.1984571] [Reference Citation Analysis]
728 Mebis W, Snoeckx A, Corthouts B, El Addouli H, Nicolay S, Van Hoyweghen A, Spinhoven M, de Beeck BO. Correlation Between Apparent Diffusion Coefficient Value on MRI and Histopathologic WHO Grades of Neuroendocrine Tumors. J Belg Soc Radiol 2020;104:7. [PMID: 32025623 DOI: 10.5334/jbsr.1925] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
729 Joish VN, Perez-olle R, Lapuerta P, Dharba S, Zacks J. Burden of Carcinoid Heart Disease in Patients With Carcinoid Syndrome Initiating Somatostatin Analogues. Clinical Therapeutics 2019;41:1716-1723.e2. [DOI: 10.1016/j.clinthera.2019.06.013] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
730 Wyld D, Moore J, Tran N, Youl P. Incidence, survival and stage at diagnosis of small intestinal neuroendocrine tumours in Queensland, Australia, 2001-2015. Asia Pac J Clin Oncol 2021;17:350-8. [PMID: 33567164 DOI: 10.1111/ajco.13503] [Reference Citation Analysis]
731 Trikalinos NA, Chrisinger JSA, Van Tine BA. Common Pitfalls in Ewing Sarcoma and Desmoplastic Small Round Cell Tumor Diagnosis Seen in a Study of 115 Cases. Med Sci (Basel) 2021;9:62. [PMID: 34698236 DOI: 10.3390/medsci9040062] [Reference Citation Analysis]
732 Chen Q, Li M, Wang P, Chen J, Zhao H, Zhao J. Optimal Cut-Off Values of the Positive Lymph Node Ratio and the Number of Removed Nodes for Patients Receiving Resection of Bronchopulmonary Carcinoids: A Propensity Score-Weighted Analysis of the SEER Database. Front Oncol 2021;11:696732. [PMID: 34367980 DOI: 10.3389/fonc.2021.696732] [Reference Citation Analysis]
733 Brighi N, La Rosa S, Rossi G, Grillo F, Pusceddu S, Rinzivillo M, Spada F, Tafuto S, Massironi S, Faggiano A, Antonuzzo L, Santini D, Sessa F, Maragliano R, Gelsomino F, Albertelli M, Vernieri C, Panzuto F, Fazio N, De Divitiis C, Lamberti G, Colao A, Fave GD, Campana D. Morphological Factors Related to Nodal Metastases in Neuroendocrine Tumors of the Appendix: A Multicentric Retrospective Study. Annals of Surgery 2020;271:527-33. [DOI: 10.1097/sla.0000000000002939] [Cited by in Crossref: 21] [Cited by in F6Publishing: 6] [Article Influence: 21.0] [Reference Citation Analysis]
734 Partelli S, Andreasi V, Rancoita PMV, Perez-Sanchez E, Muffatti F, Balzano G, Crippa S, Di Serio C, Falconi M. Outcomes after distal pancreatectomy for neuroendocrine neoplasms: a retrospective comparison between minimally invasive and open approach using propensity score weighting. Surg Endosc 2021;35:165-73. [PMID: 31953734 DOI: 10.1007/s00464-020-07375-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
735 Heidsma CM, Tsilimigras DI, van Dieren S, Rocha F, Abbott DE, Fields R, Smith PM, Poultsides GA, Cho C, Dillhoff M, Lopez-aguiar AG, Kanji Z, Fisher A, Krasnick BA, Idrees K, Makris E, Beems M, van Eijck CH, Nieveen van Dijkum EJ, Maithel SK, Pawlik TM. Indications and outcomes of enucleation versus formal pancreatectomy for pancreatic neuroendocrine tumors. HPB 2021;23:413-21. [DOI: 10.1016/j.hpb.2020.06.015] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation